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CHAPTER 1 INTRODUCTION 
1.1 Protein phosphorylation  
Proteins undergo various post translational modifications (PTMs) during their 
lifetime.   PTMs add diversity to the 20 canonical amino acids and modulate the function 
of the proteins.1  Among the various PTMs currently known, phosphorylation, the addition 
of a phosphoryl group onto a protein, represents an enzymatically-mediated, ubiquitous 
protein modification. In fact, it is estimated that 30% of cellular proteins are 
phosphorylated at least on one amino acid at a given time.2  
Phosphorylation is a reversible chemical modification mediated by two enzyme 
families, kinases and phosphatases.3 Kinases use the universal phosphoryl donor ATP 
(5’-adenosine triphosphate) and catalyze the transfer of a phosphoryl group onto a Ser, 
Thr, or Tyr residue on a protein.4 Phosphatases remove the phosphoryl group in a 
process called dephosphorylation to reverse the reaction (Figure 1.1).  
 
 
 
 
Figure 1.1:  Protein phosphorylation. Kinases transfer a phosphoryl group from 
ATP to a hydroxyl containing amino acid on cellular proteins. ADP is produced as 
a side product. Phosphatases carry out dephosphorylation by removing the 
phosphoryl group.  
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Phosphorylation alters protein function by affecting activity, stability, binding, or 
localization.5 For example, the activity of the transcription factor CREB (cAMP Response 
Element Binding-protein) is regulated by phosphorylation. CREB is activated and 
promotes transcription when phosphorylated at Ser133 by Protein Kinase A.6 In another 
example, both stability and binding interactions of the tumor suppressor p53 protein are 
regulated by phosphorylation. Cellular levels of p53 are kept low under normal conditions 
by the interaction of p53 with the E3 ubiquitin ligase MDM2 (Mouse double minute 2 
homolog), which targets p53 for degradation. However, when cells are stressed, p53 is 
phosphorylated and the interaction with MDM2 is prevented, resulting in p53 
stabilization.7 Lastly, the microtubule-associated protein 2 (MAP2) provides a fine 
example of how protein localization is regulated by phosphorylation. MAP2 associates 
with microtubules when dephosphorylated at its KXGS motifs. When phosphorylated, 
MAP2 dissociates from microtubules and localizes to the actin cytoskeleton.8 In addition, 
the nuclear transport of many proteins are also known to be dependent on 
phosphorylation.9 
1.2 Phosphorylation and signal transduction 
Protein phosphorylation plays a prominent role in signal transduction. For example, 
in RAF/MEK/ERK signaling pathway (Figure 1.2), an external ligand binding to a cell 
surface receptor triggers the auto-phosphorylation of the receptor, providing binding sites 
to the adapter protein GRB2 (Growth-factor-receptor-bound protein 2). The GRB2 bound 
RAS exchange factor, SOS (Son of sevenless), then activates RAS protein by promoting 
the exchange of GDP to GTP. Activated RAS binds and activates RAF kinase. RAF in 
turn phosphorylates and activates MEK (MAPK/ERK kinase). Sequentially, MEK 
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phosphorylates and activates ERK (Extracellular signal regulated kinase). Activated ERK 
phosphorylates a variety of substrate proteins, including transcription factors that 
promotes gene transcription.10,11Thus, phosphorylation is used as a medium in relaying 
signals in the cell. Eventually, the pathway is turned off by the activity of the PP2A 
phosphatase, which dephosphorylates MEK and ERK.12 As this example illustrates, 
reversible phosphorylation acts as a key chemical switch in cell signaling.  
 
 
Figure 1.2: RAF/MEK/ERK pathway. See the text for a detailed description. 
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1.3 Phosphorylation and diseases 
Owing to the profound role of phosphorylation in signal transduction and regulation 
of protein function in general, defects in phosphorylation are implicated in various human 
diseases. For example, aberrations in RAF/MEK/ERK kinase activities, either through 
activating mutations or the down regulation of negative regulators, such as phosphatases, 
have been shown to be root causes for cancer.13 In another example, the hyperactivity of 
PTP1B (protein-tyrosine phosphatase 1B) phosphatase, which is a negative regulator in 
insulin signaling, has been linked with obesity and diabetes.14 Further, mutations in PINK1 
and LRRK2 kinases have been shown to be associated with Parkinson’s disease.15 In 
addition, WNK and SPAK kinases have been implicated in hypertension.16 In one last 
example from a plethora of other available examples, the activity of PP1-Gadd34 
phosphatase has been shown to be perturbed during viral transfection.17  
Based on the fact that aberrant phosphorylation is a common cause of various 
human malignancies, kinases and phosphatases have emerged as popular drug targets 
in tackling diseases.18 By 2015, 28 kinase inhibitors were approved by US FDA (US Food 
and Drug Administration).19 Although most of the current drugs have been developed for 
treating cancer, a few have been approved for other diseases, such as rheumatoid 
arthritis and idiopathic pulmonary fibrosis. In addition, many other kinase and 
phosphatase inhibitors are in clinical trials.20 
1.4 Protein kinase classification, structure, mechanism and consensus sequence 
The human proteome is estimated to include 518 protein kinases.21 Broadly, 
protein kinases are classified into two classes: Tyr kinases and Ser/Thr kinases. As the 
names imply, Tyr kinases phosphorylate Tyr residues while Ser/Thr kinases catalyze the 
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phosphorylation of Ser or Thr residues. In addition, human kinases have been classified 
into eight groups (Figure 1.3) depending on the sequence of the catalytic domain and 
structural features.22  
 
Despite the differences in the overall structure and the substrate preferences, all 
eukaryotic kinases share a common catalytic core.23 PKA (cAMP dependent Protein 
Kinase A), one of the first kinase structures to be solved, provides a fine example of a 
kinase catalytic core (Figure 1.4A). The kinase core structure is arranged as two separate 
lobes. The smaller lobe contains the N-terminal domain and is composed primarily of five 
anti-parallel β-sheets. The C-terminal domain makes up the bigger lobe and is rich in α-
helices. The two lobes are connected by a linker hinge region. A deep cleft in between 
Kinases CK1 
Other
s
TK 
TKL 
ACG 
CAMK 
CMGC 
STE 
Figure 1.3: Human kinases classification.  Human protein kinases are categorized 
into 8 groups. CAMK: Calmodulin dependent protein kinase group. ACG: Includes 
PKA, PKG and PKC families. TKL: Tyrosine-kinase like family.  STE: Homologs of 
yeast Sterile 7, sterile 11 and sterile 20 kinases. CK1: Casein kinase 1 family. TK: 
Tyrosine kinase family. CMGC: Includes CDK, MAPK, GSK3 and CLK families. 
Others: kinases that does not belong to the above 7 groups.  
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the two lobes constitutes of the active site.  ATP binds in the form of MgATP with the 
adenine ring stabilized by the linker hinge region and the γ-phosphate group extending 
outwards. The hinge region contains a gatekeeper residue that interacts with the adenine 
base. The substrate binds near the edge of the cleft. 23-24  
The residues near the kinase active site are highly conserved. A conserved 
glycine-rich loop called the P-loop connecting the first two β-strands (Figure 1.4A)  is 
thought to bring the bound ATP close to the substrate.24a A conserved Lys residue (Lys72 
in PKA, Figure 1.4B) in the third β-strand interacts with the α and β phosphoryl groups of 
ATP. The conserved Lys is stabilized by a salt bridge with a Glu (Glu91 in PKA) in the C-
terminal domain.  The C-terminal lobe carries a metal binding loop composed of a 
conserved DFG domain. The Asp in the metal binding loop (Asp184 in PKA) chelates the 
Mg that contacts the β and γ phosphoryl groups of ATP. A second Mg is coordinated by 
a conserved Asn (Asn171 in PKA). A catalytic loop in the C-terminal lobe (Arg165-Asn171 
in PKA) contains the residues responsible for catalysis. An invariant Asp residue (Asp166 
in PKA) acts as a base by removing a proton from the hydroxyl of the substrate.  A Lys 
residue in the catalytic loop (Lys168 in PKA) interacts with the γ-phosphoryl group and 
balances the negative charge. With the γ-phosphoryl of ATP being correctly oriented for 
nucleophilic attack by the substrate, the substrate is phosphorylated while producing ADP 
as a by-product (Figures 1.4B and 1.5).24a, 25  
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  (A) 
C-terminal 
lobe 
Figure 1.4: The catalytic core of PKA and the critical active site residues. (A) The 
crystal structure of Protein kinase A (PKA, 1ATP) complexed with ATP (ball and stick 
structure) and a peptide substrate inhibitor (yellow). See the text for more information.  
(B) Interactions of the critical active site residues with ATP and the substrate. The 
curved arrow shows nucleophilic attack by the substrate.  
N-terminal 
lobe 
Linker 
hinge 
region 
P-loop 
(B) 
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 Although the ATP binding fold and the active site of the kinases are highly 
conserved, kinases show selectivity toward their substrates. Generally, the kinases 
recognize a conserved sequence of the substrate called the consensus sequence that 
flanks the phospho-site.25 Consensus sequences identified for some kinases show that 
certain kinases depend on the presence of acidic, basic, or proline residues in the protein 
substrate to selectively phosphorylate a given phosphosite. For example, PKA uses a 
basic consensus sequence of R-R-X-S/T (X is any amino acid) to phosphorylate Ser/Thr 
residues of the substrates. Consensus sequences for some well-known kinases are 
shown below (Table 1.1).25 More information on consensus sequence are provided in 
Chapter 2.  
Table 1.1: Consensus sequence for some kinasesa 
 
 
 
 
Kinase Consensus sequence 
PKA R-R-X-S/T 
ABL I/V/L-Y-X-X-P/F 
AKT1 R-X-R-XX-S/T 
CDK1 S/T-P-X-R/K 
CK2 S/T-X-X-D/E 
ERK1 P-X-S/T-P 
Aurora A R/K/N-R-X-S/T 
CHK1 R-X-X-S/T 
EGFR E-E-E-Y-F 
CDK2 S/T-P-X-R/K 
aX represents any amino acid.  The phosphosite is shown in bold letters.  
Figure 1.5:  Kinase mechanism. 
9 
 
 
 
1.5 Challenges associated with studying phosphorylation  
Despite the disease relevance, understanding how phosphorylation regulates 
cellular processes has been challenging. The difficulties can be attributed to both the 
ubiquity of phosphorylation and the complicated manner by which phosphorylation is 
carried out.  According to the PhosphoSitePlus data base, the human proteome contains 
about 270,000 phospho-sites,26 with many novel sites being routinely discovered. In 
addition, a single protein can be phosphorylated on multiple residues. For example, the 
iPTMnet data base27 reports 17 phosphosites for CREB1. Further, the same phosphosite 
can become phosphorylated by multiple kinases. For instance, depending on the stimuli, 
Ser133 on CREB1 can be phosphorylated by various kinases such as PKA,6 ATM28 and 
SGK29. Additionally, the human proteome carries more than 500 kinases and hundreds 
of different phosphatases.2,22 Moreover, the kinases and phosphatases in turn are 
regulated by various mechanisms, further complicating how phosphorylation is carried 
out.30 As a result, the cellular phosphorylation map remains incomplete, hindering our 
understanding of how various diseases arise.  Therefore, methods are required to study 
phosphorylation and determine the mechanisms behind numerous human disorders.  
Among the methods currently available for studying phosphorylation, γ-modified ATP 
analogs represent a powerful approach.31  
1.6 γ-modified ATP analogs 
An examination of the kinase crystal structure shows that ATP binds the kinase in 
an orientation where the γ-phosphate group is pointed outwards and is solvent exposed 
(Figure 1.4A).  As a result, kinases also tolerate γ-modified ATP analogs and show 
cosubstrate promiscuity, transferring γ-modified phosphoryl groups onto substrate 
10 
 
 
 
proteins (Figure 1.6).23, 32 when used as kinase cosubstrates, ATP analogs modified at 
the γ position with functional groups such as biotin, represent useful tools to study 
phosphorylation. The next section will discuss selected γ-modified ATP analogs and their 
use in phosphorylation research.  
 
 
 
1.6.1 ATP-γS 
The ATP-γS analog, which leads to thiophosphorylation in a kinase reaction (Figure 
1.7A), was one of the very first γ-modified ATP analogs developed.33 Compared to ATP, 
ATP-γS shows a lower catalytic efficiency.34 However, the thiophosphoryl group is stable 
to phosphatases and can be alkylated.33b Therefore, thiophosphorylation has been used 
as a method to purify phosphoproteins. For example, the alkylation of thiophosphorylated 
proteins using a biotin tagged idoacetamide derivative was used as a means of avidin 
enrichment of phosphoproteins (Figure 1.5B, I). In this case, low pH conditions were used 
to selectively alkylate the phosphorylthiol group while keeping the cysteine thiol groups 
unreactive.35  In another example, thiophosphorylated proteins were reacted with an 
idoacetamide derivative conjugated with a solid phase resin (Figure 1.5B, II). Though both 
phosphorylthiol and cysteine thiol groups reacted with idoacetamide derivative, thio-
Figure 1.6: Cosubstrate promiscuity of kinases. Kinases accept γ-modified ATP 
analogs and transfer γ-modified phosphoryl groups onto substrate proteins.  
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phosphorylated proteins were selectively eluted by peroxide assisted cleavage of the S-
P bond.36 
Shokat and colleagues used a derivative of ATP-γS modified at the N6 position 
with a bulky benzyl group (ATP-γS*) to identify the substrates of CDK1 kinase (Figure 
1.8). Here, they designed a mutant form of CDK1 kinase tolerant of the modified ATP 
analog. The use of the mutant CDK1 with ATP-γS* in lysates led to the selective 
thiophosphorylation of only CDK1 substrates. Later, the thiophosphorylated proteins were 
purified by using the resin-conjugated idoacetamide derivative described above (Figure 
1.7 B, II). The purified proteins were then analyzed by LC-MS/MS to reveal CDK1 
substrates.37  
Figure 1.7: The use of ATP-γS analog. (A) Thiophosphorylation of cellular proteins with 
ATP-γS. (B) Different strategies used for the purification of thiophosphorylated proteins. 
Blue color shows kinase substrates while orange color shows cellular proteins with 
cysteine thiol groups.    
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1.6.2 Other γ-modified ATP analogs used to study phosphorylation 
Other notable γ-modified ATP analogs used in phosphorylation research are ATP-
Atto and ATP-ferrocene (Figure 1.9). The fluorescently active ATP-Atto analog was used 
in the development of a FRET (fluorescence resonance energy transfer)-based kinase 
assay. In this case, CK2 kinase and ATP-Atto were incubated with a CK2 substrate 
peptide tagged with a CdSe/ZnS quantum dot. Kinase-catalyzed transfer of the 
phosphoryl-Atto group onto the peptide led to a FRET signal that could be measured to 
study CK2 activity.38  
Redox active ATP-ferrocene was developed by Kraatz and colleagues to facilitate 
the electrochemical detection of phosphorylation. ATP-ferrocene was used to detect the 
activity of Protein kinase C using a surface immobilized peptide and cyclic voltammetry.39 
Figure 1.8: The use of ATP-γS derivative to identify substrates of CDK1. Incubation 
of lysates with mutant CDK1 (brown) and ATP-γS* (N6-benzyl-ATP-γS) results in 
thiophosphosphorylation of only CDK1 substrates (blue). Wild type CDK1 and other 
kinases (green) are inactive towards ATP-γS* and use ATP to phosphorylate their 
substrates (pink). Subsequent purification and LC-MS/MS analysis led to the discovery 
of CDK1 substrates.  
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Later, anti-ferrocene antibodies were also developed to allow the visualization of the 
tagged phosphoproteins by Western blot.40  
Commercially available ATP-acyl-biotin (Figure 1.10) is another γ-modified ATP 
analog that has been used. ATP-acyl-biotin differs from other γ-modified ATP analogs by 
modifying the kinase instead of the substrate proteins. ATP-acyl biotin binds to the kinase 
active site and modifies a lysine residue commonly found in the ATP binding region of 
kinases and other nucleotide binding proteins. Thus, ATP-acyl biotin is widely used to 
profile kinases and other ATP binding proteins in the cell. In an illustrative example, ATP-
acyl biotin was used to study the inhibition profile of kinase inhibitors. In this case, ATP-
acyl biotin was added to inhibitor-treated and untreated lysates. Since ATP-acyl biotin 
can only bind to kinases unoccupied by the inhibitor, only uninhibited kinases are 
biotinylated while inhibited kinases are unlabeled. Thus, kinases affected by the inhibitor 
were selectively identified.41 
ATP-ferrocene 
ATP-atto 
Figure 1.9: ATP-atto and ATP-ferrocene. 
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Figure 1.10: Kinase labeling by ATP-acyl-biotin 
1.6.3 γ-modified ATP analogs used by Pflum and colleagues 
Pflum and colleagues have developed and used a number of γ-modified ATP 
analogs over the years. The Pflum lab ATP analogs have been used in different 
applications. One such analog used by Pflum group is ATP-biotin.  
1.6.3.1 ATP-biotin 
The ATP-biotin analog carries a biotin group at the γ phosphate position and leads 
to the phosphobiotinylation of cellular proteins when used by kinases (Figure 1.11).  ATP-
biotin provides the advantage of directly purifying the phosphoproteins by avidin resin, 
compared to the two step purification with ATP-γS (Figure 1.7). 
The first reported use of ATP-biotin comes from Brust and colleagues. Here, ATP-
biotin was used in a colorimetric assay to study the activity of PKA and CAMKII kinases. 
In this case, a gold nanoparticle decorated with substrate peptides of the tested kinase 
were incubated with ATP-biotin and the corresponding kinase. After the peptides were 
biotinylated, gold nanoparticles capped with avidin were added. Biotinylation resulted in 
the aggregation of the nanoparticles resulting in a colorimetric signal indicative of kinase 
activity.42 In another application, Brust and group used ATP-biotin to study the peptide 
substrate selectivity of protein kinases. Here, peptides were first immobilized on a solid 
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phase in a microarray format. Then PKA and ATP-biotin were added. Then gold 
nanoparticles coated with avidin were added. Biotinylated peptides that represent 
potential PKA substrate peptides were identified by resonance light scattering.42b 
Later, Pflum and colleagues pioneered the use of ATP-biotin as a general method 
of detecting phosphorylation in both simple systems, such as purified substrates, and 
complex mixtures, such as lysates. Specifically, recombinant kinases and ATP-biotin 
were incubated with either substrate peptides or full length proteins. Biotinylation was 
then monitored by gel based analysis using a streptavidin-cy5 conjugate. In the case of 
peptide substrates, biotinylation was also probed by HPLC and quantitative mass 
spectrometry analysis.32, 43 Importantly, a thorough characterization of biotinylation with 
26 kinases representing the kinome showed that even though the catalytic efficiency is 
slightly impaired, ATP-biotin is a general cosubstrate for kinases.43b In agreement, gel 
based visualization showed that ATP-biotin incubation with lysates leads to robust 
Figure 1.11: ATP-biotin leads to phosphobiotinylation of proteins.  
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biotinylation of cellular proteins, indicating that cellular kinases are capable of utilizing 
ATP-biotin.32  Similar to thiophosphorylation, phosphobiotinylation was phosphatase 
resistant, and therefore, suitable for phosphoprotein purification.44  
As an application of using ATP-biotin for phosphoprotein purification, Pflum and 
co-workers developed a technique called “K-BILDS (Kinase-catalyzed Biotinylation with 
Inactivated Lysates for Discovery of Substrates, Figure 1.12) for discovering kinase 
substrates. K-BILDS was used to identify PKA substrates. In this case, cellular kinases 
were inactivated by incubating the lysates with the irreversible kinase inhibitor FSBA (5′-
(4-fluorosulfonylbenzoyl adenosine hydrochloride). Excess FSBA was then removed and 
recombinant PKA was added to the lysates, along with ATP-biotin. After exogenous PKA 
biotinylated its substrates, the biotinylated proteins were purified by streptavidin. 
Proteomics analysis was then carried out to identify the PKA substrates. K-BILDS 
revealed 279 PKA candidate substrates, including 57 already known PKA substrates.45  
Figure 1.12: K-BILDS procedure. In K-BILDS, the cellular kinases are first inactivated 
(brown and purple crossed). Then an exogenous kinase (yellow) is added with ATP-
biotin. The exogenous kinase biotinylated its substrates (blue). The blue, red, pink and 
brown circles represent other proteins in the lysates that are not substrates of the 
exogenous kinase.  
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K-BILDS demonstrates how ATP-biotin acts as a powerful tool for probing cellular 
phosphorylation events. However, ATP-biotin is not cell permeable and not suitable for 
monitoring live cell phosphorylation events. Therefore, the Pflum lab developed a cell 
permeable derivative of ATP-biotin called ATP-polyamine-biotin (APB) by replacing the 
polyethylene glycol (PEG) inker of ATP-biotin with a positively charged polyamine linker 
(Figure 1.13). The reduced negative charge on APB promoted its cell delivery under 
physiological conditions. Therefore, APB was added to live HeLa cells attached to well 
plates. Then cells were lysed and biotinylation was probed by gel based methods. The 
results showed that APB biotinylated cellular proteins, confirming that APB is cell 
permeable. In contrast, no biotinylation was observed when ATP-biotin was added to live 
cells.46 Thus ATP-biotin has been used in multiple applications facilitating the study of 
phosphorylation. Chapter 3 describes another application using ATP-biotin.  
1.6.3.2 ATP-dansyl  
ATP-dansyl (Figure 1.14A) developed by the Pflum lab permits modification of 
phospho-peptides and proteins with the fluorescently active dansyl group.  Pflum and 
colleagues used ATP-dansyl to develop a FRET based assay for kinase activity (Figure 
1.14B). Specifically, ABL kinase and ATP-dansyl were incubated with an ABL substrate 
peptide bearing a rhodamine tag at the N terminus. ABL-mediated dansylation of the 
peptide resulted in a FRET signal indicative of ABL activity. As expected, the FRET signal 
Figure 1.13: ATP-polyamine biotin (APB) 
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was considerably reduced when kinase inhibitors were used. In a further step, the assay 
was also used to investigate the ABL activity in lysates. While untreated lysates produced 
a high FRET signal, lysate treatment with the general kinase inhibitor staurosporine led 
to a great reduction in the FRET signal.47 Although no further applications of ATP-dansyl 
have been reported, danyslation represents a useful way of investigating phosphorylation.  
 
1.6.3.3 γ-modified ATP analogs with photocrosslinkers 
When coupled with UV irradiation, kinase-catalyzed modification of 
phosphoproteins with photocrosslinking groups provides the advantage of generating 
stable kinase-substrate pairs for later detection (Figure 1.15A). Over the years, the Pflum 
Figure 1.14: ATP-dansyl and its application. (A) Structure of ATP-dansyl (B) The FRET 
assay used by Pflum and colleagues to assay ABL kinase activity using ATP-dansyl. A 
peptide (red wavy line) carrying a rhodamine tag (red circle) was incubated with ATP-
dansyl and ABL kinase. Dansylation followed by excitation with 360 nm resulted in a 
FRET signal (595 nm) indicative of ABL kinase activity.  
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lab has developed ATP-arylazide and ATP-benzophenone (Figure 1.15B) as analogs 
bearing photocrosslinker groups at their γ-phosphate position.48 
In an application to show the activity of photocrosslinking ATP analogs, Pflum and 
colleagues incubated recombinant CK2 kinase and a rhodamine tagged CK2 substrate 
peptide with ATP-arylazide in the presence of UV light (Figure 1.16).  When analyzed by 
gel methods, CK2 was shown to be fluorescently labeled, indicating that ATP-araylazide 
Figure 1.15: Use of photo-crosslinking ATP analogs. (A) Kinase-catalyzed modification 
of phosphoproteins with photocrosslinking groups leads to the generation of stable 
kinase-substrate complexes when UV is used. (B) Structures of ATP-arylazide and 
ATP-benzophenone. 
(A) 
(B) 
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mediated the crosslinking between the kinase and the fluorescent peptide. Similar results 
were obtained when another kinase-substrate pair, ABL, and its fluorophore tagged 
substrate peptide was used, showing that ATP-arylazide is compatible with other kinases 
as well. In a further step, CK2 and its protein substrate casein were incubated with ATP-
arylazide in UV light. Western blot analysis of CK2 showed a higher molecular weight 
band corresponding to a CK2-casein complex.48a Later, ATP-benzophenone was also 
investigated for its ability to mediate kinase-substrate crosslinking. Docking analysis and 
quantitative mass spectrometry analysis with a substrate peptide revealed ATP-
benzophenone to be a more efficient cosubstrate compared to ATP-benzophenone. 
However, when used for crosslinking CK2 and casein, ATP-benzophenone gave rise to 
multiple bands compared to a distinct band by ATP-arylazide, suggesting non-specific 
crosslinking.48b  
In another application of photocrosslinking ATP analogs, the Cole lab reported the 
use of a bifunctional ATP analog (Figure 1.17) bearing photocrosslinking arylazide groups 
on both the γ phosphate position and C8 position. Unlike ATP-arylazide and ATP-
benzophenone, the bifunctional analog requires only binding with the kinase and does 
Figure 1.16: Fluorescent labeling of CK2 kinase using ATP-arylazide. CK2 kinase was 
incubated with ATP-arylazide and a peptide substrate (wavy red line) bearing a 
rhodamine tag (red circle). ATP-arylazide mediates crosslinking of CK2 with the peptide 
leading to fluorescent labeling of CK2 kinase.  
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not depend on kinase activity for photocrosslinking. Using CSK and SRC kinases, the 
bifunctional analog was shown to cause the formation of high molecular weight 
complexes indicative of kinase-substrate crosslinking.49 Unfortunately, no further use of 
this analog has been reported. In conclusion, the discussed examples show that 
photocrosslinking γ-modified ATP analogs have provided useful probes for studying 
phosphorylation. Chapter 2 describes another application of using ATP-arylazide.  
 
 
 
 
Figure 1.17: Bifunctional ATP analog used by Cole and colleagues 
1.7 Thesis project 
The use of γ-modified ATP analogs and other methods have facilitated the study 
of phosphorylation. However, phosphorylation is ubiquitous, and a staggering number of 
phosphorylation events are known to take place in the cell. The biological significance 
and the disease relevance of many of these phosphorylation events remain unknown 
because the methods to determine which particular kinase is responsible for the particular 
phosphorylation event are limited. One goal of this thesis work was to develop a method 
for identifying the kinase that phosphorylates a given phosphosite.   
Based on our prior work with ATP-arylazide (Figure 1.16), we established a novel 
chemical tool called K-CLASP (Kinase-catalyzed CrossLinking And Streptavidin 
Purification) for phosphosite specific kinase identification. Chapter 2 describes the 
development and application of K-CLASP to two phosphosites. In a proof-of-concept 
study, the protein kinase A (PKA) peptide substrate kemptide was used to show that K-
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CLASP is capable of identifying PKA as the kinase responsible for kemptide 
phosphorylation from cell lysates.50 Then K-CLASP was used to identify the kinase(s) that 
phosphorylates Ser178 of the transcription factor called Miz1. 
Although phosphorylation is a reversible process mediated by both kinases and 
phosphatases, the study of phosphatases has lagged behind kinases because many of 
the current available techniques, including γ-modified ATP analogs, are capable of 
interrogating only the kinases.  As a result, few phosphatase substrates have been 
identified.51 Therefore, a second goal of this thesis work was to enable a new technique 
for identifying phosphatase substrates. Using ATP-biotin, we developed a method called 
K-BIPS (Kinase-catalyzed Biotinylation to Identify Phosphatase Substrates). Chapter 3 
describes the application of K-BIPS in three biological systems. First, the general 
phosphatase inhibitor okadaic acid was used to show that K-BIPS is a viable tool for the 
discovery of phosphatase substrates. Then K-BIPS was used to explore the substrates 
of PP1-Gadd34 and PP1-MYPT1 phosphatase complexes. In conclusion, both K-CLASP 
and K-BIPS provide valuable tools to study phosphorylation and deconvolute the intricate 
cell signaling pathways.  
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CHAPTER 2  K-CLASP: KINASE CATALYZED CROSS-LINKING AND 
STREPTAVIDIN PURIFICATION 
Excerpts from this chapter have been reprinted or modified with permission from 
Dedigama-Arachchige, P. M and Pflum, M. K., K-CLASP: A tool to identify phosphosite 
specific kinases and interacting proteins. ACS Chem Biol 2016. In press. Copyright 2016 
American Chemical Society.  
A significant challenge to unravel cell signaling pathways and to understand the 
molecular mechanism behind human diseases is to identify the kinase responsible for the 
phosphorylation of a given protein at a particular amino acid.  Unfortunately, the methods 
to discover cellular proteins associated with the kinase during phosphorylation are also 
limited. As a solution, we developed a novel chemical tool called K-CLASP (Kinase-
catalyzed CrossLinking And Streptavidin Purification) for both phosphosite specific kinase 
identification and the discovery of kinase associated proteins. Chapter 2 describes the 
development and application of K-CLASP in two systems. In a proof-of-concept study, 
Protein kinase A (PKA) and its known peptide substrate kemptide were used to show that 
K-CLASP is capable of identifying PKA as the kinase responsible for kemptide 
phosphorylation from cell lysates. Additionally, several protein complexes and many other 
proteins that associate with PKA were also discovered. Then K-CLASP was used to 
identify the kinase(s) that phosphorylates Ser178 of the transcription factor called Miz1. 
K-CLASP identified several kinases and many other cellular proteins that associate with 
the phosphorylation of Miz1 protein at S178. 
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2.1 Current methods available for phosphosite specific kinase identification  
The advancement of powerful mass spectrometric techniques has facilitated the 
identification of novel phosphorylated amino acids or phosphosites at an unprecedented 
rate.52 The identification of these novel phosphosites poses an important question: which 
protein kinase catalyzes phosphorylation of a specific phosphosite? With over 500 
kinases in the kinome,22  identifying the kinase that phosphorylates a specific phosphosite 
is a challenge.  Although several methods have been established to identify the 
substrates of a given kinase,53 fewer methods exist to identify the kinase for a specific 
phosphosite. One of the methods available for phosphosite specific kinase identification 
is in silico kinase prediction, as described in the next section.  
2.1.1. In silico kinase prediction  
In silico kinase prediction employs kinase consensus sequences to determine the 
probable kinase(s) that may phosphorylate a given site on a protein.54 Kinase consensus 
sequences have been formulated based on the observation that the phosphorylation 
specificity of kinases depends on the primary sequence or amino acids flanking the 
phosphosite.55 Benjamin Turk and colleagues have pioneered the use of the consensus 
sequence strategy by utilizing peptide libraries to identify consensus sequences and then 
using the sequence information to predict the substrates of given kinases.56 In addition, 
consensus sequences have also been determined by the alignment of multiple 
sequences surrounding a phosphosite known to be phosphorylated by a single kinase. 
Subsequent studies on kinase activity and binding after mutagenesis of the sequence 
around the phosphosite further confirmed the consensus sequences.57  
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Several bioinformatics tools are currently available that predicts kinase specificity 
depending on the consensus sequence.54, 58 However, the consensus sequences for 
some kinases still remain unknown, limiting the applicability of in silico kinase prediction 
methods. In addition, increasingly available phosphoproteomics data indicate that some 
kinases act on varying primary sequences and do not conform to a strict consensus 
sequence.59 Further, studies also suggest that kinase specificity may be also governed 
by the three dimensional structure around the phosphorylation site.59-60 As a result, in 
silico prediction methods have limited capabilities to accurately identify the kinase of a 
given phosphosite.  
2.1.2 Mechanism based crosslinking  
Another strategy that has been reported for phosphosite specific kinase 
identification is a mechanism based crosslinking approach (Figure 2.1) developed by the 
Shokat group. This strategy uses an adenosine containing crosslinker with an o-
phthaldialdehyde (Figure 2.2A) and a cysteine substituted substrate to covalently link a 
kinase with the substrate. Specifically, the crosslinker is expected to bind the kinase 
through the adenosine moiety and react with a catalytic lysine found in kinases (Figure 
2.1a,b). Then the crosslinker will also react with a cysteine on the substrate to form a 
kinase-substrate complex (Figure 2.1c,d).  Consistent with the hypothesis, the dialdehyde 
crosslinker led to the biotinylation of AKT1 when a biotinylated AKT1 substrate peptide 
bearing a cysteine substitution was used.61 However, when used in cell lysates, the 
dialdehyde crosslinker reacted with many proteins and proved to be non-selective. As a 
solution, a modified crosslinker (Figure 2.2B) with a less reactive thiophene-2,3-
dicarboxaldehyde moiety was used. In addition, the weakly binding adenosine moiety was 
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also replaced with a kinase inhibitor scaffold to increase crosslinker binding to the 
kinase.62 Although the modified crosslinker had reduced non-specificity, its reactivity was 
too low to be used in biological applications. As an improvement, an ATP based 
crosslinker with a phosphor-anhydride group and a methylacrylate (Figure 2.2C) was 
developed. The modified crosslinker works by first reacting with lysine on the kinase and 
then with the cysteine on the substrate (Figure 2.3). In cell lysates, the modified 
crosslinker resulted in the isolation of exogenously added Src kinase by streptavidin 
Figure 2.1: Mechanism based crosslinking with the o-phthaldialdehyde crooslinker. 
Reprinted with permission from Maly, D. J.; Allen, J. A.; Shokat, K. M., A mechanism-
based cross-linker for the identification of kinase-substrate pairs. J Am Chem Soc 2004, 
126 (30), 9160-1. Copyright (2004) American Chemical Society. More description is 
available in the text. 
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purification when biotinylated Src substrate peptide with a cysteine substitution was 
used.63 However, the use of the methylacrylate crosslinker in a proteomics experiment 
has not been reported.  
    
2.2 K-CLASP strategy  
The limitation of tools available for the identification of the upstream kinase of a 
given phosphosite has warranted the development of novel methods for phosphosite 
specific kinase detection. Based on kinase-catalyzed crosslinking with ATP-ArN3, we 
developed a method called K-CLASP (Kinase-catalyzed CrossLinking And Streptavidin 
Purification) for phosphosite specific kinase identification. In the K-CLASP method, a 
Figure 2.2: Mechanism based crosslinkers developed by Shokat and colleagues 
Figure 2.3: Mechanism based crosslinking with the methylacrylate crooslinker. Reprinted 
with permission from Riel-Mehan, M. M.; Shokat, K. M., A crosslinker based on a tethered 
electrophile for mapping kinase-substrate networks. Chem Biol 2014, 21 (5), 585-90. 
Copyright (2014) Elsevier. More description is available in the text.  
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biotin tagged peptide containing the phosphosite of interest is incubated with a cell lysate 
in the presence of ATP-ArN3 and UV irradiation. The biotinylated peptide will covalently 
crosslink to its respective kinase in the lysate via kinase-catalyzed phosphorylation and 
simultaneous UV-activated arylazide crosslinking. The covalently crosslinked complex 
can then be streptavidin purified and analyzed by mass spectrometry to identify the 
captured kinase (Figure 2.4a).  However, kinase-substrate interactions are transient, 
allowing diffusion of the biotin-tagged peptide away from the kinase after transfer of the 
photocrosslinking group (Figure 2.4b). In this scenario, the biotin-tagged peptide will 
crosslink to proteins in close proximity of the kinase, including direct and indirect 
Figure 2.4: Kinase-catalyzed labeling and the K-CLASP method. (a) An N-biotinylated 
peptide (red) carrying a phosphosite will bind to its phosphorylating kinase (yellow) and 
ATP-ArN3 in lysates. The kinase catalyzes transfer of the photocrosslinker group onto 
the peptide, while UV irradiation leads to covalent attachment of biotinylated peptide and 
kinase. The biotin-linked kinase can then be streptavidin purified and identified by 
MS/MS analysis. (b) Once the photocrosslinker is transferred, the N-biotinylated peptide 
can diffuse away from the kinase to crosslink with nearby proteins, including direct (blue) 
and indirect (green) associated proteins of the kinase. 
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associated proteins (Figure 2.4b). As a result, both the target kinase and kinase-
associated proteins are purified and observed in a K-CLASP experiment. Therefore, K-
CLASP has the potential to not only discover the kinase that phosphorylates a given 
phosphosite, but to also expose proteins interacting with the kinase under the conditions 
of the experiment. Given that classic methods for interacting protein identification, such 
as immunoprecipitation and yeast two hybrid, require stable protein-protein interactions 
and might miss low abundance or transient partners, K-CLASP also provides a useful tool 
to investigate the proteins close to the kinase during the crosslinking event.  
To establish K-CLASP as a viable tool for kinase identification, we tested the well-
known kinase substrate peptide pair, Protein kinase A (PKA) and its substrate kemptide 
(LRRASLG), in a proof-of-concept study. In addition, in a collaboration project with Prof. 
Jing Liu at Northwestern University, we also applied K-CLASP to identify possible kinases 
that phosphorylate S178 in Miz1 protein. The results from the two studies establish K-
CLASP to be a useful tool for phosphosite specific kinase identification and discovery of 
proteins interacting with the kinase during the crosslinking event.  
2.3 K-CLASP using Protein Kinase A (PKA) and kemptide 
Protein kinase A (PKA) is widely reported to phosphorylate the peptide substrate 
kemptide (LRRASLG).64 To show that K-CLASP can identify the kinase responsible for 
the phosphorylation of a given site, we used kemptide and PKA. Initially, in vitro 
crosslinking reactions were carried out using biotin tagged kemptide with recombinant 
PKA and HeLa lysates to show that ATP-ArN3 can covalently link PKA with biotin-
kemptide. Then full K-CLASP experiments were carried out after purifying crosslinked 
samples using streptavidin and then analyzing by tanderm mass spectrometry. The 
30 
 
 
 
proteomics data revealed that PKA can be isolated by K-CLASP as the kinase that 
phosphorylates kemptide. In addition, many other proteins that interact with PKA during 
crosslinking were also identified establishing K-CLASP as a tool for both phosphosite 
specific kinase identification and the discovery of kinase interacting proteins.  
2.3.1. In vitro crosslinking reactions with recombinant PKA and kemptide 
As a first step to show that ATP-ArN3 crosslinks kemptide with PKA, recombinant 
PKAα catalytic subunit was incubated with ATP-ArN3 in the presence of N-biotinylated 
kemptide and UV irradiation. We synthesized a modified kemptide sequence containing 
four N-terminal glycine residues (biotin-GGGGLRRASLG) to separate the biotin tag from 
the phosphosite and avoid steric issues. After crosslinking, samples were separated by 
SDS-PAGE, transferred onto a PVDF membrane and then stained with a streptavidin–
Cy5 conjugate to detect biotin-linked PKA kinase. Biotinylated PKA was observed in the 
presence of ATP-ArN3 (Figure 2.5a, lane 2) but not ATP (Figure 2.5a, lane 3), 
demonstrating dependence on photocrosslinking. As controls, the biotin signal was 
reduced when excess ATP (Figure 2.5a, lane 4) or non-biotinylated kemptide (Figure 
Figure 2.5: N-biotin kemptide crosslinking with recombinant PKA and lysates. 
Crosslinking reactions with recombinant PKA, biotinylated kemptide (B-kem), and ATP-
ArN3. Control reactions were carried out with N-biotin mutant kemptide (B-kem mt) 
lacking the phosphorylated Ser, 4X excess ATP, 2X excess non-biotinylated kemptide 
(kem), an N-biotinylated scrambled kemptide (scr kem), or heat inactivated PKA (HI 
PKA). Biotin signal was quantified from at least three independent trials with mean and 
standard error shown above each lane.  The repetitive trials shown in Appendix, Figure 
A2.2. 
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2.5a, lane 5) were included. In addition, biotinylation was also reduced when a scrambled 
biotin peptide (Figure 2.5a, lane 8) or heat inactivated PKA was used (Figure 2.5a, lane 
9).  
As a further control, we tested an N-biotinylated kemptide mutant where Ala 
replaced the phosphorylation site Ser (biotin-GGGGLRRAALG). PKA was biotinylated in 
the presence of N-biotin mutant kemptide, although at a reduced level compared to wild 
type kemptide (47 ± 5%, Figure 2.5, lane 6). We speculated that crosslinking of PKA with 
mutant kemptide is due to nonselective reactivity of the arylazide photocrosslinker with 
biotin-kemptide before PKA auto-phosphorylation. In this case, ATP-ArN3 may non-
specifically react with the biotin-kemptide to first form a kemptide-ATP-ArN3 conjugate. 
The conjugate may act as a co-substrate for PKA and then transferred onto another PKA 
molecule through PKA auto-phosphorylation (Figure 2.6).   
Figure 2.6: Proposed nonspecific reactivity of N-biotin mutant kemptide to account for 
background biotinylation in Figure 2.5, lane 6.  A) Nonspecific reaction of ATP-ArN3 and 
the N-biotin mutant kemptide peptide produces a peptide-ATP conjugate.  B) The peptide-
ATP conjugate is a cosubstrate for phosphorylation of a “protein” substrate in lysates by 
its kinase.  C) Phosphorylation of the “protein” with the peptide-ATP conjugate produces 
a covalent connection between the N-biotin mutant kemptide and “protein”.  To explain 
the labeling of PKA by mutant biotin-kemptide, “protein” is another PKA protein.  
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To probe our hypothesis that a pre-formed kemptide-ATP-ArN3 results in the 
labeling observed for the mutant kemptide, we pre-incubated N-biotinylated kemptide with 
ATP-ArN3 before adding PKA.  Biotinylation was still observed for both wild type biotin-
kemptide and mutant kemptide when a pre-incubated biotinylated kemptide and ATP-
ArN3, was used (Figure 2.7, lanes 2 and 3). Interestingly, when the pre-incubation was 
carried out with the N-biotinylated scrambled peptide, minimal PKA biotinylation was 
observed (Figure 2.7, lane 4), suggesting that labeling through a pre-formed kemptide-
aryl azide conjugate still requires efficient kemptide-PKA interaction. The results 
highlighted the fact that a negative control reaction will be critical to account for and 
remove background crosslinking due to the highly reactive arylazide in the K-CLASP 
method. To be rigorous, reactions with mutant kemptide were included as critical negative 
controls in future experiments.   
 
 1 2 3 4 
B-kem + + - + 
B-kem mt  - - + - 
scr kem - - - + 
ATP-ArN3 + + + + 
Pre-incubation of peptide with ATP-ArN3 no yes yes yes 
 
SA-Cy5 
Sypro®Ruby 
Figure 2.7: In vitro crosslinking reactions with recombinant PKA with biotin peptide pre-
incubated with ATP-ArN3. N-biotin kemptide (B-kem), N-biotin mutant kemptide (B-kem mt), 
or scrambled kemptide (scr kem) were separately pre-incubated with ATP-ArN3 in the 
presence of UV light. Then recombinant PKA was added and crosslinking reactions were 
carried out. After reaction, the samples were separated by SDS-PAGE and stained with 
Sypro® Ruby total protein stain (bottom) or Streptavidin-Cy5 for biotinylation (top). A control 
reaction was carried out with N-biotin kemptide (B-kem) without pre-incubation (lane 1). The 
gels are representative of three independent trials (Appendix, Figure A2.3). 
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2.3.2 In vitro crosslinking with recombinant CK2 and CK2 peptide 
To establish that K-CLASP is applicable with other kinases, we also carried out 
crosslinking reactions with recombinant Casein kinase II (CK2) and its N-biotinylated 
peptide substrate (biotin-RRREEETEEE). As observed with PKA, CK2 biotinylation was 
observed with ATP-ArN3 (Figure 2.8, lane 1), but not with ATP (Figure 2.8, lane 2). 
Similarly, CK2 labeling was reduced when excess ATP (Figure 2.8, lane 3) or a non-
biotinylated CK2 peptide (Figure 2.8, lane 4) was present. The results with CK2 
demonstrate that kinase-peptide crosslinking with ATP-ArN3 is compatible with other 
kinases. 
2.3.3 In vitro crosslinking with lysates and kemptide  
With the ultimate goal of identifying endogenous, cellular kinases of kemptide, we 
carried out crosslinking in lysates. N-biotin kemptide and ATP-ArN3 were incubated with 
HeLa lysates in the presence of UV before SDS-PAGE analysis. In order to optimize the 
reaction conditions, we performed a time course for the crosslinking reaction, with varying 
amounts of the N-biotin kemptide and subsequent gel analysis. The two hour reaction 
time with 2 mM N-biotin kemptide (Figure 2.9, Lane 8) produced an appreciable biotin 
Sypro® 
Ruby 
 
 SA-Cy5 
 1 2 3 4 
B-sub + + + + 
sub - - - + 
ATP-ArN3 + - + + 
ATP - + 4X - 
 
Figure 2.8: Crosslinking reactions with recombinant CK2, biotinylated CK2 substrate 
peptide (B-sub), and ATP-ArN3.  Control reactions were carried out with ATP, 4X excess 
ATP, and 2X excess non-biotinylated CK2 peptide (sub). The gels are representative of 
three independent trials (Appendix, Figure A2.4). 
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signal around ~41kDa where cellular PKA is expected. Therefore, 2 hours and 2 mM N- 
biotin kemptide was selected.  
Figure 2.9: Optimization of K-CLASP crosslinking with HeLa cell lysates.  HeLa cell 
lysates were pre-incubated with ATP in kinase buffer to activate endogenous PKA.  
Then, lysates were incubated with the indicated amounts of biotinylated kemptide (B-
kem: 1, 1.5, or 2 mM) and ATP-ArN3 (4 mM) under UV light for 1 hour (lanes 1-4), 1.5 
hours (lane 5), or 2 hours (lanes 6-8) at 31°C.  Reaction products were separated by 
SDS-PAGE, before visualization of biotinylated proteins using streptavidin-Cy5 (SA-Cy5) 
or total proteins with Sypro Ruby stain.  The band at the size of PKA (~41 kDa) is 
indicated with an arrow.  The molecular weight marking is shown on the far left side of 
the image, with bands corresponding to the following molecular weights: 170, 130, 95, 
72, 55, 43, 34, and 26 kDa. 
Sypro®Ruby 
SA-CY5 
PKA 
 
 1 2 3 4 5 6 7 8 
B-kem (mM) 1.5 1.0 1.5 2.0 1.5 1.0 1.5 2.0 
ATP-ArN3 (4 mM) - + + + + + + + 
Time (hours) 1 1 1 1 1.5 2 2 2 
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With the optimized conditions, in vitro crosslinking reactions were carried out with 
HeLa lysates and N-biotin kemptide. After reaction, biotinylation was visualized by gel 
methods. A biotinylated band at the size of the PKA catalytic subunit (~41kDa) was 
observed (Figure 2.10, lane 2, see arrow). In addition to PKA, many other proteins were 
also biotinylated (Figure 2.10, lane 2), consistent with possible diffusion of N-biotin 
kemptide away from the kinase after photocrosslinker transfer (Figure 2.4b).  The biotin 
signal, including that for PKA, was lost in the absence of ATP-ArN3 (Figure 2.10, lane 1). 
Reduced biotinylation was also observed with N-biotin mutant kemptide (Figure 2.10, lane 
3) or in the presence of excess non-biotinylated kemptide (Figure 2.10, lane 4) or the 
kinase inhibitor staurosporine (Figure 2.10, lane 5). These results suggest that peptide 
crosslinking is kinase-dependent and phosphosite-specific in complex mixtures, such as 
lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: N-biotin kemptide crosslinking with recombinant PKA and lysates. N-biotin 
kemptide crosslinking with ATP-ArN3 in HeLa lysates. After reaction, samples were 
separated by SDS-PAGE, stained with SA-Cy5 (top) or probed with a PKA antibody 
(anti-PKA, bottom).  The gels are representative of three independent trials (Appendix, 
Figure A2.5). 
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2.3.4 K-CLASP with kemptide and lysates  
To perform a full K-CLASP experiment, crosslinked complexes in lysates were 
purified using streptavidin resin and analyzed by tandem mass spectrometry (Figure 
A.2.6). Crosslinked samples from N-biotin mutant kemptide were used as the negative 
control to remove nonspecific background crosslinking. Compared to the mutant samples, 
324 proteins were enriched in N-biotin kemptide crosslinked samples (Table A2.1). Out 
of the 324 proteins, only 3 were protein kinases (Table 2.1). Importantly, the known 
kemptide kinase PKA (alpha catalytic subunit PRKACA) was one of the three identified 
kinases. In addition to PKA, two other kinases; CHEK1 and MAP2K7, and many non-
kinase proteins were also observed in K-CLASP. 
Gene names 
Trial 1 Fold 
enrichment  
Trial 2 Fold 
enrichment  
Trial 3 Fold 
enrichment  
MAP2K7 ∞ 0 ∞ 
CHEK1 ∞ 0.1 ∞ 
PRKACA (PKA) 2.6 1.5 4.9 
a Protein kinases observed in K-CLASP.  The fold enrichment for each trial is shown. Fold enrichment 
was calculated by dividing the peptide intensity observed for wild type crosslinking by that observed for the 
mutant peptide crosslinking. Infinity (∞) signifies that no peptides were observed in Mut samples, making 
an average ratio calculation impossible.   
  To rule out the possibility that K-CLASP is preferentially pulling down high 
abundant proteins, we analyzed the abundance of the K-CLASP hits using previously 
published values.65 A range of abundance was observed among the K-CLASP hits 
(Figure 2.11), indicating that K-CLASP is not biased towards highly expressed proteins. 
Given that K-CLASP can also identify proteins associated with the kinase during 
crosslinking event, the many non-kinase proteins and the two other kinases observed 
could be either direct or indirect interactors of PKA. In this scenario, diffusion of N-biotin 
kemptide after PKA-catalyzed photocrosslinker labeling (Figure 2.4b) may result in the 
Table 2.1: Kinases enriched in K-CLASPa 
aaaastudy 
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biotinylation of the nearby proteins of PKA. To validate that CHEK1, MAP2K7, and the 
other proteins were biotinylated due to their proximity to PKA, we performed an 
interactome analysis.  For the interactome analysis, protein-protein interactions among 
the 324 K-CLASP enriched proteins were determined using the GeneMANIA66 application 
in Cytoscape. In addition, PKA, CHEK1 and MAP2K7 substrates among the enriched 
proteins were identified using Phosphosite Plus and KinaseNET.67  The known substrates 
and interacting proteins in the K-CLASP hit list were then graphically depicted as an 
interactome map using Cytoscape (Figure 2.12).68 
   The interactome analysis confirmed that known PKA interacting proteins (Figure 
2.11, dark blue circles) and substrates of PKA (Figure 2.12, light blue circles) were among 
the 324 K-CLASP hits. Beyond direct interacting proteins and substrates, many proteins 
Figure 2.11:  Abundance values of the 324 K-CLASP hits.  Previously reported abundance 
levels of the K-CLASP hits in HeLa cells were plotted using Excel.  K-CLASP identified 
proteins with a range of abundances (lowest 0.01 ppm and highest 403 ppm), which 
spanned the 0.01 to 10,000 possible range of all proteins.  The presence of low abundance 
proteins among the K-CLASP hits documents that abundance is not the primary parameter 
for selection.   
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that interact indirectly with PKA through complexes containing substrates or binding 
partners were observed (Figure 2.12, green and orange circles). When all direct and 
Figure 2.12:  Kinase hits and interactome analysis of the PKA K-CLASP study. All 
interacting proteins and PKA substrates (60% of K-CLASP hits) were mapped using 
Cytoscape. The blue inner circles represent known PKA substrates (light) or PKA binding 
proteins (dark). Orange circles represent the other two kinases observed. Green circles 
represent indirect interacting proteins of PKA. Green hexagons represent indirect proteins 
of PKA that are also substrates of CHEK1. Green lines show direct interactions with PKA. 
Grey lines indicate interactions among the enriched proteins. Blue lines show the 
interactions of CHEK1 and MAP2K7. Line thickness and length were adjusted arbitrary to 
improve clarity.   
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indirect interactors were considered, 60% of the K-CLASP hits were accounted for in the 
PKA interactome.  The presence of direct and indirect PKA interacting proteins among 
the K-CLASP enriched hits is consistent with diffusion of N-biotin kemptide away from 
PKA after labeling (Figure 2.4b), resulting in the crosslinking and biotinylation of proteins 
located in close proximity to PKA. 
Importantly, the interactome analysis showed that CHEK1 and MAP2K7 (Figure 
2.12, orange circles) interact indirectly with PKA through common interacting partners 
(Figure 2.12 see blue lines). Therefore, CHEK1 and MAP2K7 biotinylation was likely due 
to their proximity to PKA, rather than by direct kinase-catalyzed crosslinking. In 
agreement, while several direct interacting proteins of PKA (Figure 2.13A, dark blue and 
light blue circles, green lines) were observed among the K-CLASP hits, only few direct 
interacting proteins were identified for CHEK1 (Figure 2.13B) and MAP2K7 (Figure 
2.13C). The lack of directly associated proteins of CHEK1 and MAP2K7 among K-CLASP 
hits is consistent with CHEK1 and MAP2K7 being biotinylated by peptide diffusion rather 
than by a direct kinase labeling.  Thus, the interactome analysis revealed false positive 
kinases. In addition to PKA, kemptide is phosphorylated by cyclic GMP-dependent protein 
kinase 64 and RPS6KA1 69 in vitro, and predicted to be phosphorylated by AKT and protein 
kinase C based on consensus sequence.70 However, none of these kinases were 
identified by K-CLASP. Thus, K-CLASP identified PKA as the main kinase that 
phosphorylates kemptide in lysates.  Given the wide use of kemptide in PKA studies,71 
these results reinforce that PKA is the predominant kinase for kemptide.  
 
 
40 
 
 
 
In addition to eliminating false positive hits, the interactome analysis revealed 
several cellular complexes associated with PKA under the conditions of the experiment. 
For example, PKA is known to phosphorylate several proteasome subunits.72  In 
agreement, K-CLASP identified several proteins belonging to the proteasome core 
complex (Figure 2.14a).  Additionally, many members of the ribosome complex (Figure 
2.14b) were also identified, consistent with reports that PKA regulates translation in 
response to starvation. 73 Further, PKA is known to regulate the stability of the SMN 
complex which plays a role in the assembly of snRNPs (small nuclear Ribo Nucleo 
Proteins).74 Interestingly, K-CLASP also identified several members of the SMN complex 
A. B. 
C. 
Figure 2.13:  Direct interacting proteins of the kinases observed in K-CLASP. (A) Direct 
interacting proteins of PKA (PRKACA, yellow); binding proteins (dark blue circles) and 
substrates (light blue circles). (B) Direct interacting proteins of CHEK1. No substrates 
of CHEK1 were observed. The three CHEK1 binding proteins are indirect interacting 
proteins of PKA (hence green colored). (C) Direct interacting proteins of MAP2K7. No 
substrates of MAP2K7 were observed. The only binding protein of MAP2K7 was a 
known substrate of PKA (hence light blue colored). The less number of direct interacting 
proteins observed for CHEK1 and MAP2K7 suggests that CHEK1 and MAP2K7 were 
identified by K-CLASP due to their proximity to PKA and not by a kinase-catalyzed 
crosslinking.  
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(Figure 2.14c). While K-CLASP is primarily a tool for phosphosite-specific identification of 
kinases, these results demonstrate that cellular complexes containing the kinase can also 
be uncovered.  
2.4 K-CLASP to uncover the kinase(s) that phosphorylate Miz1 protein 
The proof-of-concept study with PKA and kemptide established K-CLASP as a 
useful tool for both phosphosite specific kinase identification and the discovery of kinase 
associated proteins.  Next, in a collaboration project with Dr.Jing Liu at Northwestern, K-
CLASP was used to uncover the kinase(s) responsible for the phosphorylation of the 
protein called Miz1.  K-CLASP identified several kinases as potential enzymes that 
phosphorylate Miz1. In addition, many other proteins were also observed that could be 
associated proteins of the kinase.  
2.4.1 Miz1 protein 
Miz1, also known as ZBTB17, is a transcription factor that is involved in important 
cellular functions, such as cell division, differentiation and embryonic development. 
RPL32 
RPL37A 
RPS12 
RPL19 RPS29 
GEMIN6 
GEMIN5 GEMIN2 
PSMB7 
PSMB1 
PSMB5 
PSMB2 
P SMB6 
PSMA4 
PSMB8 
P SMB 4 
a b c Figure 2.14:  Protein complexes identified by K-CLASP. (a) Proteins belonging to the 
proteasome core identified by K-CLASP. (b) Proteins belonging to the ribosome complex 
identified by K-CLASP. (c) Proteins belonging to the SMN complex identified by K-
CLASP. Green color circles indicate indirect interacting proteins of PKA and blue color 
circles indicate direct interacting proteins of PKA.  
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Recently there have been reports that Miz1 is also involved in the attenuation of 
inflammation induced by TNF (tumor necrosis factor).75  Specifically, Miz1 has been 
shown to bind the promoter of the inflammatory amplifier C/EBPδ during the late phase 
of TNF stimulation. Bound Miz1 represses the transcription of C/EBPδ by both recruiting 
HDAC1 and blocking the binding of the transcription factor NF-kB. The suppression of 
C/EBPδ resolves inflammation and prevents the tissue damage that can occur if 
inflammation is not regulated. Phosphorylation of Miz1 at Ser178 during TNF treatment 
has been shown to be essential for Miz1’s role in inflammation regulation.76 However, the 
particular kinase that phosphorylates Miz1 at Ser178 remains unknown, making 
elucidation of the signaling cascade that leads to the resolving inflammation difficult. In 
collaboration with Liu lab, we carried out K-CLASP to identify the kinase that 
phosphorylates Miz1 at Ser178 during TNF treatment.  
2.4.2 K-CLASP with Miz1 protein  
To carry out K-CLASP with Miz1, a biotinylated peptide carrying the Miz1 Ser178 
phosphosite (biotin-GGQAESASSGAEQTEK) was synthesized. Then crosslinking 
reactions were carried out with the N-biotinylated Miz1 peptide with MEF (mouse 
embryonic fibroblast) lysates derived from cells treated with or without TNF induction. A 
control crosslinking reaction was also carried out with a mutant variant where S178 was 
mutated to Ala (biotin-GGQAESASAGAEQTEK). The crosslinked samples were then 
purified by streptavidin resin and analyzed by LC-MS/MS (Figure A.2.7). 
A total of 12 kinases were reproducibly observed in two independent replicates 
(Table 2.2). Out of these, only five were enriched in wild type peptide crosslinked samples 
from TNF treated lysates compared to both the mutant peptide crosslinked sample and 
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TNF untreated samples in both trials (Table 2.2, green colored rows). Among the five hit 
kinases, SLK was the best hit based on the enrichment fold values. In addition, when both 
trials were considered, ILK, CDK1 and PBK also showed appreciable fold enrichment in 
the wild type crosslinked sample from TNF treated lysates. The fold enrichment values 
for PAK2, however, were not significant especially in the first trial (Table 2.2). 
Nevertheless, PAK2 was still kept in the list of hit kinases. 
Table 2.2: Kinases seen in Miz1 peptide K-CLASP studya 
Kinase 
Trial 1 Fold 
Enrichment 
Trial 2 Fold 
Enrichment 
Fold enrichment 
compared to No TNF 
control (Trial 1) 
SLK ∞ 7.4 2.9 
ILK 10.4 2.7 5.5 
CDK1 2.0 2.2 10.9 
PBK 1.5 2.0 3.4 
PAK2 1.1 3.8 4.1 
MAP2K3 0.3 ∞ ∞ 
SRPK1 ∞ 0.9 ∞ 
CDK4 0.7 4.8 18.9 
MAPK1 4.2 0.0 1.0 
MAP2K2 0.8 2.2 0.3 
CAMK2D ∞ 1.0 0.6 
MAPK14 0.0 0.0 0.0 
aTrial 1 and Trial 2 fold changes were calculated by dividing the peptide intensity observed in the N-
biotin Miz1 peptide crosslinking in TNF treated sample by the peptide intensity observed for the N-biotin 
mutant Miz1 peptide crosslinking in TNF treated sample. Fold change with no TNF was calculated by 
dividing the peptide intensity observed in the N-biotin Miz1 peptide crosslinking in TNF treated sample by 
the peptide intensity observed for the N-biotin Miz1 peptide crosslinking in TNF untreated sample. Infinity 
(∞) signifies that no peptides were observed in either the N-biotin mutant Miz1 peptide crosslinking sample 
or the N-biotin Miz1 peptide crosslinking in TNF untreated lysate sample. The K-CLASP hit kinases are 
green colored. 
At a fold enrichment threshold of 2 or greater for both trials, 340 proteins were 
enriched in wild type peptide crosslinked samples from TNF-treated lysates compared to 
both the mutant peptide crosslinked sample and the TNF-untreated sample. (Table A2.2). 
In order to identify the most likely in cellulo kinase out of the five candidate kinases and 
to discover proteins associated with the potential kinase, we carried out an interactome 
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analysis using GeneMania application in Cytoscape.  The substrates of ILK, SLK, CDK1, 
PAK2 and PBK were identified from Phosphosite Plus and added manually onto the 
Cytoscape map.  
From the K-CLASP hits, 86% could be accounted for in the interactome.  Except 
for SLK, all other kinases had a number of direct interacting proteins and substrates 
among the K-CLASP hits (Table 2.3, Figure 2.15).  Out of all kinases, ILK had the highest 
number of direct interacting proteins, followed by CDK1 (Table 2.3, Figure 2.15). 
However, when the percentage of interacting proteins observed in K-CLASP was 
considered, PBK had the highest percentage (Table 2.3).  Therefore, secondary 
validation is necessary to confirm the kinase that phosphorylates S178 of the Miz1 
protein. Although SLK was the best hit when enrichment fold values were considered, 
SLK did not have any known interacting proteins or substrates among K-CLASP hits. This 
may be due to the fact that SLK is not a well characterized kinase and has only a few 
known substrates and interacting proteins (Table 2.3). In addition, the Miz1 peptide used 
for K-CLASP contained S175 that has been reported as a phosphosite.67 Therefore, it is 
possible that the kinases observed in our study are responsible for the phosphorylation 
of S175 as well. Given that the mutated peptide with S178A was used as the negative 
Table 2.3: Kinase direct interacting proteins observed by K-CLASP study with Miz1 
peptidea 
aTotal number of known directly interacting proteins was obtained from the BioGrid database. 
Percentage of interacting proteins were calculated by dividing the number of directly interacting proteins 
observed in the K-CLASP study by the total number of known directly interacting proteins.  
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control in the K-CLASP study, if a K-CLASP hit kinase is confirmed to be responsible for 
S175 phosphorylation, it would suggest that S178 phosphorylation might be a pre-
requisite for S175 phosphorylation.  
There were several Miz1 interacting proteins among the K-CLASP hits (Figure 
2.16). Under TNF treatment, the kinase that phosphorylates Miz1 may associate with 
Figure 2.15:  Direct interacting proteins and substrates of the kinases observed in K-
CLASP. The directly interacting proteins of each kinase (yellow); binding proteins (dark 
blue) and substrates (light blue). SLK did not have any known interacting proteins among 
the K-CLASP hits. TUBB (dark pink) interacts with all four kinases. ACACA, RPS25 and 
RPL36A (dark purple) interact with both PBK and ILK. YWHAZ, YWHAG and YWHAB 
(light pink) interact with both PAK2 and ILK.  MCM3, SFN and GDI2 (brick red) interact 
with both PAK2 and CDK1. EFTUD2, SSR1 and DYNC1H1 (light purple) interact with 
both CDK1 and ILK.   
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proteins that facilitate the delivery of Miz1 to the kinase, which explains the presence of 
Miz1 interacting partners among the K-CLASP hits. Out of the common interacting 
partners, the 14-3-3 adapter protein YWHAQ interacts directly with both ILK and Miz1. 
YWHAQ interacts with several other K-CLASP proteins, which in turn interact with other 
hit kinases (Figure 2.16).  The common interacting partners of Miz1 and the kinases 
observed may provide clues to what other proteins are playing a role in Miz1 
phosphorylation under TNF treatment.  Interestingly, the Miz1 direct interacting protein 
HCF1 (Figure 2.16, yellow) interacts with the K-CLASP protein RELA (NF-κB) which plays 
a major role as a transcription factor in TNF induced inflammatory response.77 HCFC1 
may represent a scaffold between NF- κB and Miz1 during inflammation.  
To see if there are any protein complexes among the K-CLASP hits, we used the 
MCODE application78 in cytoscape. MCODE identifies clusters of proteins based on the 
number of interactions. MCODE detected several protein clusters among the K-CLASP 
hits (Figure 2.17).  Proteins belonging to the proteasome complex were one of the clusters 
identified (Figure 2.16A). TNF treatment is known to downregulate proteasome activity in 
cells.21 The MCODE analysis suggests that the Miz1 kinase may also have a role in 
regulating the proteasome during TNF treatment. In addition, another cluster containing 
several components of the COP9 signalosome (COPS3, COPS7A and GPS) and DDB1 
was detected (Figure 2.17B). DDB1 is known to be associated with the COP9 
signalosome.79 The result suggests that the COP9 signalosome may play a role in TNF 
induced inflammation through the Miz1 kinase. Thirdly, MCODE also identified a cluster 
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of proteins including members of the coatomer complex (COPA, COPB1, COPB2 Figure 
2.17C), which coat Golgi-derived vesicle proteins to facilitate the protein transport from 
the ER (endoplasmic reticulum) to the trans-Golgi network.80 Among the other proteins in 
Figure 2.16:  Interacting proteins of Miz1 (ZBTB17). Yellow color represents the directly 
interacting proteins of Miz1. The direct interacting proteins of the Miz1 interacting proteins 
are also shown. Miz1 direct interacting protein YWHAQ interacts directly with ILK. Some 
of the other YWHAQ interacting proteins also interact with PAK2, CDK1 and PBK. The 
common interacting partners shared with Miz1 and the K-CLASP kinases provides hints 
to what other proteins may  be playing a role in Miz1 phosphorylation under TNF 
induction. Blue color represents direct interacting proteins of K-CLASP kinases (See 
Figure 2.14). Light blue color represents substrates of K-CLASP kinases. Brick red, light 
pink, light purple and dark pink are common interacting proteins of K-CLASP kinases (see 
Figure 2.14). The rest of the proteins are green colored. 
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this coatomer cluster, NSF is an ATPase involved in vesicle mediated transport.81 The 
rest of the members in the cluster have diverse reported functions; ACACA and IDH3G 
are both metabolic enzymes with carboxylase and dehydrogenase activities respectively, 
while DDX6 is an RNA helicase. CCT6A is a chaperone protein.82 Nevertheless, the 
MCODE result hints that the Miz1 kinase may associate with proteins in the cellular 
transport machinery during TNF treatment.  The fourth and fifth complexes recognized by 
MCODE (Figure 2.17 D, E) also have proteins with diverse reported functions ranging 
from RNA splicing to nuclear transport of proteins. Further analysis of the MCODE 
complexes may reveal additional roles of the Miz1 kinase in downstream functions upon 
TNF treatment.    
Figure 2.17:  Clusters of proteins (A-E) identified by MCODE among the K-CLASP hits. 
Blue color represents direct interacting proteins of K-CLASP kinases (See Figure 2.11). 
Light blue color represents substrates of K-CLASP kinases. Dark purple represents 
common interacting proteins of K-CLASP kinases (see Figure 2.11). The rest of the 
proteins are green colored.  
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Overall, the K-CLASP study with the Miz1 peptide identified several kinases as 
candidates for S178 phosphorylation. Out of those, ILK is the best candidate given its 
many interacting partners observed among the K-CLASP hits. However, the K-CLASP 
study may also have purified a S175 kinase since S175 is a known phosphosite. 
Additionally, the interactome analysis revealed many other proteins and protein 
complexes that may link the Miz1 kinase with other cellular pathways. First the TNF-
sensitive Miz1 kinase(s) has to be confirmed to use the additional information on the 
associated proteins provided by the K-CLASP study. Therefore validation studies are 
necessary to confirm the role of the identified kinases in Miz1 phosphorylation upon 
stimulation by TNF. These secondary validation studies are being carried out by our 
collaborator Dr. Jing Liu.  
2.5 Conclusions and Future Directions 
In conclusion, K-CLASP was developed as a discovery tool to identify the in cellulo 
kinase of a given phosphosite. In the first study with the well-known kinase-substrate pair, 
PKA and kemptide, K-CLASP identified PKA as the predominant cellular kinase of 
kemptide from a complex mixture of other proteins and kinases. In addition, interactome 
analysis of K-CLASP hits confirmed that peptide diffusion during crosslinking leads to the 
biotinylation and the subsequent identification of proteins close to the kinase. The 
interactome analysis identified several cellular complexes containing PKA and ruled out 
false positives. Identification of proteins belonging to proteasome core, ribosome and the 
SMN complex suggests that PKA was associated with the mentioned complexes during 
crosslinking.  The discovery of the said complexes among the K-CLASP hits reaffirms the 
already known role of PKA on proteasome, ribosome, and SMN complexes. Overall, the 
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proof-of-concept study with PKA provided evidence for the utility of K-CALSP, while also 
setting parameters for identification with phosphosites without a known kinase. 
 In the second study, K-CLASP identified SLK, ILK, CDK1, PAK2 and PBK as 
potential kinases that phosphorylate S178 of Miz1 in response to TNF treatment. 
Interactome analysis on the K-CLASP hits revealed many other proteins and protein 
complexes that may associate with the Miz1 phosphorylating kinase during TNF 
treatment. Once the secondary validation studies confirm which kinase(s) carries out Miz1 
phosphorylation, the information on the associated proteins uncovered by K-CLASP can 
be used to further detangle the complex cellular pathways involved in TNF induced 
inflammation. 
In the present studies, crosslinking with a mutant peptide lacking the phosphosite 
was used as the negative control in K-CLASP. However, in vitro studies with PKA and 
mutant kemptide showed that the labeling by the mutant kemptide still requires binding to 
PKA (Figure 2.7).  As a result, the inclusion of mutant peptide as the negative control may 
limit the discovery of associated proteins, although the mutant is a good control for the 
identification of hit kinases. As a solution, in future experiments, crosslinking with a 
scrambled peptide will be included to better reflect the background. While the mutant 
peptide control can be used to uncover the kinase(s), the scrambled peptide control may 
help identify the associated proteins.  
In summary, the two studies show that K-CLASP is a simple, yet powerful, method 
to probe the activity of a specific phosphosite.  Importantly, K-CLASP only requires a 
biotinylated peptide containing a known phosphosite and cell lysate where 
phosphorylation of that specific site is observed.  Given the importance of studying the 
51 
 
 
 
many phosphorylation events in a cell, K-CLASP provides an enabling technology to 
understand the intricate regulatory networks governing cellular events.  
2.6 Experimental Methods 
2.6.1. Synthesis of ATP-ArN3 
The synthesis and characterization of ATP-ArN3 has been previously 
described.48aATP-ArN3 was dissolved in HEPES (1 mM, pH 7.4) and aliquoted (5 µL 
each). Aliquots were stored at -800C until use.  
2.6.2. Peptide Synthesis and Purification 
N-biotin kemptide (biotin-GGGGLRRASLG, the phosphorylation site is 
underlined), N-biotin mutant kemptide (biotin-GGGGLRRAALG, mutated site is 
underlined), non-biotinylated kemptide (GGGGLRRASLG), scrambled N-biotin kemptide 
(biotin-LSGARGLGGRG), N-biotin CK2 substrate peptide (biotin-RRREEETEEE, the 
phosphorylation site is underlined), non-biotinylated CK2 substrate peptide 
(RRREEETEEE), N-biotin Miz1 peptide (biotin-GGQAESASSGAEQTEK, the 
phosphorylation site is underlined) and N-biotin mutant Miz1 peptide (biotin-
GGQAESASAGAEQTEK, mutated site is underlined) were synthesized as previously 
described.83 Specifically, Wang resin conjugated, Fmoc-protected C-terminal amino acid 
from each peptide (0.15 mmoles) and Fmoc-protected amino acids (0.45 mmoles) were 
used. For each coupling step, hydroxylbenzyltriazole (HOBt) (0.9 mmoles) and N,N'-
Diisopropylcarbodiimide (DIPCDI, 0.6 mmoles) were used in DMF (5 mL). After final 
deprotection, N-biotinylation was carried out by adding D-biotin (0.75 mmoles), O-
(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU) (0.9 mmoles), 
hydroxylbenzyltriazole (HOBt) (0.9 mmoles) and N,N-Diisopropylethylamine (DIPEA) (1 
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mmoles) in a 1:1 mixture of DMSO and DMF (5 mL). The biotinylation reaction was 
incubated overnight at room temperature with shaking on a Wrist-action® shaker (Burrell). 
The biotinylation step was omitted to generate non-biotinylated kemptide and CK2 
peptide. The product peptides were then cleaved off the resin using a trifluoroacetic acid: 
phenol: thioanisole: water: 1,2-ethanedithiol (82.5:5:5:5:2.5) cleavage solution (5 mL) for 
two hours. The cleaved product was precipitated in cold ether, washed three times with 
cold ether, and then dried under Argon gas. The peptides were purified by reverse phase 
chromatography using a C18 column (YMC America: 250x10mml.D, S-4µM, 8nM) on a 
Waters 1525 binary HPLC pump. The flow rate was 3mL/min and the peptides were 
detected at 214 nm. N-biotin kemptide, N-biotin mutant kemptide and scrambled N-biotin 
kemptide were purified by an elution gradient that started with 95% Buffer A (99.9% water 
with 0.1% trifluoroacetic acid) in Buffer B (acetonitrile in 0.085% trifluoroacetic acid) and 
decreased to 83% Buffer A over 11 minutes, then to 81.5% Buffer A over 5 minutes, and 
finally to 80.6% Buffer A over 9 minutes. When characterized by MALDI-TOF, the purified 
N-biotin kemptide showed a [M+H]+ of 1226.68 m/z ([M+H]+ calculated for C50H88N19O15S 
=1226.64, Figure A2.1.1B), while the purified N-biotin mutant kemptide showed a [M+H]+ 
of 1210.76 ([M+H]+ calculated for C50H88N19O14S = 1210.65, Figure A2.1.2A) and the 
purified scrambled N-biotin kemptide showed a [M+H]+ of 1226.50 m/z ([M+H]+ calculated 
for C50H88N19O15S =1226.64, Figure A2.1.4B). The non-biotinylated kemptide was purified 
using an elution gradient that started with 95% Buffer A in Buffer B and ended with 75% 
Buffer A over 16 minutes. The purified non-biotinylated kemptide showed a [M+H]+ of 
1000.85 by MALDI-TOF ([M+H]+  calculated for C40H74N17O13= 1000.57, Figure A2.1.3B). 
The synthesis, purification and the MALDI-TOF characterization of the scrambled N-biotin 
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kemptide were carried out by N.Chinthaka. N-biotin CK2 substrate peptide was purified 
using an elution gradient that started with 86.7% Buffer A in Buffer B and ended with 70% 
Buffer A in 10 minutes. Non-biotinylated CK2 substrate peptide was purified using an 
elution gradient that started with 95% Buffer A in Buffer B and ended with 77.5% Buffer 
A in 14 minutes. The purified N-biotin CK2 substrate peptide showed a [M+H]+ of 1588.14 
m/z ([M+H]+ calculated for C62H101N21O26S =1588.69, Figure A2.1.5B). The purified non-
biotin CK2 substrate peptide showed a [M+H]+ of 1362.36 m/z ([M+H]+ calculated for 
C52H87N19O24 =1362.62, Figure A2.1.6B). The synthesis, purification and the 
characterization of N-biotin CK2 substrate peptide and non-biotin CK2 substrate peptide 
were performed by T.Faner. N-biotin Miz1 peptide was purified using an elution gradient 
that started with 95% Buffer A in Buffer B and ended with 75% Buffer A over 22 minutes.  
The purified N-biotin Miz1 peptide showed a [M+H]+ of 1762.56 by MALDI-TOF ([M+H]+  
calculated for C69H111N21O31S= 1762.9, FigureA2.1.7B).  N-biotin mutant Miz1 peptide 
was purified by using an elution gradient starting from 95% Buffer A in Buffer B and ending 
in 75% Buffer A over 16 minutes. The purified N-biotin mutant Miz1 showed a [M+H]+ of 
1747.27 by MALDI-TOF ([M+H]+  calculated for C69H111N21O30S = 1746.98, Figure 
A2.1.8B). The purity of each peptide was assessed by reinjection (50 µg of each purified 
peptide) on a C18 column (YMC America: J'Sphere H80, 80Å, 4um, 250x4.6mm) and 
separation by reverse phase HPLC using a flow rate was 1 mL/min.  For non-biotinylated 
CK2 substrate peptide, an isocratic elution at 86% of Buffer A was used for reinjection. 
For all other peptides, reinjection was carried out under same elution conditions used for 
purification (FiguresA2.1.1A-A2.1.8A).  
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2.6.3. In vitro crosslinking reaction with recombinant PKA  
Crosslinking reactions contained N-biotin kemptide (4 mM), ATP-ArN3 (4 mM) and 
recombinant PKA (150 units/µL, New England BioLabs) in kinase buffer (25 mM HEPES 
at pH 7.5, 50 mM KCl and 10 mM MgCl2). The final reaction volume was 25μL. 
Photocrosslinking was performed by irradiating the reaction mixtures at 365 nm for 2 
hours at 31°C with shaking at 300rpm.  Control reactions were performed without ATP-
ArN3 or with N-biotin mutant kemptide (4 mM) in the place of N-biotin kemptide, ATP 
(4mM) in the place of ATP-ArN3, excess ATP (16 mM) in the presence of ATP-ArN3 (4 
mM), excess non-biotinylated kemptide (8 mM) in the presence of N-biotin kemptide (4 
mM), N-biotin scrambled peptide (4mM) in place of N-biotin kemptide, and heat 
inactivated PKA (95°C, 30 minutes) in place of active PKA enzyme. After reaction, 
samples were boiled at 95°C for 1 minute in 1X Laemmli sample buffer (60 mM Tris-HCl 
pH 6.8, 2% SDS, 10% glycerol, 0.0005% bromophenol blue, 2% beta-mercaptoethanol) 
and separated by 10% SDS-PAGE (section 2.6.4). For visualization of biotinylation, 
proteins were first transferred onto a onto a PVDF membrane (section 2.6.5) and then 
probed with Streptavdin-Cy5 (Life Technologies, section 2.6.7).  Total proteins were 
observed with SYPRO® Ruby stain (Thermo Fisher, section 2.6.8). After quantification of 
the biotin signal using ImageQuant (GE Healthcare), percent biotinylation signal intensity 
was determined by calculating the ratio of band intensity for each reaction compared to 
the band intensity with N-biotin kemptide and ATP-ArN3 (set to 100%), and multiplying by 
100.  Replicate trials used to calculate the mean and standard error of percent signal 
intensity are shown in A2.2. 
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2.6.4. SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
SDS-PAGE gels were produced by first preparing a lower, separating layer and 
then an upper, stacking layer as previously described (Molecular cloning, Appendix 8.40-
8.45).84 A 10% separating layer was prepared by mixing water (4.788 mL), Tris (2.5 mL, 
1.5M, pH 8.8), and 40% w/v 37:1 acrylamide:bisacrylamide (2.513 mL, OmniPur® EMD 
Milipore). The mixture was then de-gassed under vacuum for about 10 minutes. Next, 
SDS (100 µL from 10% w/v SDS in water, Fisher Scientific), and Ammonium persulfate 
(APS, 100 µL from 10% w/v APS in water, Fisher Scientific) were added. Finally, 
tetramethylethylenediamine (TEMED, 4 µL, Acros Organics) was added to initialize 
polymerization.  The mixture was then immediately poured onto a gel set up and was 
overlayed with methanol (100%). The separating layer was then allowed to polymerize 
for at least 2 hours at room temperature. After polymerization, methanol was removed 
and the top of the gel was briefly washed with deionized water. A stacking layer was then 
prepared by mixing water (2.913 mL), Tris (0.5 mL, 1 M, pH 6.8) and 40% w/v 37:1 
acrylamide:bisacrylamide (0.488 mL). The mixture was de-gassed for 10 minutes. SDS 
(40 µL from 10% SDS in water) and APS (40 µL from 10% APS in water) were added. 
After adding TEMED (4 µL), the mixture was immediately added to the gel set up. For 
protein separation, samples were loaded onto the gel after boiling in 1X Laemmli buffer 
(section 2.6.3) along with a molecular weight marker (1 µL, EZ-run™ Prestained Rec 
Protein Ladder, Fisher). The gel was run first at 110V for 10 minutes and then at 200V for 
1 hour on a gel electrophoresis system (BioRad) in running buffer (1X, 25 mM Tris, 192 
mM glycine and 0.1% SDS).   
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2.6.5. Protein transfer onto a membrane 
After protein separation by SDS-PAGE (section 2.6.4), the gel was briefly washed 
in water (~10 mL) and then equilibrated in transfer buffer (10 mL, 1X, 25 mM Tris, 192 
mM glycine and 10% v/v methanol) for 5-10 minutes.  A PVDF membrane cut to the size 
of the gel (Immobilon-P, Milipore) was first washed with methanol (~10 mL, 100%), water 
(~10 mL) and equilibrated in transfer buffer (10 mL) for 5-10 minutes. Then the gel and 
the membrane were assembled onto a transfer apparatus (Mini-Transblot Electrophoretic 
Transfer Cell apparatus, BioRad) as described by the manufacturer. Transfer was carried 
out at 90V for 2 hours on ice in the transfer buffer.   
2.6.6. Visualization of biotin with streptavidin-Cy5 and Western blot 
After transfer (2.6.5), the membrane was rocked in non-fat dry milk (Meijer, 5% 
w/v) in 1X PBST (15 mL, phosphate buffered saline with tween, 0.1% v/v Tween-20 in 1X 
PBS buffer: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) at room 
temperature overnight. The membrane was briefly washed with 1X PBST (15 mL) and 
fresh non-fat dry milk (3-5% w/v in 1X PBST (15 mL) was added. Then streptavidin-Cy5 
(7.5 µL, 1:2000 dilution, ZyMax Grade, ThermoFisher Scientific, catalog number- 438316) 
was added in dark. The container carrying the membrane was covered in foil and rocked 
at room temperature for 1 hour. Then the milk was removed and the membrane was 
briefly washed first in 1X PBST (~20 mL) and then in 1X PBS (~ 20 mL).  The biotin signal 
was then visualized using a Typhoon imager (635 nm laser, 500 PMT, 50 µm pixel size, 
Typhoon FLA 9500, GE Healthcare) and ImageQuant (GE Healthcare).   
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2.6.7. Sypro®Ruby staining for total protein visualization  
After protein separation (section 2.6.5), the gel was fixed by rocking at room 
temperature in a  fixing solution (~30 mL, 50% methanol and 7% acetic acid in water) for 
1 ½- 2 hours. Then the gel was rocked in Sypro®Ruby stain (~ 30 mL, BioRad) at room 
temperature for overnight. The Sypro®Ruby stain was removed the next day and the gel 
was destained by rocking in a destaining solution (~ 30 mL, 10% methanol and 7% acetic 
acid in water) at room temperature for 30 minutes. Then the gel was washed two times in 
water (~30 mL) by rocking at room temperature for 5 minutes each time. Next the 
Sypro®Ruby signal was visualized on Typhoon imager (532 nm, 500 PMT, 100 µm pixel) 
and ImageQuant.  
2.6.8. In vitro crosslinking with PKA after pre-incubation of N-biotin peptide and 
ATP-ArN3 
N-biotin kemptide, N-biotin mutant kemptide, or scrambled N-biotin peptide (4 mM) 
was pre-incubated with ATP-ArN3 (4 mM) in kinase buffer for 15 minutes at 31°C under 
UV irradiation at 365nM with shaking at 300rpm. Then recombinant PKA (150 units/µL) 
was added and the reaction mixtures were further irradiated at 365 nm for 2 hours at 31°C 
with shaking at 300rpm. The final reaction volume was 25 µL. As a control, crosslinking 
reactions were performed with N-biotin kemptide (4 mM) without pre-incubation. After the 
reaction, samples were boiled at 95°C for 1 minute in Laemmli sample buffer and 
separated by 10% SDS-PAGE (section 2.6.4). Total proteins were observed with 
SYPRO® Ruby stain (section 2.6.7). Biotinylation was visualized with Streptavdin-Cy5 
(section 2.6.6).  A Typhoon imager was used for gel band visualization.   
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2.6.9. In vitro crosslinking reaction with recombinant CK2 
Crosslinking reactions were carried out with N-biotin CK2 substrate peptide (0.76 
mM), ATP-ArN3 (2 mM), and recombinant CK2 (20 units/µL, New England BioLabs) in 
kinase buffer. The final reaction volume was 25µL. Photocrosslinking was performed by 
irradiating the reaction mixtures at 365nm for 2 hours at 31°C with shaking at 300rpm. 
Control reactions were performed with ATP (2 mM) in the place of ATP-ArN3, excess ATP 
(8 mM) in the presence of ATP-ArN3 (2 mM), and excess non-biotinylated CK2 substrate 
peptide (1.52 mM) in the presence of N-biotin CK2 peptide (0.76 mM). After reaction, 
samples were boiled at 95°C for 1 minute in Laemmli sample buffer and separated by 
10% SDS-PAGE (section 2.6.4). Total proteins were observed with SYPRO® Ruby stain 
(section 2.6.7). Biotinylation was visualized with Streptavdin-Cy5 (section 2.6.6). A 
Typhoon imager was used to visualize the gel bands.  
2.6.10. MEF cell culture 
MEF (Mouse Embryonic Fibroblasts) cells were a gift from Dr. Jing Liu at 
Northwestern University.  MEF cells (8 X 106) were grown in DMEM media (45 mL, 
ThermoFisher, catalog number 12430104) supplemented with 10% FBS (fetal bovine 
serum, ThermoFisher, catalog number 16000044) and 1X antibiotic/antimycotic solution 
(ThermoFisher, catalog number 15240062). After 24 hours of cell growth, cells were 
serum starved overnight by placement in DMEM media with 1% FBS without 
antibiotic/antimycotic mixture (45 mL). The next day, cells were treated with TNFalpha 
(10ng/mL in DPBS, Dulbecco's Phosphate Buffered Saline, Hyclone) or without TNF 
(DPBS,) for 15 minutes at 370C in the cell incubator. Then cells were briefly washed with 
DPBS (10 mL). The cells were then treated with trypsin-EDTA (0.25%, 12 mL, 
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ThermoFisher, catalog number 25200072) for 5 minutes. Next cold DPBS (15 mL) was 
added to the cells to stop trypsin reaction.  The cells were collected into a centrifuge tube 
and spun at 1000 rpm, at 40C for 5 minutes. The supernatant was discarded and the cells 
were re-suspended in cold DPBS (2mL). The cells were again spun at 1000 rpm, at 40C 
for 5 minutes. The supernatant was discarded ad the cell pellet was either stored at -800C 
or immediately lysed.  
2.6.11. HeLa and MEF cell lysis  
HeLa cells (20 X 106) purchased from National Cell Culture Center (Biovest) were 
lysed in lysis buffer (4 mL; 25 mM HEPES at pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 
10% glycerol, and 1X protease inhibitor cocktail (GenDepot)) at 4°C for 10 minutes with 
rotation. For MEF cells (20 X 106), 250 µL of lysis buffer was used. Cell debris was 
removed by centrifugation at 13,200 rpm at 4°C for 10 minutes. The protein concentration 
was assessed by Bradford assay (Biorad) per manufacturer’s instructions. The lysates 
were aliquoted and stored at -800C or immediately used.   
2.6.12. Optimization of crosslinking reaction with HeLa cell lysates 
HeLa cell lysates (3.75 mg/mL) were initially incubated with ATP (12 mM) in kinase 
buffer for 15 minutes at room temperature to activate endogenous PKA.  Then, the lysates 
were incubated with the indicated amounts of biotinylated kemptide (B-kem: 1, 1.5, or 2 
mM) and ATP-ArN3 (4 mM) under UV light for 1 hour, 1.5 hours, or 2 hours at 31°C in a 
final reaction volume of 40 µL.  Reaction products were separated by 10% SDS-PAGE 
(section 2.6.4), before visualization of biotinylated proteins using streptavidin-Cy5 (SA-
Cy5, section 2.6.6) or total proteins with Sypro®Ruby stain (section 2.6.7).   
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2.6.13. In vitro crosslinking reaction with HeLa lysates 
Before crosslinking, HeLa lysates (3.75 mg/mL) were incubated with ATP (12 mM) 
in kinase buffer for 15 minutes at room temperature to activate endogenous PKA. Then 
ATP-ArN3 (4 mM) and N-biotin kemptide (2 mM) were added. The final reaction volume 
was 40 μL. Crosslinking reactions were performed by irradiating the reaction mixtures at 
365nm for 2 hours at 31°C with shaking at 300rpm. Control reactions were carried out 
without ATP-ArN3, with N-biotin mutant kemptide (2 mM) in place of N-biotin kemptide, or 
non-biotinylated kemptide (2 mM) in the presence of biotin-kemptide (2 mM). For the 
staurosporine control reaction, HeLa lysate was pre-incubated with staurosporine (1 mM) 
at 37°C for 1 hour before the crosslinking reaction. After the reaction, the samples were 
boiled at 95°C for 1 minute in Laemmli sample buffer and separated on 10% SDS-PAGE 
gels (section 2.6.4). Total proteins were observed with SYPRO®Ruby stain (section 
2.6.7). After transfer onto PVDF membranes, biotinylated proteins were visualized with 
Streptavdin-Cy5 (section 2.6.6), whereas PKA was observed with an antibody to PKA α 
catalytic subunit (Santa Cruz Biotechnology- catalog number sc-28315).  Gel bands were 
visualized using a Typhoon imager. 
2.6.14. K-CLASP procedure  
For the kemptide K-CLASP study, HeLa lysates (7.5 mg/mL, 450 µg) were 
incubated with ATP (12 mM) in kinase buffer at room temperature for 15 minutes to 
activate endogenous PKA. Then, kinase-catalyzed crosslinking was initiated by adding 
ATP-ArN3 (5 mM) and N-biotin kemptide (4.1 mM) in a total volume of 60 μL.  Control 
reactions were performed without ATP-ArN3 or with N-biotin mutant kemptide (4.1 mM) 
in the place of biotin-kemptide.  For the Miz1 peptide K-CLASP study, MEF lysates (6.6 
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mg/mL, 400 µg), ATP-ArN3 (5 mM) and N-biotin Miz1 peptide (1.9 mM) were used in a 
total volume of 60 µL. Control reactions were performed with N-biotin mutant Miz1 peptide 
(1.9mM) in the place of N-biotin Miz1 peptide and TNFalpha untreated MEF lysates (6.6 
mg/mL) in the place of TNFalpha treated lysate with N-biotin Miz1 peptide (1.9mM). 
Crosslinking was carried out by incubating reaction mixtures at 31°C for 2 hours with 
shaking at 300rpm under UV irradiation at 365nm.  After reaction, excess N-biotin peptide 
and endogenous biotin were removed by filtration using 3 KDa centiprep spin columns 
(Millipore).  Specifically, the sample was diluted into water (total volume 400 µL) and then 
spun at 12,300 rpm at 4 0C for 20 minutes. After spin, the samples were diluted again in 
water (total volume 400 µL) and spun again under same conditions mentioned before. 
The same procedure was repeated again. After the third spin, the filtered samples were 
collected into clean centrifuge tubes by turning the filter upside down and spinning at 2300 
rpm at 4 0C for 2 minutes. The samples were then diluted into phosphate binding buffer 
(total volume of 250μL, 0.1 M phosphate pH 7.2, 0.15 M NaCl). Streptavidin resin (250 
µL packed beads, Genscript) was washed 3 times in phosphate binding buffer. Then the 
samples were incubated with streptavidin resin for 20 minutes at room temperature with 
rotation in phosphate binding buffer.  The resin was washed ten times with phosphate 
binding buffer (250 μL) and then four times with water (250 μL). Each wash was done 
with centrifugation at 2300 rpm at room temperature for 1 minute. The proteins were 
eluted by boiling in 2% SDS in water (250 μL) for 8 minutes. The eluate was concentrated 
and excess SDS was partially removed by filtering using 3 KDa Centiprep spin columns. 
Specifically, the elution was diluted with water (final volume 400 µL) and spun at 12, 300 
rpm at room temperature for 30 minutes. Then the concentrated samples were collected 
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by spinning at 2.3 rpm at room temperature for 2 minutes as described before. The 
concentrated elution was then boiled at 95°C for 1 minute in Laemmli sample buffer and 
separated on 10% SDS-PAGE gels (section 2.6.4). For in gel digestion (2.6.15), gels were 
run halfway. Total proteins were visualized with SYPRO®Ruby stain (section 2.6.7). In 
kemptide K-CLASP study, PKA was visualized with an antibody to PKA α catalytic subunit 
(Santa Cruz Biotechnology- catalog number sc-28315,) after transfer onto PVDF 
membranes (section 2.6.5). Gel bands were visualized using a Typhoon imager.  
2.6.15. In gel digestion  
The proteins in eluate lanes from the wild type and mutant samples described in 
the procedure (section 2.5.10) were excised from the SYPRO®Ruby stained gel 
(preserved in destaining solution–section 2.6.7 for no more than two weeks at 4 0C) and 
in gel digested as previously described.85 For PKA-kemptide K-CLASP study, gels from 
three independent trials were used, whereas for Miz1 gels from two independent 
replicates were used. Specifically, gels were washed twice in deionized water (~ 30 mL). 
Then each half run, eluate lane was sliced into four gel pieces using separate ethanol 
cleaned razor blades for each lane.  Each gel piece was then cut into smaller pieces and 
transferred into 1.5 mL Eppendorf™ LoBind Microcentrifuge Tubes (Fisher Scientific). 
The gel pieces were then soaked in a 1:1 mixture of NH4HCO3 (50 mM, 150 -200 µL, 
volume required to submerge the gel pieces, freshly prepared in a 50 mL total volume) 
and acetonitrile (100%, 150-200 µL, LC-MS grade, Sigma Alrdrich) for 5 minutes at room 
temperature. The solution was removed and then NH4HCO3 (50 mM, 150-200 µL) was 
added followed by acetonitrile (100%, 150-200 µL) after 5 minutes. The gel pieces were 
then left in the solution mixture for 15 minutes at room temperature. Next, the solutions 
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were removed and acetonitrile (100%, 150-200 µL) was added. After gel pieces became 
white and shrunken, the solution was removed and the gel pieces were dried under 
vacuum. Then a solution of TCEP (tris(2-carboxyethyl)phosphine, 150-200 µL, 50 mM in 
25 mM  NH4HCO3) was added and incubated for 10 minutes at room temperature. After 
removing the solution, iodoacetamide (150-200 µL, 55 mM in 50 mM  NH4HCO3) was 
added to the gel pieces in dark. The tubes were wrapped in foil and incubated at room 
temperature for 30 minutes with shaking on a platform shaker. Next, the solution was 
removed and NH4HCO3 (50 mM, 150-200 µL) was added with acetonitrile (100%, 150-
200 µL). After 5 minutes, the solution was removed and gel pieces were soaked in 
acetonitrile (100%, 150-200 µL) until white. The solution was then pipetted out and the 
gel pieces were dried under vacuum. A fresh trypsin solution (20 µg/mL final 
concentration) was prepared by the sequential addition of HCl (100 µL, 1 mM) and then 
of NH4HCO3 (50 mM, 810 µL) and acetonitrile (90 µL of 100% to obtain a final 
concentration of 9%) to a vial of trypsin (20 µg, Sigma-Aldrich). Trypsin solution (30-50 
µL) was added to the gel pieces. Then digestion buffer (2.5 fold of the trypsin volume, 40 
mM NH4HCO3 in 9% acetonitrile in water) was added to submerge the gel pieces. After a 
brief spin at ~ 1000 rpm, the tubes containing the gel pieces were placed on a centrifuge 
tube rack and incubated at 370C wrapped in foil. After 30 minutes, the tubes were checked 
to see if the gel pieces are fully submerged. If not, more digestion buffer was added as 
needed. Then the gel pieces were incubated at 370C overnight. The next day, formic acid 
(volume required to get a final concentration of 0.1% using a 10% stock, proteomics 
grade, Proteochem) was added to the gel pieces. After brief vortex, the solution 
containing the peptides were transferred into new 0.5 mL Eppendorf™ LoBind 
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Microcentrifuge Tubes (Fisher Scientific). A solution of 0.1% formic acid in 50% 
acetonitrile (100 µL) was added to the gel pieces. The gel pieces were then sonicated at 
370C for 10 minutes to extract any remaining peptides. The solution was then transferred 
to the Lobind tubes containing the tryptic-digestion. Finally, the gel pieces were shrunk 
by adding acetonitrile (100%, 100 µL) and the acetonitrile solution carrying any more 
peptides were added to the Lobind tubes containing the tryptic-digestion. The collected 
peptides were then dried under vacuum. The dried peptides were stored at -200C until 
submission for LC-MS/MS analysis.  
2.6.16. LC-MS/MS analysis  
LC-MS/MS analysis was performed by Dr.Joseph Caruso at the Proteomics core 
facility, Wayne State University. In Digested peptides were separated by reverse phase 
chromatography (Acclaim PepMap100 C18 pre-column, Acclaim PepMapRSLC C18 
analytical column, Thermo) using an EASY nLC-1000 UHPLC system (Thermo). The 
gradient used started with 95% Buffer A (0.1% formic acid in water) in Buffer B 
(acetonitrile) and decreased to  95% Buffer A in 2 minutes, then to 68% Buffer A over 30 
minutes. The flow rate used was 300nL/min.  The peptides were ionized using a 
Nanospray Flex Ion Source (Proxeon Biosystems A/S) and analyzed on a Q-Exactive 
mass spectrometer (Thermo). MS1 profiling was carried out over a 375-1600 m/z range 
at a resolution of 70,000. MS2 fragmentation was performed using higher energy collision 
induced dissociation (HCD) on the top 15 ions using a 1.6 m/z window and normalized 
collision energy of 29. Dynamic exclusion was turned on (15 s). MS raw data was 
processed using MaxQuant (version 1.5.2.8) against a human protein database from 
UniProt (downloaded 2016.04.07, 20159 entries). Searches included up to 2 missed 
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tryptic cleavages.  Mass tolerances for parent ions were 20 ppm for the first search and 
4.5 ppm for the second search and 20 ppm for fragment ions.  The iodoacetamide 
derivative of cysteine was specified as a fixed modification.  Oxidation of methionine and 
acetylation of protein N-termini were set as variable modifications. Minimum protein and 
peptide identification probabilities were set at ≤1% false discovery rate (FDR) as 
determined by a reversed database search and proteins required just 1 unique peptide. 
All other parameters were left at their default settings.  Fold enrichment was calculated 
by dividing the peptide intensity observed for wild type crosslinking by that observed for 
the mutant peptide crosslinking. For the kemptide K-CLASP study, a hit list was 
constructed by identifying proteins with at least 2 fold enrichment in wild type crosslinked 
sample compared to the mutant crosslinked samples in at least two replicates. For Miz1 
peptide K-CLASP study, all kinases that showed fold enrichment greater than 1 compared 
to both the mutant crosslinked sample and the No TNF treated lysate crosslinking 
samples were considered as K-CLASP hit kinases. For the rest of the proteins, a hit list 
was constructed by identifying proteins with at least 2 fold enrichment in wild type 
crosslinked sample compared to both the mutant crosslinked samples and the No TNF 
treated lysate crosslinking samples. 
2.6.17. Interactome analysis  
The known physical protein-protein interactions among the proteins identified by 
K-CLASP were mapped using the GeneMANIA application in Cytoscape 3.3.0.66  Known 
substrates of the hit kinases K-CLASP hits were identified from Phospho Site plus and 
kinaseNET.67 The identified substrates were then manually added. MCODE application 
was used to identify the potential cellular complexes among K-CLASP hits. 
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CHAPTER 3 K-BIPS (KINASE-CATALYZED BIOTINYLATION TO 
IDENTIFY PHOSPHATASE SUBSTRATES) 
Excerpts from this chapter have been taken from two manuscripts submitted for 
publication. Dedigama-Arachchige, P. M.; Chinthaka, N.; Pflum, M. K., K-BIPS, a method 
for phosphatase susbtrate identification. Dedigama-Arachchige, P. M.; Zhang, X.; Yi, Z.; 
Pflum, M. K., Kinase-catalyzed biotinylation reveals novel susbtrates of PP1-MYPT 
phosphatase.  
Protein phosphatases are key players in cell signaling pathways with implications 
in human diseases. However, understanding the precise cellular functions of 
phosphatases has been hampered by the scarcity of tools to identify phosphatase 
substrates. In addition, most cellular phosphatases exist in multimeric complexes, further 
complicating the efforts of developing phosphatase substrate identification methods. As 
a solution, we developed a method called K-BIPS (Kinase-catalyzed Biotinylation to 
Identify Phosphatase Substrates). Chapter 3 describes the application of K-BIPS in three 
biological systems. First, in a proof-of-concept study, K-BIPS was used to identify the 
substrates of okadaic acid-sensitive phosphatases (section 3.6). Then K-BIPS was used 
to explore the substrates of PP1-Gadd34 (section 3.7) and PP1-MYPT1 (section 3.8) 
phosphatase complexes. The results from the three studies established K-BIPS as a 
viable tool for phosphatase substrate identification, while also uncovering previously 
known functions for the tested phosphatase systems.  
3.1 Background 
The following section details protein phosphatases and methods available for 
phosphatase substrate identification. 
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3.1.1 Protein Phosphatases 
Phosphatases catalyze dephosphorylation or removal of phosphoryl groups from 
cellular proteins, and thus play an essential role in signal transduction in the cell (Section 
1.2).86 When phosphatase function is altered either due to inactivation or over-expression, 
proper cell signaling is perturbed and results in various human diseases.87   For example, 
PP2A phosphatase malfunction has been reported as a cause for tumor invasiveness 
and metastasis.88 In addition, the hyperactivity of PTP1B phosphatase has been linked 
with diabetes and obesity.89 Consequently, phosphatases have been identified as drug 
targets.90   
3.1.1.1 Protein Tyr phosphatases (PTPs)  
Broadly, protein phosphatases are classified into two families; Protein Tyr 
phosphatases (PTP) and Ser/Thr phosphatases.91 The PTP super family is further divided 
into two main branches: Tyr phosphatases and dual specificity phosphatases. Tyr 
phosphatases, as the name implies, act on phosphorylated Tyr residues and exist either 
as transmembrane receptors or non transmembrane proteins (Figure 3.1).92 Dual 
specificity phosphatases act on both Tyr and Ser/Thr substrates. The well-known mitogen 
activated protein kinase phosphatase family (MKPs) provide an example for dual 
specificity phosphatases.93  Structure wise, PTPs contain a single subunit comprising one 
or more catalytic domains and regulatory domains.94 Although the catalytic domain is 
conserved throughout different members of tyrosine phosphatase family, the regulatory 
domains generate structural diversity and dictate the activity, localization, and substrate 
specificity.92, 95 For example, the non-receptor Tyr phosphatase, PTP1B contains multiple 
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regulatory domains that can participate in specific protein-protein interactions and a 
number of post translational modifications through which its activity is regulated.96 
3.1.1.2 Ser/Thr Phosphatases 
Ser/Thr phosphatases dephosphorylate phosphorylated Ser/Thr residues and are 
further classified into PPP and PPM families. The PPP family consists of PP1, PP2A, 
PP2B, PP4, PP5, PP6 and PP7 phosphatases, while the PPM family includes PP2C 
phosphatase.94 Out of these, PP1 and PP2A are most abundant and carry out more than 
90% of Ser/Thr dephosphorylation in cells.88 PPP family members are evolutionarily 
related and exist in multimeric complexes. For example, PP1 phosphatase comprises 
different phosphatase complexes composed of a common catalytic subunit and different 
regulatory subunits (Figure 3.2). The catalytic subunit binds the phosphorylated protein 
Figure 3.1: Transmembrane receptor tyrosine phosphatases and non-receptor tyrosine 
phosphatases. Adapted with permission from Soulsby, M.; Bennett, A. M., Physiological 
signaling specificity by protein tyrosine phosphatases. Physiology 2009, 24, 281-9. 
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substrate and catalyzes the dephosphorylation. The substrate specificity is governed by 
the assembly of different regulatory subunits with the common catalytic subunit.97In 
addition to the regulatory subunit, other accessory subunits, such as adapters, also 
associate with the multimeric phosphatase complexes. Remarkably, it is known that more 
than a hundred regulatory subunits exists for PP1 alone.48a  PP2C phosphatase, however, 
is distinct from the PPP family phosphatases in that they occur as single subunit proteins 
containing both a catalytic domain and diverse regulatory domains.94  
Despite the importance of phosphatases in cell signaling, research progress on 
phosphatase has been slow compared to the kinases. As a result, very few methods have 
been developed for phosphatase substrate identification. Currently available methods 
include substrate trapping mutants for Tyr phosphatases and phosphoproteomics studies 
following inactivation for Ser/Thr phosphatases, as discussed in the next sections.  
Figure 3.2: Multimeric nature of the PPP Ser/Thr phosphatase family. PPP phosphatases 
exist in multimeric complexes where a common catalytic subunit is shared to form 
different phosphatase complexes by associating with different regulatory subunits. The 
substrate specificity is usually determined by the regulatory subunit.  
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3.1.2 Substrate trapping mutant strategy for phosphatase substrate identification 
The substrate trapping strategy was pioneered by Tonks and colleagues for the 
identification of protein tyrosine phosphatases. The technique employs catalytically 
inactive tyrosine phosphatase mutants that bind more tightly to their phosphorylated 
substrates compared to the wild type phosphatase. The stabilized phosphatase-substrate 
complexes with mutants can be later isolated. Although most trapping mutants have been 
generated by mutating the catalytic Cys, other residues have also been used.98  
The first reported study of substrate trapping mutants led to the identification of 
EGFR as a novel substrate of PTP1B phosphatase. In this case, an Asp residue that acts 
as a general acid during catalysis was mutated to an Ala to produce a substrate trapping 
variant of PTP1B. Then the mutated PTP1B was expressed in COS cells. The cells were 
next treated with EGF to discover EGF sensitive PTP1B substrates. The cells were lysed, 
immunoprecipitated using a PTP1B antibody and the effect on tyrosine phosphorylation 
was monitored by Western blot. A band corresponding to the size of EGFR showed 
increasing tyrosine phosphorylation. Further validation experiments confirmed that EGFR 
is a PTP1B substrate.51 
Later, the substrate trapping strategy was coupled with affinity purification and 
MS/MS analysis to enable the unbiased discovery of tyrosine phosphatase substrates. In 
an illustrative example, an Asp/Cys double mutant was used to identify the substrates of 
PTPN22 phosphatase. In this example, Jurkat cells were first treated with the tyrosine 
phosphatase inhibitor pervandate to promote phosphorylation. Then cells were lysed and 
recombinant PTPN22 mutant was incubated with the lysates. PTPN22 was then affinity 
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purified and the potential substrates co-purified were analyzed by MS/MS. The study 
revealed three novel and two previously known PTPN22 substrates.99 
The substrate trapping technique has been a valuable tool in producing the 
substrate profile of as many as 20 tyrosine phosphatases.98  However, substrate trapping 
has not been used for studying Ser/Thr phosphatase. While the ability to generate 
trapping mutations in Ser/Thr phosphatases has not been explored, the major obstacle 
of using trapping for Ser/Thr phosphatases can be attributed to their multimeric nature, 
where the substrate specificity is dictated by regulatory subunits. In this case, trapping by 
the mutant phosphatase cannot distinguish substrates of different regulatory complexes.  
3.1.3 Phosphoproteomics for discovery of phosphatase substrates 
Although not widely reported, phosphoproteomics following phosphatase 
inactivation represents a possible method for looking at Ser/Thr phosphatases. A few 
studies have reported the use of phosphoproteomics for discovering both tyrosine and 
Ser/Thr phosphatase substrates. In these cases, the phosphatase of interest was 
inactivated and the effect on phosphorylation was studied by isolating phosphopeptides 
using IMAC (Immobilized metal affinity chromatography) and then MS analysis. As an 
example, phosphoproteomics was used to discover possible substrates of PP6 
phosphatase. Here, the catalytic subunit of PP6 was silenced and phosphoproteomics 
was carried out. The study revealed 220 proteins with increased phosphorylation.100 
In another report, the Drosophilla tyrosine phosphatase Ptp61F was knocked down 
and phosphoproteomics studies were carried out. The study uncovered 288 phosphosites 
affected by Ptp61F knockdown.101 A recent study detailed the application of 
phosphoproteomics with the inactivation of a regulatory subunit of PP1 phosphatase. In 
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this study, which will be further discussed in section 3.8, the PP1 regulatory subunit, 
MYPT1 was knocked down. The resulting proteomics study disclosed many novel 
proteins as candidate PP1-MYPT1 substrates.102 
 Although phosphoproteomics presents a useful tool, it has not been widely 
employed for discovering phosphatase substrates. One limitation of phosphoproteomcs 
strategies is the inability to distinguish dynamic phosphorylation events from static events. 
Since the majority of phosphosites are non-dynamic,102-103 the detection of dynamic 
phosphorylation events, especially low abundance phosphosites, can be difficult with 
IMAC-based phosphopeptide purification. In addition, IMAC has also been shown to have 
a bias towards peptides with acidic residues.104 Furthermore, phosphatase inactivation 
during phosphoproteomics may increase the phosphorylation status of some kinases, 
leading to increased phosphorylation of some proteins through kinase activation. In such 
cases, phosphoproteomics strategies are incapable of distinguishing direct phosphatase 
substrates from proteins indirectly affected by the inactivated phosphatase. Therefore, to 
provide an alternative, general method for phosphatase substrate identification, we 
developed a novel method based on our prior work on kinase-catalyzed ATP-biotin 
labeling of phosphoproteins.  
3.1.4 Phosphatase activity is required for kinase-catalyzed biotinylation 
Kinase cosubstrate promiscuity has allowed the usage of ATP-biotin to label 
phosphoproteins in complex mixtures, such as lysates. Detailed studies of ATP-biotin 
labeling of cellular phosphoproteins revealed that, while the phosphobiotin tag was 
insensitive to phosphatases, efficient biotinylation indeed required the activity of 
phosphatases.44 Specifically, in prior work published by Pflum lab, 2D gel analysis of the 
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ATP and ATP-biotin labeling reactions were carried out with HeLa lysates with and 
without phosphatase inhibitors.44 In the case of ATP, the phosphate signal (Pro-Q-
Diamond Stain) was increased in the presence of phosphatase inhibition (Figure 3.3A, 
compare boxed regions), indicating increased phosphorylation. However, for ATP-biotin 
labeling, the biotin signal (Streptavidin-Cy5) was reduced when the lysate was treated 
with phosphatase inhibitors (Figure 3.3B, compare boxed regions), suggesting that the 
activity of phosphatases is required for biotinylation. Based on the observation that 
phosphatases are required for efficient biotinylation, we developed a novel method for 
phosphatase substrate identification called K-BIPS.  
Figure 3.3: ATP-biotin labeling requires phosphatases. 2D gel analysis of HeLa lysate 
phosphobiotinylation with and without phosphatase inhibitor treatment.30 Boxed region 
highlights changes in ATP and ATP-biotin labeling with and without phosphatase inhibitor 
treatment. Senevirathne, C.; Pflum, M. K., Biotinylated phosphoproteins from kinase-
catalyzed biotinylation are stable to phosphatases: implications for phosphoproteomics. 
Chembiochem 2013, 14 (3), 381-7. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission. 
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3.1.5 The K-BIPS strategy 
To provide an alternative tool for the discovery of phosphatase substrates, we 
developed a new method called K-BIPS (Kinase-catalyzed Biotinylation to Identify 
Phosphatases Substrates). We reasoned that phosphate groups present on cellular 
proteins have to be removed in order for biotinylation to occur (Figure 3.3A). Therefore, 
in K-BIPS, biotinylation is carried out with ATP-biotin in lysates with and without 
inactivating a phosphatase of interest (Figure 3.3B). In the phosphatase-inactivated 
sample, the substrates of the inactivated phosphatase will remain phosphorylated and 
will be immune to biotinylation. Therefore, phosphatase substrates will be less 
biotinylated in the phosphatase-inactive sample compared to the phosphatase-active 
sample. Then, the biotinylated proteins are purified by streptavidin resin and analyzed by 
Figure 3.4: The K-BIPS method. (A) A phosphatase removes phosphate groups from 
its substrate (blue). When the particular phosphatase is inactivated, its substrate is 
maintained in the phosphorylated form. (B) When biotinylation is carried out, the 
dephosphorylated substrate is biotinylated, while the phosphorylated substrate is 
prevented from biotinylation. (C) The biotinylated proteins are then purified from both 
samples and analyzed by LC-MS/MS to reveal the proteins that showed reduced 
biotinylation in the phosphatase-inactivated sample. 
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liquid chromatography tandem mass spectrometry (LC-MS/MS, Figure 3.3C). Finally, the 
candidate substrates of the inactivated phosphatase can be identified by detecting the 
proteins that showed a loss in biotinylation in the phosphatase-inactive sample. Further 
validation studies must then be carried out to confirm the identified proteins as the 
substrates of a particular phosphatase.  
To establish K-BIPS as a viable method for the identification of phosphatase 
substrates, we used K-BIPS with three Ser/Thr phosphatase systems. Although K-BIPS 
is amenable to both Tyr and Ser/Thr phosphatases, we specifically selected Ser/Thr 
phosphatases due to the fact that Ser/Thr phosphatases are less studied than Tyr 
phosphatases. In the first study, we used the general phosphatase inhibitor okadaic acid 
to inactivate a majority of PPP family phosphatases and used K-BIPS in a proof-of-
concept experiment (section 3.2.1). Then in a discovery approach, we used K-BIPS to 
explore possible substrates of PP1-Gadd34 complex in the context of unfolded protein 
response (section 3.2.2). Finally, in a collaboration project with Dr.Zhengping Yi at 
College of Pharmacy and Health Sciences at Wayne State University, we used K-BIPS 
to uncover novel substrates of PP1-MYPT1 system (3.2.3).  
3.2 Results 
3.2.1 K-BIPS using okadaic acid mediated phosphatase inactivation  
As a proof of concept study to demonstrate that K-BIPS is a feasible method, the 
well-known phosphatase inhibitor okadaic acid (OA) was used. OA is a broad 
phosphatase inhibitor that inhibits a majority of the PPP family phosphatases, including 
PP1 and PP2A.105 Given that PP1 and PP2A phosphatases have a large number of 
known substrates, K-BIPS with OA will serve as a validation method for the feasibility of 
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K-BIPS for phosphatase substrate identification.  Specifically, by comparing known 
substrates of PPP phosphatases with the substrates identified by K-BIPS, the viability of 
our method can be determined. In addition, unknown substrates of PPP family 
phosphatases can also be identified. 
3.2.1.1 K-BIPS with OA-mediated phosphatase inhibition 
To show that K-BIPS is a viable method for phosphatase substrate identification, 
we inhibited cellular phosphatases with OA and probed the levels of biotinylation by 
strepatavidin purification after treatment with ATP-biotin. OA inhibits PP2A, PP4, PP5 and 
PP6 at a concentration of 1-2 nM, while PP1 is inhibited at around 1 uM.106  We carried 
out K-BIPS with OA treatment in HeLa lysates. HeLa cells were untreated or treated with 
OA at either 10 nM or 1 uM concentrations to differentially influence PP2A and PP1. After 
cell lysis, biotinylation was carried out by incubating each lysate sample with ATP-biotin 
either in the absence or the presence of OA to keep the phosphatases activity consistent. 
The biotinylated proteins were then purified by streptavidin resin and separated by gel. 
The amounts of protein eluted were visualized using Sypro®Ruby total protein stain. As 
expected, reduced protein levels were observed in the elution of OA-treated compared to 
untreated lysates (Figure 3.5 and B.1, compare lanes 4, 5, 6), confirming that inactivation 
of phosphatases results in less biotinylation. As anticipated, the sample treated with 1 µM 
OA showed the most reduction (Figure 3.5 and B.1, compare lane 4 to 5 and 6). The 
results confirmed that efficient biotinylation requires the activity of phosphatases, and 
inactivation of phosphatases leads to a reduction in biotinylation.  
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To identify the substrates of phosphatases inhibited by OA, we next performed LC-
MS/MS analysis after in-gel digesting the proteins eluted from 1 uM OA-treated and 
untreated samples (Figure 3.5, lanes 4 and 5). TMT (Tandem mass tag™)-based 
quantitation was used to select proteins enriched by at least 1.5-fold in the phosphatase-
active compared to the OA-treated sample. K-BIPS identified 71 proteins as hits (Table 
B.1).  
A literature search revealed that 15 proteins from the K-BIPS hits (21% of hits, 
Table 3.1, Table B.1-green colored rows) are known PP1 or PP2A substrates, showing 
that K-BIPS is capable of discovering known phosphatase substrates. In addition, 18 of 
the remaining proteins (25% of the hits, Table 3.2, Table B.1-blue colored rows) were 
known interactors of PP1, PP2A, PP4, PP5 and PP6 catalytic subunits or their regulatory 
subunits. In fact, most of the known substrates also directly interact with the catalytic or 
Figure 3.5: K-BIPS study with OA. Streptavidin purification of biotinylated proteins 
after kinase-catalyzed biotinylation. Biotinylation was carried out with lysates from cells 
treated with (1 um or 10 nm) or without OA (input in lanes 1-3). After reaction, 
biotinylated proteins were enriched (elution in lanes 4-6), separated by SDS-PAGE, 
and stained for total proteins using SYPRO® Ruby stain. Replicates are shown in 
Figure B.1. 
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regulatory subunits (Table 3.1, Table B1-green colored rows). Therefore, the 18 K-BIPS 
hits known to interact with the inactivated phosphatases (Table 3.2) are also likely 
substrates. Overall, 46% from the K-BIPS hits were either known substrates or had known 
interactions with the inhibited phosphatase complexes. 
Table 3.1: Known phosphatase substrates among the K-BIPS hits from OA-mediated 
phosphatase inactivationa 
 aThe primary literature demonstrating the K-BIPS hits as known phosphatase substrates is cited. The 
interaction information was obtained from Uniprot and BioGrid databases.122 The gene names of 
phosphatase catalytic and regulatory subunits are shown. For example, PPP1CA refers to PP1 alpha 
isoform of catalytic subunit whereas PPP2CA refers to PP2A alpha isoform of catalytic subunit. PPP1R7 
refers to Regulatory subunit 7 of PP1.  
Protein  Gene 
Substrate 
of 
Interactions 
Catalytic 
subunits 
Regulatory 
subunits 
Structural maintenance of 
chromosomes protein 1A107 SMC1A 
PP1or 
PP2A 
  
Eukaryotic translation initiation factor 2 
subunit 1108 EIF2S1 
PP1 PPP1CC 
 
PPP1R7 
Tubulin beta chain109 TUBB 
PP1 or 
PP2A 
PPP1CC PPP2R2A 
60 kDa heat shock protein, 
mitochondrial110 HSPD1 
PP2A  PPP2R1B 
PPP2R1A 
PPP2R2C 
Nucleolin111 NCL 
PP1 or 
PP2A 
PPP1CB RRP1B 
Ezrin112 EZR PP1   
Voltage-dependent anion-selective 
channel protein 1113 VDAC1 
PP2A   
DNA replication licensing factor 
MCM3114 MCM3 
PP2A  PPP2R1B 
PPP2R1A 
HORMA domain-containing protein 1115 
HORM
AD1 
PP1   
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2116 
ARFGE
F2 
PP1 and 
PP2A 
  
Ryanodine receptor 2117 RYR2 
PP1 or 
PP2A 
PPP1CA 
PPP1CB 
PPP1CC 
PPP2CA 
 
Elongation factor 2118 EEF2 
PP2A PPP2CA PPP2R1B 
PPP2R1A 
PPP2R2B 
Moesin119 MSN PP1  PPP1R2 
Calreticulin120  CALR PP2A   
Pyruvate kinase PKM121 PKM PP1 PPP1CA  
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The identification of K-BIPS hits, PCNA (Table 3.2, Table B1 entry #22) and LDHA 
(Table B1, entry #40) further supported the conclusion that K-BIPS discovered proteins 
that are potential phosphatase substrates. In addition to being a known interacting protein 
of PP2A (Table 3.2, Table B1 entry #22), the nuclear transport of PCNA has been shown 
to be inhibited by OA and regulated by a PP2A-mediated mechanism.123 The observation 
of PCNA among the K-BIPS hits suggests that PCNA may be a PP2A substrate and PP2A 
may dephosphorylate PCNA to effect nuclear transport. Further, the K-BIPS hit, LDHA 
(Table B1, entry #40) could also be a possible PP2A substrate as the knock down of 
CIP2A, the endogenous inhibitor of PP2A, is known to reduce LDHA activity.124 Functional 
analysis using Gene Ontology125 revealed that K-BIPS hits belonged to diverse functions, 
such as metabolism, cellular processes and localization (Figure 3.6), consistent with the 
wide spectrum of biological roles associated with phosphatases.126 Finally, to dismiss the 
possibility that K-BIPS hits were identified due to their high abundance, the abundance of 
the K-BIPS hits were also analyzed by using previously reported values.65 The results 
showed that proteins with low abundance were identified (Figure 3.7), demonstrating that 
K-BIPS is not abundance dependent. Overall, the results confirm that K-BIPS identified 
phosphatase substrates. 
Table 3.2: K-BIPS hits from the OA-mediated phosphatase inactivation that are not 
known substrates, but known to interact with phosphatasea 
Protein  Gene 
Known interactions 
Catalytic 
Subunits 
Regulatory 
Subunits 
Complement component 1 Q subcomponent-
binding protein, mitochondrial C1QBP   
PPP2R1A 
RRP1B 
PPP2R2A 
Translational activator GCN1 GCN1L1   PPP6R1 
Heat shock protein HSP 90-beta HSP90AB1 PPP5C PPP6R3 
Eukaryotic initiation factor 4A-III EIF4A3   PPP6R3 
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ATP-dependent RNA helicase DDX1 DDX1 PPP1CA PPP1R8 
HLA class I histocompatibility antigen, B-59 
alpha chain HLA-B PPP2CB PPP1R16A 
ATP-dependent RNA helicase A DHX9 PPP1CB   
Proliferating cell nuclear antigen PCNA 
PPP1CA 
PPP1CC PP2A  
Exostosin-like 3 EXTL3   PPP6R2 
Endoplasmin127 HSP90B1 PPP5C  
Calnexin CANX   PPP2R1A 
Ral GTPase-activating protein subunit alpha-
1 RALGAPA1   RRP1B  
Importin subunit beta-1128 KPNB1 PPP2CA PPP2R2A 
Trifunctional enzyme subunit alpha, 
mitochondrial HADHA   PPP6R1 
CAD protein CAD 
PPP1CA  
PPP2CA   
Trifunctional enzyme subunit beta, 
mitochondrial HADHB   PPP6R1 
60S ribosomal protein L27129 RPL27 PPP1CC REPOMAN 
Protein PML130 PML PPP1CA  
aExcept when cited, the information on interactions were obtained from Uniprot and BioGrid 
database.122Gene names are shown in the “Interactions” column.  
  
Figure 3.6:  Functional classification of the proteins identified by the K-BIPS study with 
OA. The proteins were classified based on their biological processes by the enrichment 
analysis tool available on Gene Ontology Consortium. 
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Figure 3.7: The analysis of abundance of hits from the K-BIPS study with OA-mediated 
phosphatase inactivation.  Proteins with a range of abundance values (0.01-8785ppm) 
were identified by K-BIPS from HeLa cells which carries proteins with abundances 
ranging from 0.01 to 10,000. The abundance data was obtained from previously published 
values65 available on Pax database.131 
In summary, K-BIPS was carried out after inactivating phosphatases with OA. 
While gel-based experiments confirmed that phosphatase activity is necessary for 
efficient biotinylation, proteomics studies revealed both known phosphatase substrates 
and proteins that are potential phosphatase substrates. Together, the study with OA 
showed that K-BIPS is an applicable method for phosphatase substrates identification. 
3.2.2: K-BIPS for PP1-Gadd34 substrate identification 
Having established that K-BIPS is a viable strategy for phosphatase substrate 
identification, we used K-BIPS to discover potential substrates of the PP1-Gadd34 
phosphatase complex. Gadd34 (PPP1R15A) is a regulatory subunit of PP1 that plays a 
key role during unfolded protein response (UPR).108, 132  UPR is induced when cells are 
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faced with various insults that disrupt correct protein folding. As a result, misfolded 
proteins accumulate in the ER (endoplasmic reticulum) causing ER stress. Consequently, 
ER stress triggers the activation of three main stress sensors in the cell, IRE1α, PERK 
and ATF6, to induce a cascade of downstream pathways in the UPR. In a bid to restore 
cellular protein homeostasis and save the cell from apoptosis, UPR promotes the 
expression of a series of proteins involved in various restorative processes, such as 
protein folding, protein degradation, and apoptosis suppression. In addition, through 
PERK-mediated phosphorylation of the translation initiation factor EIF2α, UPR also 
blocks the synthesis of new proteins by stalling translation and allowing the cell to recover 
from stress.  As cells rebound from stress, Gadd34 is induced in a feedback loop. The 
PP1-Gadd34 complex acts to dephosphorylate EIF2α and remove the block on 
translation.132-133 Thus PP1-Gadd34 functions a key modulator of UPR and has been 
implicated in various neurodegenerative diseases, cancer and viral infections.17, 133b, 134 
Despite being a feedback regulator of UPR, surprisingly, the only known UPR-involved 
PP1-Gadd34 substrate is EIF2α.  
Given the disease relevance of the PP1-Gadd34 phosphatase, we aimed to use 
K-BIPS to explore unknown substrates of PP1-Gadd34 in the context of the UPR. To 
inhibit the PP1-Gadd34 complex for K-BIS-Phos, we used the small molecule guanabenz 
(Gb), which was reported to inactivate the PP1-Gadd34 complex by disrupting the binding 
of Gadd34 with the PP1 catalytic subunit.135 To create the conditions to promote UPR, 
we also used the known ER stressor tunicmaycin (Tm).135   
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3.2.2.1: Inactivation of PP1-Gadd34 system leads to a loss in biotinylation  
As a first step, we tested if inactivation of the PP1-Gadd34 complex by Gb leads 
to a reduction in biotinylation of cellular proteins. We treated HeLa cells with or without 
Gb to inactivate PP1-Gadd34. Since our goal was to identify the PP1-Gadd34 substrates 
in the context of UPR, cells were also simultaneously stressed with Tm. Then, cells were 
lysed and the expression of Gadd34 was monitored by Western blot. The results showed 
that Gb treatment did not affect Gadd34 expression (Figure 3.8, compare lanes 2 & 3).  
Biotinylation was next carried out by incubating treated lysates with ATP-biotin. For 
the Gb treated samples, Gb was also added to the lysates to maintain the PP1-Gadd34 
complex in a dissociated state during biotinylation. After reaction, cellular proteins were 
separated by SDS-PAGE, transferred to a membrane, and then probed with streptavidin-
cy5 to detect biotinylation. A reduction in biotinylation was observed in the Gb-treated 
lysate compared to the untreated lysate (Figure 3.9, Compare bracketed region and 
 1 2 3 
Tm - + + 
Gb - - + 
 
Figure 3.8: Expression of Gadd34 in HeLa lysates treated with Tm and Gb. Gadd34 
expression was probed with Western blot (Top gel) in untreated cells (Lane 1), cells 
treated with only Tm (Lane 2) and cell treated with both Tm and Gb (Lane 3). The 
bottom Sypro-Ruby stained gel shows equal protein loading. Replicates and full gel 
images shown in Figure B.2. 
Anti-Gadd34 
Sypro®Ruby 
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regions pointed by arrow in lanes 2 & 3), consistent with the expectation that inactivation 
of PP1-Gadd34 leads to loss of biotinylation. 
3.2.2.2: K-BIPS with PP1-Gadd34 inactivated lysates 
To perform a full K-BIPS experiment and identify UPR-implicated PP1-Gadd34 
substrates, biotinylated proteins obtained from UPR-induced lysates treated with or 
without Gb were purified with streptavidin resin. The purified proteins were then separated 
by SDS-PAGE (Figure B.4) and analyzed by LC-MS/MS. After analysis with label free 
 1 2 3 
Tm - + + 
Gb - - + 
 
Figure 3.9: Biotinylation with PP1-Gadd34 inactivated lysates. Biotinylation was carried 
out with ATP-biotin and PP1-Gadd34 active and inactive HeLa lysates. A Control 
reaction was also carried out with HeLa lysates untreated with both Tm and Gb. After 
biotinylation, proteins were separated on SDS-PAGE and visualized with Streptavdin-
Cy5 (Top) and SyproRuby (bottom). Replicates shown in Figure B.3.  
SA-Cy5 
Sypro®Ruby 
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quantitation, 130 proteins (Table B2) reproducibly enriched by at least 1.3-fold in the 
untreated versus the Gb-treated sample were identified as PP1-Gadd34 candidate 
substrates. Importantly, the known PP1-Gadd34 substrate, EIF2α (EIF2S1, Table 3.3, 
Table B.2, green colored) was among the enriched proteins (Table 3.3), confirming the 
ability of K-BIPS to discover PP1-Gadd34 substrates. In addition to EIF2α, three other 
proteins involved in translation initiation136 (EIF4G3, EIF3M and EIF3G, Table B2) were 
also observed among the enriched proteins, consistent with the role of PP1-Gadd34 in 
translation. Further, ribosomal proteins RPS12, RPL10A, RPL26L1 and RPLP0 (Table 
B2) were also among the enriched proteins. Additionally, several K-BIPS identified 
proteins were known interactors of either the catalytic subunit of PP1 or Gadd34 (Table 
3.3) and hence possible substrates. Overall, the results suggest that K-BIPS revealed 
new candidate PP1-Gadd34 substrates. 
Table 3.3: PP1 and Gadd34 interacting proteins among K-BIPS hitsa 
Protein (Gene name) 
Fold Enrichment 
Interactions Trial 1 Trial 2 
EIF2α 2.4 2.3 PPP1CC,GADD34 
CTBP2 4.9 ∞ GADD34 
MAPK1 2.9 ∞ PPP1CA,PPP1CC 
PPP2R4 ∞ 2.5 PPP1CA 
MYO18A 2.0 ∞ PPP1CB 
SYNCRIP ∞ 1.8 PPP1CA 
WDR5 ∞ 1.4 PPP1CB 
COPS5 ∞ 1.3 PPP1CC, GADD34 
UBE2Z 18.4 3.0 PPP1CA 
PPA1 15.2 1.6 PPP1CC 
NACA 10.1 1.3 PPP1CC 
PRKAR2A 6.0 1.3 PPP1CB 
SFPQ 3.3 1.3 PPP1CA 
PRKAR1A 3.2 1.3 PPP1CA 
aFold enrichment was calculated by dividing the peptide intensity in the Gb-untreated sample by that of the 
treated sample. Fold enrichment of infinity (∞) was observed when the protein was identified only in the Gb-
untreated sample. Interaction information was obtained from Uniprot and BioGrid databases.122  
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To verify that the identification of the 130 K-BIPS hits was not abundance 
dependent, we performed an abundance analysis using reported values.65 The data 
showed that K-BIPS hits belonged to a range of abundance (Figure 3.10), indicating that 
abundance was not a factor for K-BIPS identification. Then we carried out a literature 
search to see if the K-BIPS hits have biological functions related to PP1-Gadd34. In fact, 
many K-BIPS hits had known roles in UPR, ER stress and stress granules (Table 3.4), 
confirming that K-BIPS discovered likely PP1-Gadd34 substrates. 
Figure 3.10: The abundance of proteins identified from the K-BIPS study with PP1-
Gadd34 inactivation.  K-BIPS identified proteins with a range of abundance (0.02-5188). 
The reported range of abundance in HeLa cells is from 0.01 to 10,000. The abundance 
values were obtained from previous data65 deposited on Pax database.131  
To further validate the K-BIPS results, we selected a few hits that are known to 
have cellular functions similar to that of Gadd34, but have not been previously identified 
as PP1-Gadd34 substrates. Specifically, the K-BIPS hits, COPS5 and WDR5 represented 
strong candidates to be PP1-Gadd34 substrates. Besides being known interacting 
proteins of PP1 (Table 3.3), COPS5 and WDR5 also had known roles in UPR137 (Table 
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3.4). In addition, COPS5 was also known to associate with Gadd34 (Table 3.3). 
Therefore, COPS5 and WDR5 were picked for further validation. In addition, the K-BIPS 
hits, CAPRIN1 and G3BP1 were also selected. Both CAPRIN1 and G3BP1 were known 
to be involved in the formation of stress granules138(Table 3.4), a downstream event in 
the UPR cascade. In fact, K-BIPS identified several stress granule proteins, suggesting 
an unprecedented role for PP1-Gadd34 in stress granule formation. Therefore CAPRIN1 
and WDR5 were also selected for validation experiments. 
Table 3.4: K-BIPS hits with biological function related to PP1-Gadd34a 
Associated with K-BIPS hits  
UPR COPS5,DNAJB11,ATP6V0D1,WDR5,CSNK2A3,EIF2S1,FKBP10 
ER stress 
ERLIN1,ITPR1,RELA,CAPN2,RNF213,IDH3A,HM13,PSMC2,UBQLN2,  
PDIA6,PSMC3,MAPK1 
Stress granules CAPRIN1,TIAL1 ,IGF2BP3,G3BP1,FXR1 
Oxidative stress  PRDX4,PGAM1 
aInformation on function was obtained from Uniprot.  
For secondary validation of K-BIPS results, we checked the differential 
biotinylation of COPS5, WDR5, CAPRIN1 and G3BP1 by gel methods. Specifically, 
proteins from untreated and Gb-treated lysates were biotinylated using ATP-biotin. Then 
the biotin-labeled proteins were purified by streptavidin resin and separated on SDS-
PAGE. After transfer of the proteins onto a membrane, the levels of each protein was 
checked by Western blot. The results showed reproducible loss in all selected proteins in 
the Gb-treated sample compared to the untreated sample (Figure 3.11, compare lanes 3 
and 4), confirming that PP1-Gadd34 affects phosphorylation of the selected proteins. 
Notably, the validation of COPS5 and WDR5, which showed only modest enrichment in 
the proteomics experiment (Table 3.3, fold enrichment 1.3 and 1.4 respectively), also 
rationalized the 1.3-fold threshold enrichment used for K-BIPS hit selection. Importantly, 
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the data also showed that the levels of tested proteins in lysates were equal in the 
samples treated with and without Gb (Figure 3.11, compare lanes 1 and 2), verifying that 
the changes in biotinylation was not due to Gb-mediated differences in expression. 
Altogether, the results validate COPS5, WDR5, CAPRIN1 and G3BP1 as previously 
unknown PP1-Gadd34 substrates and establish K-BIPS as a method for phosphatase 
substrate identification. 
3.2.2.3 K-BIPS exposed novel roles of PP1-Gadd34 in UPR 
The use of K-BIPS with PP1-Gadd34 inactivation resulted in the enrichment of 
many candidate UPR-related PP1-Gadd34 substrates. Notably, K-BIPS with Gb identified 
the known PP1-Gadd34 substrate EIF2α. In addition, many other UPR related proteins 
were also observed. Among these were chaperone proteins, such as PDIA6, FKBP10 
and DNABJ11, which assist in protein refolding during UPR. Another chaperone enriched 
was DNAJA1, though it was not previously known to be involved in UPR.  The E3 ligase 
RNF213 is known to play a role in ER stress and was also observed. RNF213 may 
ubiquitinate misfolded proteins to facilitate their degradation. Although not previously 
implicated in UPR, another E3 ligase UBE3A and the E2 ubiqutin conjugating enzyme 
G3BP1 
CAPRIN1 
WDR5 
COPS5 
Elution Input 
 1 2 3 4 
Tm + + + + 
Gb + - + - 
 
Figure 3.11: Secondary validation of COPS5, WDR5, CAPRIN1 and G3BP1. 
Biotinylation was carried out with ATP-biotin and PP1-Gadd34 active and inactive 
HeLa lysates. Biotin tagged proteins were enriched by streptavidin and probed by 
Western blot after separated on SDS-PAGE. Replicates shown in figures B.5-B.8.  
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UBE2Z were also among the enriched proteins. Additionally, the UPR-associated protein 
UBQLN2, which is thought to mediate the transfer of ubiquitnated proteins from the ER 
to the cytosolic proteasome complex for degradation, was also among the enriched 
proteins. The discovery of UPR-related proteins by K-BIPS validates that the identified 
hits are likely to be PP1-Gadd34 substrates. In addition, the data also suggest that PP1-
Gadd34 may be involved in other UPR-related functions besides EIF2α 
dephosphorylation. 
Cellular stress conditions that cause the stalling of translation, such as Tm 
treatment, are also known to cause the formation of cytoplasmic bodies called stress 
granules in cells. Stress granules contain transient aggregates of mRNA and translation 
pre-intiation complexes, and allow the rapid recovery of translation once the stress is 
resolved.139 Overexpression of Gadd34 has been shown to reduce the formation of stress 
granules under conditions that otherwise promote stress granule formation, suggesting a 
role for Gadd34 in the dissociating of stress granules. In agreement, treatment with Gb 
was also shown to increase the formation of stress granules.140 Interestingly, several 
stress granule proteins, such as TIAL1,139b G3BP1, CAPRIN1,138 FMR1, FXR1139b and 
IGF2BP3,141 were identified by K-BIPS. Importantly, both CAPRIN1 and G3BP1 were 
further validated by gel methods. Overall the K-BIPS data suggests a model where 
Gadd34 may regulate stress granule assembly as cells recover form stress by affecting 
their phosphorylation status.  
UPR is a tightly regulated process that culminates in either cell survival or cell 
death depending on the severity of the stress.142 A recent study reported crosstalk 
between UPR and Hippo pathway. The pro-apoptotic Hippo pathway promotes the 
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phosphorylation of the transcriptional coactivator YAP1 and blocks its nuclear 
translocation, suppressing the proliferative activities of YAP1. Expression of Gadd34 was 
previously shown to correlate with increased phosphorylation and cytoplasmic retention 
of YAP1 under Tm treatment, suggesting a link between UPR and Hippo pathways.143 
Notably, the Hippo pathway kinase STK3 (MST2), which promote phosphorylation of 
Yap1 through LATS kinase, was one of the K-BIPS hits. The identification of STK3 by K-
BIPS suggests a possible mechanism where Gadd34 may indirectly affect the 
phosphorylation of YAP1 through dephosphorylation of STK3. The crosstalk between 
UPR and the pro-apototic Hippo pathway may represent a regulatory mechanism through 
which the balance between cell survival and cell death under cell stress conditions is 
determined. Beyond the Hippo pathway, STK3 is known to interact with the scaffolding 
protein SLC9A3R1, which in turn associates with PKA through cytoplasmic proteins EZR 
and RDX.144 Interestingly, K-BIPS also identified SLC9A3R1 and PKA regulatory 
subunits, PRKAR1A and PRKAR2A, suggesting connections between the Hippo pathway 
and PKA signaling during UPR. 
The Gadd34 interacting protein COPS5 (JAB1) identified by K-BIPS is both a 
transcriptional coactivator and a component of the COP9 signalosome. COPS5 is known 
to regulate key cellular processes, such as cell proliferation, apoptosis and cell cycle 
arrest.145 COPS5 plays a role in ER stress through association with the ER stress 
modulating protein IRE1α. COPS5 interacts with IRE1α under normal conditions, but 
dissociates when ER stress is induced. The dissociation of COPS5 was shown to be 
necessary for the downstream activation of IRE1α during UPR.137b Importantly, validation 
experiments further confirmed that PP1-Gadd34 affects COPS5 phosphorylation. The 
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identification of COPS5 as a likely substrate of PP1-Gadd34 hints of a possible 
mechanism where reversible phosphorylation may mediate the role of COPS5 during 
UPR. Phosphorylation may regulate IRE1α binding of COPS5 under ER stress 
conditions, controlling both activation of IRE1α and COPS5 activities in UPR. Once the 
UPR is resolved, Gadd34 may dephosphorylate COPS5 and allow association of COPS5 
with IRE1α restoring regular cellular processes.  
Overall, the K-BIPS study with Gb revealed many potential proteins that could be 
substrates of PP1-Gadd34. Notably, K-BIPS identified the known PP1-Gadd34 substrate, 
EIF2α and several proteins with functions in translation initiation, protein folding, protein 
degradation and stress granule formation, consistent with the role of Gadd34 in UPR.  
The presence of PP1 and Gadd34 interacting proteins among the K-BIPS data further 
suggests that identified K-BIPS hits are likely PP1-Gadd34 substrates. Interestingly, the 
K-BIPS study also detected the Hippo pathway kinase STK3 and PKA regulatory 
subunits, suggesting potential crosstalk between UPR and other cellular pathways. 
Finally, the discovery of COPS5 as a substrate of Gadd34 may represent additional 
regulatory mechanisms of the UPR process. Altogether, the K-BIPS study indicates a 
bigger role for PP1-Gadd34 in UPR than previously appreciated and further validates the 
use of K-BIPS as a phosphatase substrate identification method. 
3.2.3: K-BIPS for PP1-MYPT1 substrate identification 
MYPT1, which is also known as Myosin phosphatase targeting subunit 1 or 
PPPR12A, is a regulatory subunit of PP1. The most known function of the PP1-MYPT1 
complex, which is also known as the Myosin light chain phosphatase (MLCP), is to trigger 
muscle relaxation in smooth muscle cells by dephosphorylating S19 on the myosin 
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regulatory light chain(MLC20).146,147 Given that the cytoskeleton is composed of an acto-
myosin (actin-myosin) network, PP1-MYPT1 has also been implicated in cytoskeleton 
organization, with roles in cell migration and adhesion. In agreement, either the knock 
down or the impaired expression of MYPT1 has been shown to disrupt the cytoskeletal 
architecture of the cell.148  Further, a prior study also showed that disassembly of 
microtubules affects the polymerization of actomyosin and formation of stress fibers 
through promoting the phosphorylation of MYPT1, suggesting effects of PP1-MYPT1 on 
microtubules as well.149 Besides myosin light chain, the other reported substrates of PP1-
MYPT1 are merlin150, retinoblastoma protein151 and PLK1.152 PLK1 (Polo Like Kinase 1) 
is a key kinase involved in mitosis. Additionally, MYPT1 has also been reported to interact 
with Shugoshin, a protein known to protect centromeres.153 Together, the reports 
suggests a role for PP1-MYPT1 in cell division. Recently, the Yi lab at Wayne State 
University, College of Pharmacy and Health Sciences identified that MYPT1 interacts with 
the insulin responsive protein IRS1, implying a possible role of PP1-MYPT1 in insulin 
signaling as well.154 Given the interesting biological roles of PP1-MYPT1, we used K-
BIPS to explore the unknown substrates of the PP1-MYPT1 complex in a collaborative 
project with Prof. Yi. 
3.2.3.1: K-BIPS with PP1-MYPT1 inactivated lysates 
In order to use K-BIPS and identify PP1-MYPT1 substrates, we generated MYPT1 
inactivated lysates using a L6 muscle cell line transected with an inducible knock down 
MYPT1 plasmid that we received from Prof. Yi.102 Specifically, MYPT1 knock down was 
induced in L6 myoblast cells by treatment with doxycycline. Then cells were harvested 
and lysed. Control lysates were prepared from untreated cells. The knock down of MYPT1 
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was confirmed in lysates by Western Blot. The results showed reduced MYPT1 levels in 
Dox treated lysates (Figure 3.12, compare lanes 1 and 2), confirming MYPT1 knock 
down. Biotinylation was then carried out with ATP-biotin in Dox-treated and untreated 
lysates. Biotinylated proteins were purified using streptavidin resin, separated by SDS-
PAGE (Figure B.10) and analyzed by LC-MS/MS using three independent replicates. 
Label free quantitation was then used to select for proteins that were enriched in the 
MYPT1-active sample compared to the MYPT1-inactivated sample.  
From the K-BIPS enriched proteins, fourteen proteins showed reproducible 
enrichment in all three replicates (at least 2 unique peptides, P value < 0.05 on the t-test, 
1.5 average fold enrichment, Table 3.5, Table B.3) in the MYPT1-active sample and 
represented strong candidates to be PP1-MYPT substrates. In addition, 161 proteins 
showed significant enrichment (fold enrichment of at least 2, Table B.4) in at least two 
trials. Out of the 161 proteins, 12 (Table 3.6, green rows) were known interacting proteins  
of PP1 while 3 were known to interact with MYPT1 (PPP1R12A, Table 3.6, green rows) 
itself. Additionally, many of the 161 proteins had roles in cytoskleton organization, cell 
Figure 3.12: Knockdown of MYPT1 in L6 lysates treated with Dox. MYPT1 knock down 
was assessed using Western blot (Top gel) in untreated cells (lane 1), and Dox treated 
cells (Lane 2). The bottom Sypro-Ruby stained gel shows equal protein loading. Full gel 
image and repetitive trials shown in Figure B.9.  
Anti-MYPT1 
Sypro®Ruby 
 1 2 
Dox - + 
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adhesion, motility and cell division (Table 3.6), consistent with the known activities of 
MYPT1 and, therefore, representing likely substrates of the PP1-MYPT1 complex.   
Table 3.5: Hits showing reproducible enrichment in all three replicates from the K-BIPS 
study with PP1-MYPT1 inactivated lysatesa 
aThe fold enrichment for each replicate is shown. The fold enrichment was calculated by dividing the 
peptide intensity observed in the MYPT1-active sample by that of the MYPT1-inactive sample. ∞ was 
observed when the protein was only observed in the MYPT1-active sample. The interaction information 
was obtained from BioGrid database.122 
From the fourteen K-BIPS hits enriched in all three replicates, the Ser/Thr kinase 
AKT1 (Table 3.5, Entry # 6) is known to regulate the cytosketon during cell movement 
and adhesion.155 Importantly, AKT1 is known to associate with and be dephosphorylated 
by PP1 catalytic subunit as well.156 Further, previous studies have shown that silencing 
Entry Protein Gene 
Trial 
1 
Trial 
2 
Trial 
3 
Aver
age 
Interactions 
1 Coatomer subunit gamma-2  Copg2 1.3 ∞ 1.4 ∞  
2 Annexin A1 anxa1 1.1 2.7 2.6 2.1  
3 
RAT Glutamate 
dehydrogenase 1, 
mitochondrial  Glud1 1.2 2.6 2.2 2.0 
 
4 
Protein disulfide-isomerase 
A3  Pdia3 1.5 3.5 2.6 2.5 
 
5 
2,3-cyclic-nucleotide 3-
phosphodiesterase  Cnp 2.7 ∞ 1.8 ∞ 
PPP1CA 
6 
RAC-alpha serine/threonine-
protein kinase  Akt1 ∞ ∞ 1.4 ∞ 
PPP1CA 
PPP1CB 
PPP1CC 
7 Neuroplastin  Nptn 7.4 12.9 1.5 7.3  
8 Actin-related protein 2  Actr2 1.3 7.2 1.8 3.4  
9 
Fragile X mental retardation 
syndrome-related protein 1 Fxr1 1.4 3.2 2.7 2.4 
 
10 
Protein disulfide-isomerase 
A6  Pdia6 1.1 2.1 1.6 1.6 
 
11 
Peptidyl-prolyl cis-trans 
isomerase FKBP9  Fkbp9 2.1 3.1 1.4 2.2 
 
12 
COP9 signalosome complex 
subunit 4  Cops4 1.1 5.5 2.0 2.9 
 
13 
BRCA1-A complex subunit 
BRE  Bre 1.1 3.2 1.4 1.9 
 
14 
4-
trimethylaminobutyraldehyde 
dehydrogenase  
Aldh9
a1 1.2 1.8 9.1 4.0 
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of AKT leads to an increase in the inhibitory phosphorylation of MYPT1, consistent with 
a role of AKT in MYPT1 regulation.157 Therefore, AKT1 is a likely substrate and a regulator 
of PP1-MYPT1 complex, possibly through a feedback mechanism. Additionally, GSK3A, 
a known substrate of AKT158 was enrriched in two replicates (Table B.4). The data 
suggests that MYPT1 may affect the phosphorylation of GSK3A either directly or indirectly 
through AKT1.  
The activity of MYPT1 is regulated by the RhoA protein. RhoA affects MYPT1 
activity by associating with ROCK1 kinase and mediating the inhibitory phophorylation of 
MYPT1.159 Further, RhoA levels in the cell are regulated through degradation by the 
neddylated CUL3 ubiquitin ligase.160 The neddylation of CUL3 is controlled by COP9 
siganalosme,161 and hence COP9 siganalasome indirectly affect RHOA and MYPT1 
activity.  The inhibition of either CUL3 or neddylation has been shown to induce 
morphological changes in the cytoskeleton, further demonstrating involvement of CUL3 
and the COP9 signalsome in MYPT1 related activities.160, 162 Interestingly, the COP9 
signalosome subunit, COPS4 was enriched in K-BIPS in all three replicates (Table 3.5, 
entry # 12). Additionally, COPS3 and COPS8 (Table B.4), other subunits of the 
signalosome complex along with CUL3 and RhoA (Table 3.6), were obsereved among 
the 161 proteins showing enrichment in two replicates. Consequently, the discovery of 
RhoA, CUL3 and COP9 subunits as possible PP1-MYPT1 substrates suggests a feed 
back mechanism where MYPT1 may regulate itself and affect  cytosketon arrangement. 
Table 3.6: PP1 and MYPT1 interacting proteins and proteins related to PP1-MYPT1 
activity from among the K-BIPS hits enriched in only two replicates 
Protein 
Gene 
Name Interactions  Involved In 
GrpE protein homolog 1, 
mitochondrial  Grpel1  PPP1CC   
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RNA polymerase II subunit A C-
terminal domain phosphatase  Ssu72  PPP1CC   
Cullin-3  Cul3  
PPP1CA,PP
P1CB 
Cytoskeleton organization 
via RhoA160 
Focal adhesion kinase 1  Ptk2  
PPP1CA,PP
P1CB Cell adhesion and motility 
Amyloid beta A4 App  PPP1CC Cell adhesion and motility 
Actin, cytoplasmic 1 Actb  
PPP1CA, 
PPP1CC Cytoskeleton 
Calcineurin B homologous protein 1 Chp1  PPP1CB   
Platelet-activating factor 
acetylhydrolase IB subunit alpha  
PAFAH1
B1 PPP1CA Microtubule arrangement 
Actin-related protein 2/3 complex 
subunit 2  Arpc2  PPP1R12A Cytoskeleton organization 
Interferon-induced, double-stranded 
RNA-activated protein kinase  Eif2ak2  
PPP1CA,  
PPP1CC  
Alpha-aminoadipic semialdehyde 
dehydrogenase Aldh7a1  PPP1CA   
Serine--tRNA ligase, cytoplasmic  Sars  PPP1CC   
Serine/threonine-protein kinase 
WNK1  Wnk1  PPP1CA   
Prolyl 3-hydroxylase 1 Lepre1  PPP1R12A   
Transforming protein RhoA  Rhoa   PPP1R12A 
Cytoskeleton organization 
through ROCK1159 
Shootin-1  SHTN1   Cytoskeleton organization 
Afadin  Mllt4    Cell junction 
 1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
gamma-1  Plcg1    
Cytoskeleton organization, 
cell motilty 
Glycogen synthase kinase-3 alpha  Gsk3a    Regulates cell plasticity 
Programmed cell death protein 10  Pdcd10    Cell motility 
Nek7  Nek7    
Regulates microtubule 
activity during cell division 
Microtubule-actin cross-linking 
factor 1  Macf1    Cytoskeleton organization 
Protein kinase C iota type  Prkci    Cytoskeleton organization 
Myc box-dependent-interacting 
protein 1  Bin1    
Meidates actomycin filament 
assembly into sarcomeres 
Kinesin-like protein KIF3C  Kif3c    
Microtubule associated 
motor protein 
Kinesin-like protein KIF1B  Kif1b    
Microtubule associated 
motor protein 
Integrin alpha-1  Itga1    Cell adhesion  
Tyrosine-protein phosphatase non-
receptor type 1  Ptpn1    Cell adhesion and motility 
Ezrin  Ezr    Cytoskeleton organization  
Caspase-3  Casp3    Cell adhesion 
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Kinetochore protein Spc25  Spc25    
Associated with 
microtubules during cell 
division 
Kinesin-like protein KIF2C  Kif2c    
Associated with 
microtubules during cell 
division 
Dihydropyrimidinase-related protein 
3  Dpysl3    Cytoskeleton organization  
Gelsolin  Gsn    Cytoskeleton organization  
Actin-related protein 2/3 complex 
subunit 1A  Arpc1a    Cytoskeleton organization  
Alpha-actinin-1  Actn1    Cytoskeleton organization  
a Except when referenced, the information on interactions and functional association with PP1-MYPT1 
was obtained from Uniprot and BioGrid database.122  The proteins in green colored rows are known to 
interact with either PP1 or MYPT1 (PPP11R12A). 
The finding of many actin-regulating proteins, such as ARPC1A, ARPC2 and 
MACF1 (Table 3.6), among K-BIPS data suggests the possibility that PP1-MYPT1 may 
dephosphorylate other actomyosin-related proteins beside myosin regulatory light chain 
to affect the cytoskeleton organization. Thus the data predicts a more prominent role for 
PP1-MYPT1 complex in cytoskeletal arrangement than previously appreciated. In 
addition, PP1-MYPT1 is known to influence cell division by acting on PLK1 and  
shugoshin. The discovery of several cell division associated proteins, such as NEK7, 
SPC25 and KIF2C, by K-BIPS hints that PP1-MYPT1 may be a bigger player in cell 
division than anticipated.  Thus K-BIPS data reveals unknown functions of PP1-MYPT1 
complex. 
Another PP1 interacting kinase enriched by K-BIPS is the tyrosine kinase PTK2 
(FAK1, Table 3.6). PTK2 is known to be present on focal adhesions, which are adhesive 
contact points where the actomycin stress fibers of the cytoskeleton are bridged to the 
extracellular matrix through transmembrane integrin proteins. PTK2 has been shown to 
affect actomycin assembly directly through phosphorylation of stress fiber associated 
protein ACTN1 (alpha-actinin) and indirectly through regulating the activity of MYPT1 via 
98 
 
 
 
ROCK1 mediated MYPT1 phosphorylation.163 In addition to PTK2, K-BIPS identified both 
ACTN1 and the integrin protein ITGA1 (Table 3.6) as possible substrates, indicating a 
previously unknown role for MYPT1 in cytoskeletal organization at focal adhesions.  
In summary, the K-BIPS study with MYPT1 inactivation uncovered many possible 
substrates of the PP1-MYPT1 complex.  Importantly, the study identified many proteins 
that have diverse roles in cytoskeleton regulation, further emphasizing the involvement of 
PP1-MYPT1 complex in various aspects of cytoskeleton rearrangement with effects on 
cell migration, adhesion and cell division. In addition, some of the proteins uncovered by 
K-BIPS were already established interacting partners of either PP1 or MYPT1, increasing 
the likelihood they are PP1-MYPT1 substrates. Interestingly, the study also revealed 
MYPT1-regulating proteins also as potential substrates, suggesting that MYPT1 may 
regulate itself through feedback mechanisms. Overall, the K-BIPS study with MYPT1 
inactivation helped identify novel substrates and shed further light on the cellular roles of 
PP1-MYPT1. 
3.3 Conclusions and future directions  
In conclusion, we used kinase-catalyzed biotinylation to develop K-BIPS as a tool 
for discovering phosphatase substrates. The application of K-BIPS to three Ser/Thr 
phosphatase systems established the use of K-BIPS, while also revealing novel biological 
functions of phosphatases.  In the first K-BIPS study, OA-mediated phosphatase 
inactivation led to the identification of already known phosphatase substrates and many 
other candidate substrates. K-BIPS with PP1-Gadd34 inactivated lysates revealed many 
potential substrates, while also suggesting a bigger role for PP1-Gadd34 in UPR than 
previously appreciated.  Importantly, K-BIPS also identified the known substrate EIF2S1, 
99 
 
 
 
confirming the use of K-BIPS as a tool for phosphatase substrate identification. Lastly, 
the K-BIPS study with PP1-MYPT1 inactivated lysates identified many likely substrates 
with roles in cytoskeleton and cell division, implying PP1-MYPT1 as a key modulator in 
cytoskeleton organization. Overall, the studies established K-BIPS as a discovery tool for 
phosphatase substrate identification.  
Given that K-BIPS depends on the inactivation of a given phosphatase, K-BIPS 
provides a general substrate discovery method applicable to both Tyr and Ser/Thr 
phosphatases. Although the present study focused on three Ser/Thr phosphatase 
systems, future experiments with inactivation of Tyr phosphatases will confirm the general 
use of K-BIPS to discover the substrates of all protein phosphatases.  Compared to the 
currently available phosphoproteomic methods, K-BIPS has the advantage of detecting 
dynamically changing phosphorylation events due to the use of kinase-catalyzed 
biotinylation. Therefore, K-BIPS also discovered substrates of low abundance. In 
contrast, IMAC purification used in phosphoproteomics enrich all phosphoproteins 
regardless of dynamics. Similar to the phosphoproteomics, K-BIPS may also discover 
both direct phosphatase substrates and proteins indirectly affected by the inactivated 
phosphatase through kinase activation. However, kinase activation will lead to increased 
biotinylation in K-BIPS compared to increased phosphorylation in the case of 
phosphoproteomics. While phosphoproteomics strategies rely on the identification of 
proteins with increased phosphorylation in the phosphatase-inactive sample as candidate 
substrates, K-BIPS selects for proteins showing reduced biotinylation. Therefore, K-BIPS 
will not discover proteins with increased phosphorylation by kinases as substrates. As a 
result, K-BIPS is expected to produce fewer false positive hits compared to 
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phosphoproteomics.  However, false positives may be observed in K-BIPS due to 
expression differences of proteins in the phosphatase-active and inactive samples. 
Therefore, secondary studies are necessary to confirm that discovered proteins are the 
substrates of a particular phosphatase.  
A deficiency in the present K-BIPS studies was the identification of full length 
protein substrates, in contrast to phosphopeptides, which will enable the recognition of 
the phosphosite dephosphorylated by the tested phosphatase. Given that a single protein 
may carry more than one phosphosite, the phosphorylation status, and hence the 
biotinylation status of a protein, might be regulated by other kinases and phosphatases 
in addition to the inactivated phosphatase. Therefore, in future experiments, proteins from 
the phosphatase-active and inactive samples will be trypsin-digested after ATP-biotin 
labeling.  The biotinylated peptides can be then purified by streptavidin enrichment. 
Subsequent LC-MS/MS studies will reveal both the phosphatase substrate and the 
phosphosite affected by the inactivated phosphatase.  
In addition to its use in exploring substrates, K-BIPS may also serve as a validation 
tool for substrate confirmation. While the current validation methods usually require in 
vitro incubation of candidate substrates with purified phosphatases, K-BIPS only requires 
phosphatase inactivation and can be used in lysate conditions. Taken together, K-BIPS 
provides an enabling tool to explore the biological role of phosphatases.  Given the 
importance of protein phosphatases in cell signaling, K-BIPS will assist in unraveling the 
complex regulatory network in the cell to reveal mechanisms behind human diseases. 
3.4 Experimental methods 
3.4.1. Synthesis of ATP-biotin 
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The synthesis and characterization of ATP-biotin has been previously described.32 
Purified ATP-biotin was dissolved in deionized water and aliquoted (5 µL each). Aliquoted 
ATP-biotin was stored at -800C until use. 
3.4.2. OA treatment of HeLa cells 
HeLa cells (20X106) were grown in F12 media (45 mL, ThermoFisher, catalog 
number 11765070) containing 10% FBS (fetal bovine serum, ThermoFisher, catalog 
number 16000044) and 1X antibiotic/antimycotic solution (ThermoFisher, catalog number 
15240062). When cells reached 80% confluency, cells were serum starved overnight in 
F12 media (45 mL) without FBS or antibiotic/antimycotic. The next day cells were treated 
with OA (1 µM or 10nM in ethanol, 45 µL, Santa Cruz Biotechnology, catalog number SC-
3513) or without OA (0.1% ethanol, EMD) in F12 media without FBS or 
antibiotic/antimycotic for 30 minutes at 370C in the cell incubator. Cells were harvested 
as described in section 3.4.5.  
3.4.3. Induction of UPR and guanabenz (Gb) treatment of HeLa cells 
HeLa cells (20X106) plated in F12 media (45 mL) supplemented with 10% FBS 
and 1X antibiotic/antimycotic solution were allowed to grown to at least 80% confluence. 
Then all cells were treated with Tunicamycin (Tm, 2.5 µg/mL in DMSO, 45 µL, Sigma, 
catalog number T7765). At the same time, cells were also treated with Guanabnez (Gb, 
50 uM in ethanol, 45 µL, Sigma-Aldrich, catalog number G110) or without Gb (0.1 % 
ethanol, EMD and 0.1% DMSO, ATCC).  The cells were then incubated at 370C for 6 
hours and harvested as described in section 3.4.5.  
 
 
102 
 
 
 
3.4.4. Inactivation of MYPT1 in L6 cells  
L6 muscle cell line stably transected with an inducible knock down MYPT1 plasmid 
was a gift from Prof. Zhengping Yi.102 L6 cells were grown in DMEM media (45 mL, 
ThermoFisher, catalog number 12430104) containing 10% FBS and 1X antimycotic 
antibiotic solution.  When cells became ~80% confluent, doxycycline (45 µL, 100µg/mL 
dissolved in DMEM media without FBS and antibiotic) was added.  Two days later, the 
media was removed and fresh media containing doxycycline  (45 µL, 100µg/mL dissolved 
in same DMEM media without FBS and antibiotic) was added. The next morning, cells 
were serum starved with FBS-free DMEM containing doxycycline (45 µL, 100µg/mL 
dissolved in same DMEM media without FBS and antibiotic) and 0.1% BSA (Bovine 
serum albumin, GenDEPOT, catalog number A0100-010). Then cells were kept at 370C 
for 4 hours and harvested as detailed in section 3.4.5. 
3.4.5: Cell harvesting 
After cell treatment (sections 3.4.2, 3.4.3 and 3.4.4), media was removed. Then the 
adherent cells were briefly washed once with DPBS (Dulbecco's Phosphate Buffered 
Saline, 10 mL, ThermoFisher, catalog number SH30028FS). The cells were then 
incubated with trypsin-EDTA (0.25%, 12 mL, ThermoFisher, catalog number 25200072) 
for 5 minutes at 370C. Next, cold DPBS (15 mL) was added to the cells to stop the trypsin 
reaction.  The released cells were collected into a centrifuge tube and spun at 1000 rpm, 
at 40C for 5 minutes. The supernatant was discarded and the cells were resuspended in 
cold DPBS (2mL). The cells were again spun at 1000 rpm, at 40C for 5 minutes. The 
supernatant was discarded and the cell pellet was either stored at -800C or immediately 
lysed.  
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3.4.6: Cell lysis 
The cell pellets were resuspended in lysis buffer (150-300 µL, 50mM Tris pH 7.5, 
150mM NaCl, 0.5% Triton X-100 and 10% glycerol), and rocked at 40C for 20 minutes. 
Then the samples were spun at 13.2 rpm for 20 minutes. The supernatant was aliquoted 
into single reaction volumes and saved at -800C. Protein concentration was determined 
by Bradford assay (BioRad) per manufacturer’s instructions. 
3.4.7: ATP-biotin labeling of OA treated lysates for K-BIPS  
Lysates from OA-treated cells (500 µg total protein) were pre-incubated with OA 
(1µM or 10nM in water) for 10 minutes at room temperature. Lysates from untreated cells 
were also incubated for 10 minutes at room temperature. Biotinylation was initiated by 
adding ATP-biotin (2 mM) to the lysates in a final reaction volume of 60 µL. Reactions 
were incubated for 2 hours at 310C. Then biotinylated proteins were purified by 
streptavidin affinity chromatography as described in section 3.4.10. 
3.4.8: ATP-biotin labeling of PP1-Gadd34 inactivated lysates  
Lysates from Tm and Gb-treated cells were pre-incubated with Gb (50 µm in 0.1 
% ethanol) at room temperature for 15 minutes. Lysates from only Tm treated cells were 
pre-incubated with vehicle (0.1% ethanol) at room temperature for 15 minutes as well. 
For biotinylation reactions that did not include streptavidin purification (Figure 3.9), lysates 
(100 µg) were used in a final volume of 20 µL with ATP-biotin (2 mM). After reaction, 
samples were separated by 10% SDS-PAGE (section 2.6.4). Total proteins were 
visualized by Sypro®Ruby gel stain (section 2.6.7). For visualizing biotin, proteins were 
transferred onto a PVDF membrane (section 2.6.5) and probed with a Streptavidin-Cy5 
conjugate (section 2.6.6). For K-BIPS reactions (Figure B.3), lysates (500 µg) were used 
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in a volume of 30 µL with ATP-biotin (2 mM). Biotinylation reactions were carried out for 
2 hours at 310C. Then biotinylated proteins were purified by streptavidin resin as 
described in section 3.4.10. 
3.4.9: ATP-biotin labeling of PP1-MYPT1 inactivated lysates for K-BIPS 
L6 lysates (600 µg) with and without MYPT1 knocked down were incubated with 
ATP-biotin (2 mM) for 2 hours at 310C in a final reaction volume of 32 µL. Then 
biotinylated proteins were isolated by streptavidin enrichment as described in section 
3.4.10. 
3.4.10: Streptavidin purification of biotinylated proteins for K-BIPS 
After biotinylation, a fraction of lysates (80 µg for OA treated lysates and PP1-
Gadd34 inactivated lysates and 100 ug for PP1-MYPT1 inactivated lysates) was saved 
to be analyzed as the input. The rest of the lysates were filtered using 3 KDa centiprep 
spin columns (section 2.6.14) to remove excess ATP-biotin and endogenous biotin. 
Streptavidin resin (200 µL of packed beads for OA treated lysates and PP1-Gadd34 
inactivated lysates and 250 µL for PP1-MYPT1 inactivated lysates, Genscript) was 
washed three times with phosphate binding buffer (200-250 µL; 0.1 M phosphate pH 7.2, 
0.15 M NaCl). The filtered samples were then allowed to bind to the streptavidin resin by 
rotating for 1 hour at room temperature. The flow through was collected by spinning at 
2300 rpm at room temperature for 1 minute and streptavidin beads were washed with 
phosphate binding buffer (200-250 µL) ten times and four times with water (200-250 µL). 
Each wash was performed by spinning at 2300 rpm at room temperature for 1 minute. 
The final wash was collected. The bound, biotinylated proteins were eluted by boiling the 
beads in 2% SDS in water (200 µL for OA treated lysates and PP1-Gadd34 inactivated 
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lysates and 250 µL for PP1-MYPT1 inactivated lysates) for 8 minutes. The eluate was 
then concentrated to dryness by lyophilization. The dried eluate was re-suspendend in 
water (~ 30 µL). The input, flow through, last wash, and the concentrated eluate were 
boiled at 95°C for 1 min in Laemmli sample buffer and separated by 10% SDS-PAGE 
(section 2.6.4) gels. SYPRO®Ruby stain was used to visualize total proteins (section 
2.6.7).  
3.4.11: In gel digestion  
The proteins in eluate lanes from gels described in section 3.4.10 were excised 
and in gel digested, as described in section 2.6.15 .85 For OA-inactivated and PP1-
Gadd34 inactivated K-BIPS studies, gels from two independent replicates were used. For 
MYPT1 knocked down K-BIPS study, gels from three independent trials were used. In all 
the K-BIPS studies, gels were run completely the whole length and each eluate lane was 
cut into 8 gel slices. Only for the OA-inactivated K-BIPS study, the peptide samples  
derived from each lane (after digestion of the 8 slices) were combined into single tubes 
resulting in four separate tubes containing digested peptides representing the two 
samples ( OA-untreated, OA-treated) in two trials.  
3.4.12: TMT labeling of peptides and LC-MS/MS analysis for K-BIPS study with OA-
mediated phosphatase inactivation 
Digested dry peptides (section 3.4.11) were then resuspended in TEAB 
(triethylammonium bicarbonate, 30 µL, 100 mM) and labeled with TMT (0.5 mg of tag, 
Tandem Mass Tag™, ThermoFisher Scientific) per manufacturer’s instructions. 
Specifically, the peptides from the OA-untreated sample from the two trials were labeled 
with TMT reporters 127N and 128N respectively. The peptides derived from the OA-
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treated samples from the two trials were labeled with the TMT tags 127C and 128C. After 
labeling for 1 hour at room temperature, the reactions were quenched by adding 
hydroxylamine (8 µL, 5% w/v) and maintaining the sample at room temperature for 15 
minutes.  The TMT labeled peptide samples representing each trial were pooled into a 
single tube for LC-MS/MS analysis. LC-MS/MS analysis was carried out by Dr. Joseph 
Caruso at Protemomics Core Facility at Wayne State University. The peptides were first 
separated by reverse phase chromatography over a 90 min gradient (5% - 28% 
acetonitrile in 0.1% formic acid) followed by a 20 min gradient (28% - 40% acetonitrile in 
0.1% formic acid) using an Easy-nLC pump (Thermo) at 300 nl/min. Peptides were 
analyzed with an Orbitrap Fusion Tribrid mass spectrometer (Thermo). MS1 scans were 
performed within the orbitrap at a 120,000 resolution and 350-1600 m/z scan range. The 
top 10 ions with a charge of +2 to +7 were isolated in the ion trap and fragmented with 
CID (30% collision energy; activation Q = 0.25). Dynamic exclusion was turned on (after 
1 isolation the ion was excluded for analysis for 30 s). Quantitation of isobaric TMT tags 
was performed with MS3 scans. The top 10 fragment ions were isolated, re-fragmented 
by HCD (65% collision energy) and sent to the orbitrap for analysis (60,000 resolution 
over a scan range of 100-500 m/z).   
3.4.13: LC-MS/MS analysis for K-BIPS study with PP1-Gadd34 and PP1-MYPT1 
inactivation  
Biotinylated proteins from eluate lanes from gels described in section 3.4.10 were 
excised from gel and trypsin digested as previously described in section 2.6.15.85 LC-
MS/MS analysis was performed by Dr.Joseph Caruso at Protemomics Core Facility at 
Wayne State University as described in section 2.6.16.  
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3.4.14: MS data analysis for K-BIPS study with OA-mediated phosphatase 
inactivation, PP1-Gadd34 and PP1-MYPT1 inactivation  
MS raw data was analyzed by MaxQuant (version 1.5.2.8). A human protein 
database from UniProt (downloaded 2016.04.07, 20159 entries) was used for the K-BIPS 
studies with HeLa. A rat database from Uniprot was used for K-BIPS study with L6 lysates. 
Searches allowed 2 missed tryptic cleavages. The iodoacetamide derivative of cysteine 
was set as a fixed modification, while oxidation of methionine and acetylation of protein 
N-termini were set as variable modifications. Mass tolerances for parent ions were 20 
ppm for the first search and 4.5 ppm for the second search and 20 ppm for fragment ions.  
Minimum protein and peptide identification probabilities were specified at ≤1% false 
discovery rate (FDR) as determined by a reversed database search and proteins required 
1 unique peptide. All other parameters were used at their default settings.  Fold 
enrichment for OA-mediated K-BIPS study was calculated by dividing the TMT reporter 
intensity observed for the OA-untreated sample by that of the OA-treated sample. 
Proteins showing fold enrichment of at least 1.5 in both replicates were considered as K-
BIPS hits.  For PP1-Gadd34 inactivated K-BIPS study, fold enrichment was calculated by 
dividing the peptide intensity observed in the PP1-Gadd34-active sample by that 
observed for the PP1-Gadd34-inactive sample. Proteins showing fold enrichment of at 
least 1.3 in both replicates in the PP1-Gadd34 active sample compared to the PP1-
Gadd34 inactive sample were considered hits (Table B.2).  For K-BIPS study with MYPT1 
knock down, first proteins showing enrichment in all three trials (fold enrichment >1) were 
selected. Then, Student’s paired t-test with a two-tailed distribution was carried out and 
the average fold enrichment was calculated. Fourteen proteins showing P value > 0.05, 
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average fold enrichment >1.5 and at least 2 unique peptides were selected as the best 
candidates (Table 3.5 and B.3). In addition proteins that showed at least 2-fold enrichment 
in the MYPT1-active sample compared to the MYPT1-inactive sample in at least out of 
the three replicates were also considered as potential hits (Table 3.6 and B.4).  
3.4.15: Streptavidin enrichment of COPS5, WDR5, CAPRIN1 and G3BP1 from PP1-
Gadd34 inactivated lysates 
Biotinylated proteins from section 3.4.8 (using 16.7 mg/mL lysates) were 
streptavidin enriched as described in section 3.4.10.  The eluted proteins (30% of eluate 
for COPS5 and 100% for WDR5, CAPRIN1 and G3BP1) and the input, flow through, and 
the last wash from streptavidin enrichment (section 3.4.10) were separated on SDS-
PAGE (section 2.6.4). The proteins were then transfereed onto a PVDF membrane and 
probed by specific antibodies; COPS5 (Santa Cruz-SC-9074, 1:200 dilution), WDR5 
(Bethyl Laboratories, A302-429A-T, 1:1000 dilution), CAPRIN1 (Bethyl Laboratories, 
A303-881A-T, 1:1000 dilution), G3BP1 (Bethyl Laboratories, A302-033, 1:1000 dilution).  
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APPENDIX A – CHAPTER 2 SUPPORTING INFORMATION 
A2.1 Peptide characterization  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.1.1: Characterization of N-biotin kemptide (biotin-GGGGLRRASLG). (A) 
Reinjection of 50ug of purified N-biotin kemptide (arrow). Elution gradient used started 
with 95% Buffer A (99.9% water with 0.1% trifluoroacetic acid) in Buffer B (acetonitrile in 
0.085% trifluoroacetic acid) and decreased to 83% Buffer A over 11 minutes, then to 
81.5% Buffer A over 5 minutes, and finally to 80.6% Buffer A over 9 minutes. The flow 
rate was 1mL/min and the peptides were detected at 214 nM. (B) When characterized by 
MALDI-TOF, the purified N-biotin kemptide showed a [M+H]+ of 1226.68 m/z ([M+H]+ 
calculated for C50H88N19O15S =1226.64). 
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Figure A2.1.2: Characterization of N-biotin mutant kemptide (biotin-GGGGLRRAALG). 
(A) Reinjection of 50ug of purified N-biotin mutant kemptide (arrow). Elution gradient used 
started with 95% Buffer A in Buffer B and decreased to 83% Buffer A over 11 minutes, 
then to 81.5% Buffer A over 5 minutes, and finally to 80.6% Buffer A over 9 minutes. The 
flow rate was 1mL/min and the peptides were detected at 214 nM. (B) When characterized 
by MALDI-TOF, the peptide showed a [M+H]+ of 1210.76 ([M+H]+ calculated for 
C50H88N19O14S = 1210.65). 
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Figure A2.1.3: Characterization of non-biotinylated kemptide (GGGGLRRAALG). (A) 
Reinjection of 50ug of purified non-biotinylated kemptide (arrow). Elution gradient used 
started with 95% Buffer A in Buffer B and ended in 75% Buffer A over 16 minutes. The 
flow rate was 1mL/min and the peptides were detected at 214 nM. (B) When characterized 
by MALDI-TOF, the peptide showed a [M+H]+ of 1000.85 ([M+H]+ calculated for 
C40H74N17O13 = 1000.57). 
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Figure A2.1.4: Characterization of scrambled N-biotin kemptide (biotin-
LSGARGLGGRG). (A) Reinjection of 50ug of purified scrambled N-biotin kemptide 
(arrow). Elution gradient used started with 95% Buffer A in Buffer B and decreased to 
83% Buffer A over 11 minutes, then to 81.5% Buffer A over 5 minutes, and finally to 80.6% 
Buffer A over 9 minutes. The flow rate was 1mL/min and the peptides were detected at 
214 nM. (B) When characterized by MALDI-TOF (performed by N.Chinthaka), the peptide 
showed a [M+H]+ of 1226.50 ([M+H]+ calculated for C50H88N19O15S= 1226.64). 
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Figure A2.1.5: Characterization of N-biotin CK2 substrate peptide (biotin-
RRREEETEEE, performed by T.Faner). (A) Reinjection of 50ug of purified N-biotin CK2 
substrate peptide (arrow). Elution gradient used started with 86.7% Buffer A in Buffer B 
and decreased to 70% Buffer A over 10 minutes. The flow rate was 1mL/min and the 
peptides were detected at 214 nM. (B) When characterized by MALDI-TOF, the peptide 
showed a [M+H]+ of 1588.14 ([M+H]+ calculated for C62H101N21O26S= 1588.69). 
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Figure A2.1.6: Characterization of Non-biotinylated CK2 substrate peptide 
(RRREEETEEE, performed by T.Faner). (A) Reinjection of 50ug of purified non-
biotinylated CK2 substrate peptide (arrow). Isocratic elution at 86% was used. The flow 
rate was 1mL/min and the peptides were detected at 214 nM. (B) When characterized by 
MALDI-TOF, the peptide showed a [M+H]+ of 1362.36 ([M+H]+ calculated for 
C52H87N19O24= 1362.62). 
 
 
 
 
 
 
 
 
(A) 
A
U
0.00
1.00
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
(B) 
115 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.1.7: Characterization of N-biotin Miz1 peptide (biotin-
GGQAESASSGAEQTEK). (A) Reinjection of 50ug of purified N-biotin Miz1 peptide 
(arrow). Elution gradient used started with 95% Buffer A in Buffer B and decreased to 
75% Buffer A over 22 minutes. The flow rate was 1mL/min and the peptides were detected 
at 214 nM. (B) When characterized by MALDI-TOF, the peptide showed a [M+H]+ of 
1762.56 ([M+H]+ calculated for C69H111N21O31S =1762.90). 
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Figure A2.1.8: Characterization of N-biotin mutant Miz1 peptide (biotin-
GGQAESASAGAEQTEK). (A) Reinjection of 50ug of purified N-biotin mutant Miz1 
peptide (arrow). Elution gradient used started with 95% Buffer A in Buffer B and 
decreased to 75% Buffer A over 16 minutes. The flow rate was 1mL/min and the peptides 
were detected at 214 nM. (B) When characterized by MALDI-TOF, the peptide showed a 
[M+H]+ of 1747.27 ([M+H]+ calculated for C69H111N21O30S =1746.98). 
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Figure A.2.2: Replicates (A-G) of in vitro crosslinking reactions with recombinant PKA 
shown in Figure 2.5. Crosslinking reactions were carried out with recombinant PKA, N-
biotin kemptide (B-kem) and ATP-ArN3. After reaction, the samples were separated by 
SDS-PAGE and stained with Sypro® Ruby total protein stain (bottom) or Streptavidin-
Cy5 for biotinylation (top). Control reactions were carried out with a mutant biotin 
kemptide lacking the phosphorylated Ser (B-kem mt), 4X excess ATP, 2X excess non-
biotinylated kemptide (kem), with N-biotin scrambled peptide (scr kem) and heat 
inactivated PKA (HI PKA). Trial A and F are shown in Figure 2.5. The molecular weight 
marker is shown, with bands corresponding to the following molecular weights: 170, 130, 
95, 72, 55, 43, 34, and 26 kDa. 
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Figure A.2.3: Replicates of in vitro crosslinking reactions with recombinant PKA with 
biotin peptide pre-incubated with ATP-ArN3 shown in Figure 2.7. N-biotin kemptide (B-
kem), N-biotin mutant kemptide (B-kem mt), or scrambled kemptide (scr kem) was pre-
incubated with ATP-ArN3 in the presence of UV light. Then recombinant PKA was added 
and crosslinking reactions were carried out. After reaction, the samples were separated 
by SDS-PAGE and stained with Sypro® Ruby total protein stain (bottom) or Streptavidin-
Cy5 for biotinylation (top). Control reactions were carried out without pre-incubation. The 
first trial is shown in Figure 2.7. 
 
 
 
 
 
 
 
 1 2 3 4 1 2 3 4 5 6 1 2 3 4 5 6 
B-kem + + - - + + - - - - + + - - - - 
B-kem mt  - - + - - - + + - - - - + + - - 
scr kem - - - + - - - - + + - - - - + + 
ATP-ArN3 + + + + + + + + + + + + + + + + 
Pre-incubation no yes yes yes no yes no yes no yes no yes no yes no yes 
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Figure A.2.4: Replicates of in vitro crosslinking reactions with recombinant CK2 shown 
in Figure 2.8. Crosslinking reactions were carried out with recombinant CK2, N-biotin CK2 
substrate peptide (B-sub) and ATP-ArN3. After reaction, the samples were separated by 
SDS-PAGE and stained with Sypro® Ruby total protein stain (bottom) or Streptavidin-
Cy5 for biotinylation (top). Control reactions were carried out with ATP, 4X excess ATP 
and 2X excess non-biotinylated CK2 substrate peptide (sub). Trial 1 is shown in Figure 
2.8. 
 
 
 
 
 
 
 
 
 1 2 3 4  1 2 3 4  1 2 3 4  
B-sub + + + +  + + + +  + + + +  
sub - - - 2X  - - - 2X  - - - 2X  
ATP-ArN3 + - + +  + - + +  + - + +  
ATP - + 4X -  - + 4X -  - + 4X -  
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Figure A.2.5: Three replicates of crosslinking reactions in HeLa lysates shown in Figure 
2.10. Crosslinking reactions contained HeLa lysates, N-biotin kemptide (B-kem), and 
ATP-ArN3 (lane 2). Control reactions were carried out with a N-biotin mutant kemptide 
lacking Ser (B-kem mt, lane 3), in the presence of 1X non-biotinylated kemptide (kem, 
lane 4), or after pre-incubation with the kinase inhibitor staurosporine (lane 5). The top 
gel was Streptavidin-Cy5 stained to visualize biotinylated proteins, the middle gel was 
SYPRO® Ruby stained to observe all proteins, and the bottom gel was immunoblotted 
with an anti-PKA antibody to assure the presence of PKA. Trial 1 is shown in Figure 2.10.  
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Figure A.2.6: Gel images from the kemptide K-CLASP experiment. Crosslinking 
reactions were carried out with HeLa lysate and N-biotin kemptide (B-kem) in the 
presence of ATP-ArN3 (lanes 2, 5, and 8 in first gel and lanes 2, 5, and 9 in second gel). 
Control reactions were performed without ATP-ArN3 (lanes 1, 4, and 7) or with N-biotin 
mutant kemptide (B-kem mt) in place of N-biotin kemptide (lanes 3, 6, and 9 in first gel 
and lanes 2, 5, and 7 in second gel). After reaction, biotinylated proteins were enriched 
using streptavidin resin. The input before streptavidin enrichment (11% loaded per gel, 
lanes 1-3), flow through (8% loaded per gel, lanes 4-6), and the elution from each sample 
(33% loaded per gel, lanes 7-9) were separated by SDS-PAGE and then stained for total 
proteins using SYPRO® Ruby stain (top gel). PKA was visualized using an anti-PKA 
antibody (bottom gel). The shown gels were used in LC-MS/MS analysis.  
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Table A.2.1: Full listing of the 324 kemptide K-CLASP hitsa  
Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
SNAP23 3.8E+08 3.2E+08 2.3E+07 0.0E+00 2.5E+08 1.1E+08 1.2 ∞ 2.4 
PSMD9 5.6E+07 2.2E+07 2.7E+06 1.1E+07 2.8E+07 0.0E+00 2.5 0.3 ∞ 
GAPDHS 2.7E+07 0.0E+00 2.2E+07 0.0E+00 1.8E+07 0.0E+00 ∞ ∞ ∞ 
AP3D1 1.9E+07 3.1E+06 0.0E+00 0.0E+00 2.7E+07 1.1E+07 6.1 0 2.5 
CCS 1.1E+08 0.0E+00 0.0E+00 5.0E+07 1.7E+07 0.0E+00 ∞ 0 ∞ 
MAP2K7 1.7E+07 0.0E+00 0.0E+00 0.0E+00 3.9E+07 0.0E+00 ∞ 0 ∞ 
PDCD5 1.7E+09 1.7E+08 5.0E+07 4.6E+07 1.6E+07 5.3E+06 10.4 1.1 3 
SLC9A3R1 3.5E+08 9.7E+07 7.8E+07 0.0E+00 8.4E+07 0.0E+00 3.7 ∞ ∞ 
CHEK1 6.2E+06 0.0E+00 9.0E+05 9.5E+06 7.4E+07 0.0E+00 ∞ 0.1 ∞ 
GEMIN2 5.4E+07 8.4E+07 7.9E+06 0.0E+00 1.3E+07 0.0E+00 0.7 ∞ ∞ 
GIPC1 1.4E+08 1.7E+08 4.5E+07 1.8E+07 1.5E+08 6.9E+07 0.9 2.5 2.3 
PPP1R12A 2.0E+07 2.0E+06 0.0E+00 0.0E+00 3.3E+07 1.5E+07 10 0 2.2 
PFAS 6.8E+07 0.0E+00 0.0E+00 1.5E+07 9.7E+08 1.1E+07 ∞ 0 86.2 
SCAMP1 4.7E+07 0.0E+00 6.6E+06 0.0E+00 1.3E+08 6.8E+07 ∞ ∞ 1.9 
CTAGE5 4.4E+07 0.0E+00 0.0E+00 0.0E+00 2.3E+07 1.2E+07 ∞ 0 2 
ZW10 3.6E+07 1.6E+07 0.0E+00 0.0E+00 1.3E+08 5.1E+07 2.3 0 2.6 
TPD52L2 4.1E+09 1.7E+09 6.4E+08 5.1E+08 1.1E+09 5.4E+08 2.5 1.3 2.1 
EPB41L2 3.6E+08 6.4E+06 4.0E+06 0.0E+00 1.7E+08 1.1E+08 55.8 ∞ 1.6 
DENR 6.9E+07 3.2E+08 4.8E+07 7.1E+06 7.1E+08 2.8E+08 0.3 6.9 2.6 
HTATSF1 4.8E+08 2.7E+07 1.8E+07 0.0E+00 3.8E+08 2.8E+08 17.9 ∞ 1.4 
NUDT21 1.6E+09 1.1E+09 1.3E+08 3.1E+07 4.7E+08 1.5E+08 1.5 4.2 3.2 
LANCL1 4.9E+08 2.1E+08 1.5E+08 2.8E+08 4.1E+08 1.9E+08 2.4 0.6 2.2 
RAD21 1.0E+08 2.9E+07 1.1E+08 0.0E+00 1.1E+08 1.2E+08 3.6 ∞ 0.9 
GMFB 1.9E+08 7.8E+07 0.0E+00 0.0E+00 6.9E+07 0.0E+00 2.4 0 ∞ 
EIF4E2 1.7E+07 5.2E+06 0.0E+00 0.0E+00 3.7E+07 0.0E+00 3.3 0 ∞ 
DNAJA2 4.8E+08 1.8E+08 3.2E+07 4.6E+07 4.1E+08 2.0E+08 2.7 0.8 2.1 
CUTA 1.5E+08 1.0E+08 6.8E+06 0.0E+00 2.1E+08 6.7E+07 1.5 ∞ 3.1 
CLASP2 1.1E+07 0.0E+00 0.0E+00 0.0E+00 2.7E+06 0.0E+00 ∞ 0 ∞ 
NDUFS7 1.7E+07 0.0E+00 2.4E+07 0.0E+00 0.0E+00 0.0E+00 ∞ ∞ 0 
ZPR1 6.5E+07 2.1E+07 4.3E+06 0.0E+00 3.4E+07 8.6E+07 3.1 ∞ 0.4 
ERLIN1 4.2E+07 0.0E+00 0.0E+00 0.0E+00 1.9E+07 0.0E+00 ∞ 0 ∞ 
TIPRL 1.1E+08 6.9E+07 1.4E+07 0.0E+00 1.2E+08 1.3E+07 1.6 ∞ 9.6 
NUP155 1.2E+08 4.7E+06 9.4E+06 2.3E+06 6.4E+08 4.5E+08 26.5 4.1 1.5 
DCTN3 1.2E+09 4.2E+08 2.8E+07 4.1E+07 7.7E+07 2.2E+07 2.8 0.7 3.5 
SNCG 2.3E+08 2.3E+07 8.9E+05 0.0E+00 0.0E+00 3.7E+07 10.2 ∞ 0 
UBXN7 3.3E+07 0.0E+00 2.3E+07 0.0E+00 9.1E+07 7.8E+07 ∞ ∞ 1.2 
PROSC 1.5E+08 7.6E+07 6.1E+07 8.2E+07 1.9E+08 8.4E+07 2 0.8 2.3 
GLS 4.5E+08 8.2E+07 0.0E+00 0.0E+00 5.5E+08 1.3E+08 5.5 0 4.3 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
HEXIM1 9.4E+07 0.0E+00 2.0E+07 2.2E+07 4.8E+07 1.8E+07 ∞ 1 2.6 
KIF4A 1.3E+07 4.8E+06 0.0E+00 0.0E+00 2.7E+08 8.1E+07 2.9 0 3.4 
PGM3 1.2E+08 1.6E+08 1.5E+08 5.8E+07 2.2E+08 8.3E+07 0.8 2.6 2.7 
UTS2 0.0E+00 0.0E+00 1.3E+09 2.0E+07 3.9E+07 0.0E+00 0 69.1 ∞ 
TDP2 2.0E+07 0.0E+00 8.9E+06 0.0E+00 2.0E+07 2.8E+07 ∞ ∞ 0.8 
DDAH2 6.3E+07 0.0E+00 1.3E+07 6.5E+06 1.4E+07 5.3E+07 ∞ 2 0.3 
ACTL6A 4.4E+08 1.7E+08 2.6E+07 1.4E+08 1.1E+09 1.6E+08 2.7 0.2 7.2 
GLUD1 4.6E+08 7.5E+08 6.5E+08 1.5E+08 1.9E+09 1.1E+08 0.7 4.3 17.1 
HPRT1 1.8E+09 3.5E+08 2.9E+08 1.2E+08 3.1E+08 2.3E+07 5.1 2.6 13.7 
AK1 1.1E+09 5.4E+08 1.9E+08 4.3E+07 3.1E+08 2.9E+07 2.2 4.5 10.6 
ALDOA 4.8E+10 2.9E+10 1.2E+10 5.4E+09 5.7E+10 4.9E+09 1.7 2.2 11.6 
SOD2 2.1E+09 2.2E+09 2.2E+08 7.9E+07 2.9E+09 3.5E+08 1 2.9 8.5 
EIF2S1 4.0E+09 3.0E+09 1.9E+09 9.8E+08 4.0E+09 1.7E+09 1.4 2 2.5 
S100A6 4.4E+10 2.3E+10 6.9E+09 2.5E+08 6.5E+08 1.3E+10 2 27.4 0.1 
EPHX1 3.4E+07 0.0E+00 3.4E+07 0.0E+00 8.6E+07 3.6E+07 ∞ ∞ 2.5 
ANXA2 4.0E+10 2.7E+10 1.1E+10 4.1E+09 4.4E+10 2.2E+09 1.6 2.8 20.1 
APRT 1.6E+09 7.9E+08 4.4E+08 2.4E+08 1.5E+09 4.4E+08 2.1 1.9 3.4 
SNRNP70 0.0E+00 1.9E+07 8.3E+07 3.8E+07 6.9E+07 3.3E+07 0 2.2 2.2 
ANXA5 7.7E+09 6.0E+09 1.7E+09 4.5E+08 9.3E+09 4.2E+09 1.3 3.8 2.3 
HMGB1 1.1E+09 1.3E+09 1.3E+08 5.5E+07 1.8E+09 6.4E+08 0.9 2.4 2.9 
DLD 1.3E+08 3.8E+08 8.5E+08 3.6E+08 2.7E+09 5.9E+08 0.4 2.4 4.6 
SNRPA1 1.2E+09 1.0E+09 3.0E+08 1.3E+08 8.0E+08 2.0E+08 1.2 2.3 4.1 
ALDOC 3.8E+09 1.8E+09 6.8E+08 5.5E+08 3.2E+09 3.8E+08 2.1 1.3 8.4 
CHTF8 0.0E+00 0.0E+00 3.0E+07 0.0E+00 3.6E+07 0.0E+00 0 ∞ ∞ 
DLAT 1.3E+08 2.1E+08 3.3E+07 8.3E+06 5.5E+08 2.8E+08 0.7 4.1 2 
ESD 6.1E+08 4.0E+08 1.2E+07 0.0E+00 1.2E+08 0.0E+00 1.6 ∞ ∞ 
IGF2R 1.4E+08 1.1E+07 2.9E+06 0.0E+00 2.1E+08 1.7E+08 12 ∞ 1.3 
CKMT1A 2.3E+07 0.0E+00 8.7E+06 0.0E+00 4.0E+07 0.0E+00 ∞ ∞ ∞ 
APEH 3.9E+07 0.0E+00 9.2E+07 7.1E+07 3.7E+08 1.8E+08 ∞ 1.3 2 
ENO3 3.2E+08 7.8E+07 2.0E+07 1.2E+07 7.0E+08 3.6E+08 4.1 1.7 2 
MTHFD2 1.5E+08 3.1E+07 1.1E+07 0.0E+00 9.3E+07 1.2E+08 4.8 ∞ 0.8 
FDPS 4.2E+09 5.1E+08 3.2E+08 1.8E+08 1.5E+09 3.6E+08 8.3 1.9 4.2 
CPM 2.6E+07 1.4E+07 2.2E+06 0.0E+00 4.8E+07 0.0E+00 1.9 ∞ ∞ 
CD46 4.3E+08 2.0E+08 8.4E+07 1.4E+07 8.1E+07 5.2E+07 2.2 6.1 1.6 
NME1 5.2E+09 1.8E+09 7.1E+08 4.2E+07 1.6E+09 4.8E+08 3 17 3.4 
DSP 5.1E+07 1.9E+06 0.0E+00 8.8E+06 1.9E+08 6.6E+07 27.1 0 3 
NQO2 5.3E+08 1.5E+08 5.7E+07 1.7E+07 5.5E+07 0.0E+00 3.5 3.4 ∞ 
FAH 0.0E+00 1.6E+07 2.3E+07 1.1E+07 1.8E+07 5.3E+06 0 2.1 3.5 
STMN1 8.5E+08 4.4E+08 1.1E+08 1.0E+08 2.3E+08 8.6E+07 2 1.1 2.7 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
ITGA2 2.3E+08 0.0E+00 0.0E+00 2.5E+07 6.0E+08 3.1E+08 ∞ 0 2 
PRKACA 3.0E+08 1.2E+08 5.6E+06 3.8E+06 4.4E+08 9.0E+07 2.6 1.5 4.9 
CAPN2 0.0E+00 0.0E+00 1.2E+07 0.0E+00 7.6E+07 3.9E+07 0 ∞ 2 
LGALS3 4.6E+09 1.9E+09 2.4E+08 4.6E+08 4.0E+09 1.3E+09 2.5 0.6 3.1 
ATP5J 1.3E+08 4.0E+07 0.0E+00 6.0E+05 3.6E+07 0.0E+00 3.3 0 ∞ 
PSMB1 1.5E+09 1.8E+09 5.9E+08 1.8E+08 8.0E+08 1.8E+08 0.9 3.4 4.5 
ATP6V1C1 3.4E+08 1.0E+08 1.2E+06 0.0E+00 1.3E+08 1.6E+08 3.4 ∞ 0.9 
SCP2 2.1E+08 1.0E+08 0.0E+00 0.0E+00 3.1E+07 0.0E+00 2.2 0 ∞ 
NME2 6.5E+07 7.3E+07 2.6E+07 0.0E+00 1.3E+08 0.0E+00 0.9 ∞ ∞ 
FDXR 2.8E+07 0.0E+00 9.4E+06 2.5E+06 3.7E+07 3.1E+07 ∞ 3.8 1.3 
TUBG2 1.5E+08 2.6E+07 7.4E+06 0.0E+00 7.6E+06 0.0E+00 5.9 ∞ ∞ 
NFYA 2.3E+07 0.0E+00 0.0E+00 0.0E+00 1.4E+07 0.0E+00 ∞ 0 ∞ 
ACP1 2.3E+09 9.3E+08 3.2E+08 1.8E+08 7.1E+08 1.7E+08 2.5 1.8 4.2 
MPST 3.2E+08 3.8E+08 5.9E+07 1.6E+07 1.1E+08 2.4E+07 0.9 3.8 4.4 
RPS12 1.1E+10 4.7E+09 1.3E+09 6.1E+08 3.4E+09 1.2E+09 2.3 2.2 2.9 
PSMA4 8.3E+08 5.7E+08 3.3E+08 1.6E+08 1.5E+09 3.3E+08 1.5 2.1 4.6 
S100P 4.2E+09 1.7E+07 7.3E+08 9.3E+08 2.1E+09 1.1E+09 248.6 0.8 2 
TARS 2.8E+09 1.2E+09 1.5E+09 1.4E+09 6.7E+09 1.6E+09 2.3 1.1 4.3 
PSMB8 2.6E+08 1.3E+08 4.7E+07 1.3E+07 1.3E+08 0.0E+00 2 3.7 ∞ 
PSMB4 2.1E+09 2.0E+09 9.6E+08 4.1E+08 1.0E+09 2.5E+08 1.1 2.4 4.3 
PSMB6 2.3E+09 2.2E+09 1.0E+09 4.6E+08 1.2E+09 2.2E+08 1.1 2.3 5.5 
PSMB5 1.4E+09 1.1E+09 7.8E+08 2.6E+08 1.6E+09 1.0E+08 1.3 3 16.1 
TM4SF1 0.0E+00 0.0E+00 3.6E+07 0.0E+00 8.9E+06 0.0E+00 0 ∞ ∞ 
CASP14 2.4E+08 1.7E+07 0.0E+00 1.2E+07 3.4E+08 3.4E+07 14.4 0 10 
KIF5B 2.3E+08 4.3E+07 4.5E+07 1.6E+07 8.1E+08 1.9E+09 5.4 2.8 0.5 
SPR 5.5E+08 2.2E+08 3.6E+07 1.0E+08 8.3E+07 0.0E+00 2.6 0.4 ∞ 
FUS 1.1E+09 2.0E+08 2.1E+07 6.0E+07 1.8E+08 8.4E+07 5.7 0.4 2.2 
GLRX 2.8E+08 1.4E+07 7.2E+06 0.0E+00 0.0E+00 0.0E+00 20 ∞ 0 
ARL2 2.7E+08 2.8E+07 5.0E+07 3.0E+07 1.5E+08 0.0E+00 9.8 1.7 ∞ 
NUDT1 4.5E+08 2.5E+07 2.8E+07 0.0E+00 0.0E+00 0.0E+00 17.7 ∞ 0 
NUP62 3.8E+07 0.0E+00 0.0E+00 1.6E+07 5.5E+07 0.0E+00 ∞ 0 ∞ 
TXLNA 1.8E+07 1.2E+08 4.2E+07 1.9E+07 1.7E+08 7.0E+07 0.2 2.2 2.4 
NAA10 5.3E+08 1.6E+08 0.0E+00 3.6E+07 4.6E+08 1.9E+08 3.4 0 2.5 
PPP1R2P3 5.1E+08 1.2E+07 0.0E+00 1.6E+07 5.6E+08 1.6E+08 43.7 0 3.7 
STAT1 5.3E+07 8.0E+07 4.8E+07 1.1E+07 3.3E+08 1.5E+08 0.7 4.6 2.3 
EPS15 3.9E+07 0.0E+00 0.0E+00 5.0E+06 5.5E+07 2.6E+07 ∞ 0 2.2 
CRKL 1.5E+08 2.0E+08 1.7E+07 0.0E+00 3.8E+07 0.0E+00 0.8 ∞ ∞ 
ALDH9A1 9.3E+07 1.3E+08 1.9E+07 0.0E+00 6.3E+08 4.8E+07 0.8 ∞ 13.2 
DHPS 8.2E+07 0.0E+00 1.2E+07 0.0E+00 0.0E+00 0.0E+00 ∞ ∞ 0 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
PRIM1 2.1E+07 9.0E+06 1.1E+07 0.0E+00 2.4E+07 3.0E+07 2.4 ∞ 0.8 
PSMB2 1.4E+09 4.4E+08 1.7E+08 1.3E+08 4.7E+08 1.0E+08 3.3 1.4 4.7 
EIF2B2 1.0E+08 4.4E+08 4.3E+07 0.0E+00 1.6E+08 5.2E+07 0.3 ∞ 3.1 
NUP153 3.8E+07 0.0E+00 0.0E+00 0.0E+00 2.0E+07 0.0E+00 ∞ 0 ∞ 
NT5C2 1.6E+07 0.0E+00 5.7E+06 0.0E+00 3.1E+07 1.0E+07 ∞ ∞ 3 
SEPHS1 8.4E+07 7.0E+06 2.3E+07 0.0E+00 2.1E+07 0.0E+00 12 ∞ ∞ 
KNTC1 1.9E+07 2.6E+07 8.1E+07 0.0E+00 3.4E+08 1.5E+08 0.8 ∞ 2.3 
PPT1 5.5E+08 0.0E+00 3.1E+07 0.0E+00 7.7E+07 3.1E+07 ∞ ∞ 2.6 
FXR2 3.6E+07 0.0E+00 2.2E+06 0.0E+00 2.2E+07 4.4E+07 ∞ ∞ 0.6 
MMP15 0.0E+00 0.0E+00 1.1E+07 0.0E+00 7.2E+07 3.8E+07 0 ∞ 2 
SMARCA4 2.2E+07 0.0E+00 0.0E+00 5.4E+06 8.0E+07 3.0E+07 ∞ 0 2.7 
METAP1 6.4E+07 0.0E+00 2.5E+07 1.8E+07 1.2E+08 0.0E+00 ∞ 1.4 ∞ 
BID 2.0E+08 2.6E+07 1.9E+07 0.0E+00 3.2E+07 6.2E+07 8 ∞ 0.6 
KCNQ4 7.1E+08 7.0E+08 4.6E+07 0.0E+00 3.9E+08 0.0E+00 1.1 ∞ ∞ 
SEC61G 1.9E+08 0.0E+00 0.0E+00 4.1E+06 3.7E+07 1.3E+07 ∞ 0 2.9 
CXCR4 0.0E+00 6.2E+07 3.2E+07 1.4E+07 9.8E+07 0.0E+00 0 2.4 ∞ 
UBE2K 3.6E+08 5.7E+08 5.1E+08 1.8E+08 3.2E+08 8.2E+07 0.7 2.9 3.9 
RPL37A 6.9E+08 1.3E+09 1.7E+08 7.7E+07 5.6E+08 2.6E+08 0.6 2.2 2.3 
HSPE1 1.4E+09 6.7E+08 3.5E+08 2.7E+08 5.6E+08 1.2E+08 2.2 1.3 4.7 
SUMO2 1.2E+09 0.0E+00 1.4E+08 1.0E+08 2.8E+08 8.4E+07 ∞ 1.4 3.4 
RPS29 8.0E+08 3.5E+08 4.4E+07 1.2E+07 9.6E+08 6.6E+07 2.4 3.7 14.6 
CNBP 9.8E+07 5.8E+07 4.9E+06 0.0E+00 6.2E+07 2.8E+07 1.8 ∞ 2.3 
RPL32 2.8E+09 3.3E+09 2.5E+08 5.8E+07 2.7E+09 1.1E+09 0.9 4.4 2.6 
DYNLT1 2.0E+08 4.7E+07 0.0E+00 1.6E+07 1.6E+07 7.5E+06 4.3 0 2.2 
UBE2I 6.6E+08 2.6E+08 1.5E+07 0.0E+00 1.4E+08 2.0E+07 2.6 ∞ 7.2 
HIST2H3A 1.5E+09 5.4E+08 3.8E+08 5.5E+08 1.5E+09 7.1E+08 2.8 0.7 2.2 
GSTO1 1.6E+09 3.2E+08 1.2E+08 4.2E+07 9.1E+07 1.1E+08 4.9 2.8 0.9 
MRPS34 1.7E+08 2.5E+08 2.1E+07 0.0E+00 2.4E+08 1.2E+08 0.7 ∞ 2.1 
RPL36AL 1.2E+09 1.9E+09 1.9E+08 4.9E+07 6.6E+08 2.9E+08 0.7 4 2.3 
RPL19 4.7E+09 1.2E+09 8.3E+08 9.7E+08 4.2E+09 8.9E+08 4.1 0.9 4.8 
SPTBN1 4.4E+08 0.0E+00 2.9E+08 1.4E+08 5.5E+08 6.5E+08 ∞ 2.1 0.9 
HMGCS1 2.2E+07 0.0E+00 1.3E+07 0.0E+00 1.1E+08 1.4E+08 ∞ ∞ 0.9 
AKAP12 2.8E+08 1.6E+07 3.9E+07 3.2E+07 5.1E+08 2.0E+08 16.8 1.3 2.6 
GLO1 4.0E+09 1.2E+09 9.6E+08 6.2E+08 1.4E+09 5.9E+08 3.5 1.6 2.4 
PLP2 1.4E+09 5.5E+08 9.4E+06 0.0E+00 1.9E+08 3.3E+08 2.7 ∞ 0.6 
TJP1 4.8E+07 1.2E+07 0.0E+00 0.0E+00 1.7E+08 6.3E+07 4 0 2.7 
KLC1 4.2E+07 0.0E+00 0.0E+00 0.0E+00 5.1E+07 2.1E+07 ∞ 0 2.4 
DHX9 6.6E+08 1.6E+08 5.2E+08 1.6E+08 1.8E+09 1.9E+09 4.2 3.4 1 
CRYZ 7.5E+08 3.5E+08 1.2E+08 9.3E+07 6.0E+08 8.3E+06 2.2 1.3 71.7 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
HDHD1 1.0E+08 1.3E+08 4.4E+07 0.0E+00 2.9E+07 0.0E+00 0.8 ∞ ∞ 
AP1B1 8.8E+06 0.0E+00 0.0E+00 0.0E+00 2.2E+08 3.7E+07 ∞ 0 6 
LMAN2 1.3E+09 6.7E+08 1.6E+08 1.1E+09 2.5E+09 5.2E+08 2 0.2 4.9 
ANK3 1.0E+07 0.0E+00 0.0E+00 0.0E+00 1.6E+07 7.7E+06 ∞ 0 2.1 
MTAP 1.6E+08 1.8E+07 0.0E+00 0.0E+00 5.2E+06 0.0E+00 8.8 0 ∞ 
SRSF6 0.0E+00 3.7E+08 3.0E+07 1.4E+07 2.3E+08 3.0E+07 0 2.2 7.7 
PDAP1 4.2E+08 1.1E+08 5.6E+07 3.1E+07 4.6E+07 1.7E+07 3.7 1.9 2.8 
CUL1 9.3E+07 3.6E+07 4.8E+06 6.1E+06 4.1E+08 1.3E+08 2.6 0.8 3.1 
FHL3 5.1E+07 7.4E+07 4.2E+07 0.0E+00 6.0E+07 0.0E+00 0.7 ∞ ∞ 
COTL1 2.5E+09 1.9E+09 6.2E+08 5.9E+07 6.1E+08 1.8E+08 1.4 10.6 3.5 
IL18 2.1E+08 5.0E+07 5.0E+06 0.0E+00 3.3E+07 0.0E+00 4.3 ∞ ∞ 
SCRIB 2.9E+07 0.0E+00 1.8E+07 0.0E+00 1.4E+08 1.5E+08 ∞ ∞ 1 
ENDOG 3.6E+07 0.0E+00 1.1E+07 1.5E+06 7.6E+06 0.0E+00 ∞ 7.2 ∞ 
SMC1A 8.6E+08 1.4E+08 1.6E+07 8.6E+07 2.0E+09 8.1E+08 6.2 0.2 2.5 
EXOSC7 9.6E+07 8.5E+07 5.3E+06 0.0E+00 3.0E+07 1.2E+07 1.2 ∞ 2.6 
ARL6IP1 2.1E+08 0.0E+00 5.7E+06 0.0E+00 1.0E+08 2.9E+07 ∞ ∞ 3.5 
RAB3GAP
1 1.7E+07 0.0E+00 0.0E+00 0.0E+00 2.9E+07 0.0E+00 ∞ 0 ∞ 
PAFAH1B3 5.3E+07 0.0E+00 1.3E+08 1.1E+08 1.1E+08 5.0E+07 ∞ 1.3 2.2 
PPA1 5.2E+09 2.1E+09 3.0E+08 3.1E+08 1.3E+09 4.5E+08 2.5 1 3 
RSU1 2.5E+08 4.2E+07 5.0E+06 0.0E+00 2.3E+08 2.7E+08 6 ∞ 0.9 
SEC23B 0.0E+00 2.1E+07 2.9E+07 8.6E+06 1.7E+08 3.8E+07 0 3.4 4.4 
SKIV2L 9.9E+07 0.0E+00 0.0E+00 0.0E+00 8.8E+07 3.1E+07 ∞ 0 2.9 
SLC9A3R2 8.7E+07 0.0E+00 2.1E+07 0.0E+00 9.0E+07 5.0E+07 ∞ ∞ 1.8 
SF1 5.4E+08 1.5E+08 2.8E+08 7.4E+07 2.8E+08 6.3E+08 3.7 3.9 0.5 
UBE2V2 6.4E+08 4.9E+08 2.7E+08 7.5E+07 1.4E+08 6.8E+07 1.4 3.6 2.1 
FXN 1.9E+07 1.8E+08 2.4E+06 0.0E+00 6.6E+07 0.0E+00 0.2 ∞ ∞ 
DECR1 8.4E+08 1.7E+08 2.1E+07 9.7E+07 1.4E+08 6.6E+07 5 0.3 2.1 
TST 3.4E+08 1.3E+08 1.7E+07 1.4E+07 2.6E+08 1.1E+08 2.6 1.2 2.5 
GUK1 5.6E+07 0.0E+00 3.8E+07 1.2E+07 5.4E+07 4.1E+07 ∞ 3.2 1.4 
HAGH 5.8E+07 0.0E+00 4.2E+07 4.9E+07 7.2E+07 0.0E+00 ∞ 0.9 ∞ 
IMMT 3.2E+07 3.5E+06 1.0E+08 4.5E+07 2.6E+08 1.2E+08 9.3 2.3 2.1 
HFE 1.4E+07 0.0E+00 0.0E+00 0.0E+00 3.2E+07 1.6E+07 ∞ 0 2 
NADK2 1.3E+08 2.1E+08 3.3E+07 1.4E+07 2.1E+08 3.9E+07 0.7 2.3 5.6 
TBC1D10B 3.4E+07 4.6E+07 7.1E+07 0.0E+00 1.2E+08 4.8E+07 0.8 ∞ 2.6 
HS1BP3 2.0E+07 0.0E+00 0.0E+00 0.0E+00 1.3E+07 0.0E+00 ∞ 0 ∞ 
RRP12 6.0E+06 0.0E+00 6.3E+06 0.0E+00 1.4E+08 6.6E+07 ∞ ∞ 2.2 
EXOSC6 6.8E+08 6.7E+08 7.9E+07 5.2E+06 1.7E+08 1.1E+07 1.1 15.2 16.3 
HP1BP3 0.0E+00 5.2E+07 8.0E+07 1.7E+07 2.8E+08 1.2E+08 0 4.8 2.4 
RARS2 1.0E+07 0.0E+00 0.0E+00 0.0E+00 7.6E+05 0.0E+00 ∞ 0 ∞ 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
UBAP2 4.1E+06 0.0E+00 0.0E+00 0.0E+00 3.0E+07 0.0E+00 ∞ 0 ∞ 
KIF24 3.4E+08 1.3E+08 1.2E+08 9.0E+07 5.2E+08 4.9E+07 2.8 1.4 10.7 
NT5DC1 1.5E+08 1.8E+08 9.8E+07 3.9E+07 6.1E+08 2.6E+08 0.9 2.5 2.4 
RNF20 2.3E+07 0.0E+00 0.0E+00 4.6E+07 2.4E+08 1.2E+08 ∞ 0 2 
LYPLAL1 5.8E+07 1.3E+07 0.0E+00 0.0E+00 2.7E+07 0.0E+00 4.5 0 ∞ 
RRAGA 3.2E+07 4.7E+07 1.5E+07 0.0E+00 1.8E+07 0.0E+00 0.7 ∞ ∞ 
RNF213 9.0E+07 3.0E+07 6.7E+06 0.0E+00 0.0E+00 5.2E+06 3.1 ∞ 0 
NSUN5P2 0.0E+00 0.0E+00 1.0E+07 0.0E+00 1.7E+07 0.0E+00 0 ∞ ∞ 
FAM91A1 0.0E+00 0.0E+00 2.6E+06 0.0E+00 8.9E+07 2.1E+07 0 ∞ 4.3 
MZT2B 2.5E+07 3.0E+07 1.6E+06 0.0E+00 1.1E+08 4.3E+07 0.9 ∞ 2.7 
MRPL14 1.3E+06 0.0E+00 5.9E+06 0.0E+00 2.3E+07 1.4E+07 ∞ ∞ 1.7 
METTL2B 7.3E+07 0.0E+00 3.5E+07 1.5E+07 7.2E+07 6.7E+07 ∞ 2.5 1.1 
PGM2L1 5.6E+07 0.0E+00 0.0E+00 0.0E+00 6.7E+07 0.0E+00 ∞ 0 ∞ 
RANBP10 6.0E+07 0.0E+00 1.8E+07 0.0E+00 9.0E+07 0.0E+00 ∞ ∞ ∞ 
QSOX2 2.4E+07 1.3E+07 0.0E+00 0.0E+00 1.9E+06 0.0E+00 2 0 ∞ 
UBE2R2 1.4E+08 6.4E+07 5.0E+06 0.0E+00 0.0E+00 0.0E+00 2.3 ∞ 0 
NUP54 2.2E+07 0.0E+00 0.0E+00 0.0E+00 1.9E+07 0.0E+00 ∞ 0 ∞ 
NUFIP2 1.7E+07 0.0E+00 4.9E+07 6.2E+06 0.0E+00 2.0E+07 ∞ 8.1 0 
IRF2BP2 2.0E+08 1.1E+08 1.1E+07 0.0E+00 5.5E+07 7.9E+07 2 ∞ 0.8 
GLRX5 1.1E+08 3.8E+08 5.0E+07 2.1E+07 7.8E+07 0.0E+00 0.3 2.4 ∞ 
SETD3 2.7E+07 0.0E+00 2.7E+07 3.9E+06 3.0E+07 1.7E+07 ∞ 7 1.8 
ZC3H18 9.5E+06 0.0E+00 0.0E+00 0.0E+00 4.2E+07 1.4E+07 ∞ 0 3 
ERC1 1.0E+08 0.0E+00 0.0E+00 0.0E+00 4.3E+08 4.0E+07 ∞ 0 10.7 
CCAR1 1.4E+07 0.0E+00 0.0E+00 8.3E+06 4.9E+07 2.6E+07 ∞ 0 2 
SUPV3L1 1.4E+08 1.4E+08 1.4E+07 0.0E+00 9.1E+07 3.5E+07 1.1 ∞ 2.6 
PHACTR4 0.0E+00 0.0E+00 9.0E+06 0.0E+00 2.9E+07 9.3E+06 0 ∞ 3.1 
EHBP1L1 7.2E+07 3.0E+07 3.9E+06 0.0E+00 5.3E+08 1.4E+08 2.4 ∞ 3.7 
TTC9C 1.2E+08 5.9E+07 7.9E+06 0.0E+00 7.6E+07 5.3E+07 2.1 ∞ 1.5 
NPEPL1 9.6E+06 0.0E+00 0.0E+00 5.2E+07 1.1E+08 1.5E+07 ∞ 0 7.4 
MRPL30 3.5E+07 1.2E+08 1.1E+07 3.8E+06 5.0E+06 0.0E+00 0.3 3.1 ∞ 
CEP192 3.8E+07 0.0E+00 0.0E+00 0.0E+00 2.8E+08 1.7E+07 ∞ 0 16.3 
GEMIN5 5.3E+07 0.0E+00 1.4E+07 3.7E+06 3.8E+08 2.6E+08 ∞ 3.8 1.5 
SHROOM3 7.5E+06 0.0E+00 1.6E+08 3.4E+05 0.0E+00 0.0E+00 ∞ 459.2 0 
PTPMT1 2.2E+07 0.0E+00 0.0E+00 4.9E+06 4.9E+07 2.2E+07 ∞ 0 2.3 
LEO1 4.6E+07 2.0E+07 7.3E+06 6.7E+06 1.4E+08 6.7E+07 2.3 1.1 2.1 
PCNP 8.1E+08 1.9E+08 0.0E+00 0.0E+00 1.3E+07 0.0E+00 4.3 0 ∞ 
NELFB 1.7E+08 6.3E+07 8.2E+07 4.3E+07 2.5E+08 2.8E+08 2.7 2 0.9 
GEMIN6 2.1E+08 1.1E+08 0.0E+00 0.0E+00 2.4E+07 0.0E+00 2.1 0 ∞ 
DDX1 5.8E+08 2.3E+08 2.3E+08 5.4E+08 2.6E+09 1.0E+09 2.5 0.5 2.6 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
ANP32B 4.0E+09 2.1E+09 3.1E+08 5.4E+08 3.2E+09 1.4E+09 2 0.6 2.4 
DLG3 2.2E+07 9.3E+06 0.0E+00 0.0E+00 1.5E+07 0.0E+00 2.4 0 ∞ 
ZNF622 2.0E+07 0.0E+00 9.2E+06 0.0E+00 1.4E+07 1.9E+07 ∞ ∞ 0.8 
PSMG2 1.0E+08 1.7E+07 3.0E+07 0.0E+00 1.6E+08 0.0E+00 6.3 ∞ ∞ 
ISOC2 5.7E+07 1.9E+07 0.0E+00 0.0E+00 3.6E+07 0.0E+00 3 0 ∞ 
FERMT2 2.8E+07 0.0E+00 6.3E+07 6.8E+06 1.1E+08 1.4E+08 ∞ 9.4 0.8 
ISOC1 5.3E+08 1.1E+08 9.8E+07 2.0E+07 3.1E+08 1.2E+08 4.9 4.9 2.6 
FLYWCH2 1.4E+09 1.7E+08 1.4E+08 6.8E+07 7.1E+07 4.8E+07 8.2 2.1 1.5 
MALSU1 9.0E+07 2.5E+07 6.7E+06 6.0E+06 5.7E+07 0.0E+00 3.6 1.2 ∞ 
DAZAP1 9.1E+07 0.0E+00 0.0E+00 0.0E+00 4.6E+07 2.2E+07 ∞ 0 2.1 
MED30 5.3E+07 0.0E+00 2.4E+05 1.4E+07 4.9E+07 0.0E+00 ∞ 0.1 ∞ 
PGAM5 1.7E+08 1.8E+05 3.6E+07 3.4E+07 1.3E+08 0.0E+00 928.3 1.1 ∞ 
DDRGK1 6.7E+07 2.1E+08 1.2E+08 4.5E+07 1.3E+08 2.6E+07 0.4 2.8 5 
TMX3 0.0E+00 0.0E+00 4.8E+07 0.0E+00 2.7E+08 0.0E+00 0 ∞ ∞ 
PRRC1 2.2E+07 0.0E+00 0.0E+00 0.0E+00 9.2E+06 3.5E+06 ∞ 0 2.7 
C16orf13 1.2E+07 0.0E+00 0.0E+00 0.0E+00 4.0E+07 0.0E+00 ∞ 0 ∞ 
ADO 1.2E+08 0.0E+00 1.9E+07 0.0E+00 0.0E+00 0.0E+00 ∞ ∞ 0 
MMS19 1.2E+06 0.0E+00 0.0E+00 0.0E+00 1.6E+07 0.0E+00 ∞ 0 ∞ 
MYCBP 2.8E+08 1.3E+08 1.8E+07 0.0E+00 6.4E+07 2.5E+07 2.3 ∞ 2.6 
PSMB7 1.2E+07 7.7E+07 5.0E+07 1.1E+07 1.3E+08 2.4E+07 0.2 4.6 5.6 
PARK7 2.2E+09 9.3E+08 1.1E+08 3.9E+07 1.7E+08 9.6E+07 2.4 2.9 1.8 
TSG101 0.0E+00 7.4E+07 8.7E+06 0.0E+00 2.0E+08 3.6E+07 0 ∞ 5.6 
BAG1 4.9E+08 2.2E+08 3.0E+07 1.5E+07 7.4E+08 9.2E+07 2.3 2.1 8.1 
MACROD1 2.7E+07 0.0E+00 2.4E+07 1.0E+07 4.4E+08 2.3E+08 ∞ 2.4 2 
VKORC1 9.3E+07 2.4E+08 4.2E+06 0.0E+00 6.6E+07 0.0E+00 0.4 ∞ ∞ 
TXNDC17 1.5E+08 7.5E+07 1.6E+07 0.0E+00 2.6E+07 0.0E+00 2 ∞ ∞ 
ADPGK 0.0E+00 1.7E+07 5.4E+06 0.0E+00 3.1E+07 0.0E+00 0 ∞ ∞ 
NTPCR 1.5E+08 2.3E+07 0.0E+00 0.0E+00 2.0E+08 0.0E+00 6.7 0 ∞ 
MED18 3.5E+07 0.0E+00 0.0E+00 0.0E+00 1.1E+07 0.0E+00 ∞ 0 ∞ 
HNRNPUL
1 0.0E+00 2.0E+07 1.2E+07 0.0E+00 2.3E+08 7.5E+07 0 ∞ 3.2 
HTATIP2 9.3E+08 9.5E+08 4.3E+08 2.0E+08 9.0E+08 4.5E+08 1 2.3 2 
APOO 1.9E+08 7.8E+07 1.2E+07 1.9E+07 3.3E+07 0.0E+00 2.5 0.6 ∞ 
WDR18 0.0E+00 2.6E+07 2.3E+07 0.0E+00 1.3E+08 2.3E+07 0 ∞ 5.7 
KIFC3 2.1E+08 0.0E+00 0.0E+00 0.0E+00 7.3E+07 1.8E+06 ∞ 0 40.2 
SFXN3 5.1E+07 3.9E+07 3.0E+06 0.0E+00 1.6E+08 5.3E+07 1.3 ∞ 3 
AP1M1 2.3E+08 5.3E+07 0.0E+00 0.0E+00 2.0E+08 8.5E+07 4.4 0 2.4 
NUF2 3.8E+07 3.2E+07 3.8E+07 0.0E+00 5.6E+07 0.0E+00 1.2 ∞ ∞ 
SH3BGRL
3 0.0E+00 0.0E+00 5.6E+07 0.0E+00 5.4E+07 2.2E+07 0 ∞ 2.5 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
PDCL3 2.6E+07 1.8E+08 1.7E+07 0.0E+00 2.4E+08 6.2E+07 0.2 ∞ 3.9 
RAB3GAP
2 1.4E+07 0.0E+00 0.0E+00 0.0E+00 1.5E+08 7.0E+07 ∞ 0 2.2 
PPA2 4.5E+08 4.6E+08 8.9E+07 1.8E+07 1.6E+08 4.0E+07 1 5 4 
RABEP2 0.0E+00 0.0E+00 1.6E+07 0.0E+00 3.7E+07 1.3E+07 0 ∞ 2.8 
RANBP3 5.4E+07 1.1E+07 1.5E+07 7.7E+06 1.1E+08 2.8E+07 5.1 2 3.9 
DCTPP1 3.9E+08 2.6E+07 0.0E+00 0.0E+00 4.4E+07 0.0E+00 14.7 0 ∞ 
L2HGDH 3.4E+07 2.4E+08 6.6E+07 1.7E+07 2.1E+08 7.4E+07 0.2 3.9 3 
COPS7B 3.5E+07 0.0E+00 4.4E+07 0.0E+00 8.5E+07 2.1E+08 ∞ ∞ 0.4 
C12orf10 1.6E+08 8.1E+07 4.4E+06 0.0E+00 3.2E+08 7.5E+06 2 ∞ 42.9 
SDF2L1 1.4E+08 1.8E+08 4.7E+07 0.0E+00 4.5E+07 0.0E+00 0.8 ∞ ∞ 
SRA1 9.3E+07 1.7E+07 1.3E+07 0.0E+00 0.0E+00 0.0E+00 5.5 ∞ 0 
CHMP1A 2.2E+07 0.0E+00 2.9E+07 0.0E+00 0.0E+00 0.0E+00 ∞ ∞ 0 
VTA1 4.4E+08 4.6E+08 1.1E+08 4.4E+07 3.6E+08 1.3E+08 1 2.6 2.7 
MRPS30 2.8E+07 5.3E+05 0.0E+00 1.3E+07 4.4E+07 5.4E+06 52.5 0 8.3 
DMAP1 0.0E+00 0.0E+00 1.4E+07 0.0E+00 2.2E+08 4.3E+07 0 ∞ 5.3 
ANLN 1.4E+08 5.7E+07 0.0E+00 1.8E+07 1.6E+08 1.1E+07 2.5 0 14.1 
ACSS2 0.0E+00 0.0E+00 4.0E+06 0.0E+00 5.4E+07 2.0E+07 0 ∞ 2.7 
DIABLO 7.1E+08 2.5E+08 6.3E+07 0.0E+00 2.2E+08 7.1E+07 2.9 ∞ 3.1 
OSTC 0.0E+00 0.0E+00 6.2E+06 0.0E+00 5.1E+07 0.0E+00 0 ∞ ∞ 
DROSHA 2.0E+09 0.0E+00 0.0E+00 0.0E+00 2.4E+07 0.0E+00 ∞ 0 ∞ 
IARS2 2.3E+07 0.0E+00 4.0E+07 0.0E+00 2.8E+08 2.2E+08 ∞ ∞ 1.3 
ABCF3 2.7E+07 1.8E+07 1.8E+07 0.0E+00 1.5E+08 7.2E+07 1.6 ∞ 2.1 
NUDT15 6.6E+07 0.0E+00 8.3E+06 1.6E+07 7.3E+07 0.0E+00 ∞ 0.6 ∞ 
FANCI 7.1E+06 0.0E+00 0.0E+00 0.0E+00 1.8E+08 4.6E+07 ∞ 0 3.9 
NLE1 0.0E+00 1.1E+08 5.5E+07 9.6E+05 2.2E+07 0.0E+00 0 56.9 ∞ 
GIN1 0.0E+00 0.0E+00 2.0E+07 1.9E+06 3.2E+08 1.3E+08 0 10.4 2.5 
BRE 5.3E+07 1.9E+07 3.3E+06 0.0E+00 6.6E+07 6.0E+07 2.9 ∞ 1.1 
CDKN2AIP 2.3E+08 2.3E+08 1.3E+08 2.9E+07 3.5E+08 3.4E+07 1 4.4 10.6 
DNAJB12 9.7E+07 4.5E+07 0.0E+00 4.1E+07 1.6E+08 3.9E+07 2.2 0 4.2 
PPP4R2 3.2E+07 0.0E+00 0.0E+00 0.0E+00 2.8E+07 0.0E+00 ∞ 0 ∞ 
MRPL39 6.0E+07 3.4E+07 9.6E+05 0.0E+00 1.2E+08 8.0E+06 1.8 ∞ 15 
FKBP11 1.8E+08 0.0E+00 6.6E+07 3.1E+07 6.5E+07 3.1E+07 ∞ 2.2 2.1 
FAM120A 1.0E+08 1.5E+07 1.0E+07 3.4E+07 4.5E+08 2.2E+08 6.9 0.3 2.1 
SPG21 0.0E+00 4.1E+07 1.6E+07 0.0E+00 1.4E+07 0.0E+00 0 ∞ ∞ 
TMEM9 0.0E+00 0.0E+00 2.5E+07 0.0E+00 3.9E+07 0.0E+00 0 ∞ ∞ 
DIP2B 1.9E+07 0.0E+00 0.0E+00 0.0E+00 9.2E+07 4.3E+07 ∞ 0 2.2 
STARD9 5.3E+07 6.3E+07 3.1E+07 0.0E+00 7.2E+07 1.6E+07 0.9 ∞ 4.7 
NRBP1 3.6E+07 0.0E+00 2.6E+07 2.1E+07 1.6E+08 7.0E+07 ∞ 1.3 2.4 
VPS51 6.6E+06 0.0E+00 7.6E+06 1.4E+07 1.0E+08 5.7E+05 ∞ 0.6 182.5 
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Gene 
name 
T1 WT T2 MT T2 WT T2 MT T3 WT T3 MT 
T1 fold 
change 
T2 fold 
change 
T3 fold 
change 
AK3 3.0E+08 1.5E+08 0.0E+00 1.6E+07 2.0E+07 6.0E+06 2.1 0 3.4 
MRTO4 1.6E+08 3.0E+08 1.4E+08 5.4E+07 3.0E+08 7.4E+07 0.6 2.7 4.1 
TMCO1 6.8E+07 3.2E+07 7.4E+06 0.0E+00 1.8E+08 8.5E+07 2.2 ∞ 2.1 
LIMCH1 2.3E+07 0.0E+00 0.0E+00 0.0E+00 1.3E+08 6.4E+07 ∞ 0 2.1 
VDAC3 9.0E+07 5.8E+07 1.5E+07 6.6E+06 3.3E+07 0.0E+00 1.6 2.3 ∞ 
GDA 5.6E+07 0.0E+00 1.2E+07 0.0E+00 1.5E+08 3.6E+07 ∞ ∞ 4.3 
YARS2 2.7E+07 1.4E+08 1.5E+07 0.0E+00 2.2E+08 7.5E+07 0.2 ∞ 2.9 
SBDS 3.7E+08 5.5E+07 3.1E+08 1.3E+07 3.2E+08 1.4E+08 6.8 23.8 2.3 
RRP15 2.0E+07 0.0E+00 0.0E+00 5.3E+06 1.6E+07 0.0E+00 ∞ 0 ∞ 
RNF114 4.6E+07 0.0E+00 2.1E+07 0.0E+00 3.9E+07 3.4E+07 ∞ ∞ 1.2 
NUB1 6.1E+07 0.0E+00 0.0E+00 0.0E+00 6.6E+07 2.5E+07 ∞ 0 2.7 
NUBP2 1.9E+08 1.1E+08 3.1E+07 0.0E+00 2.2E+08 3.4E+07 1.9 ∞ 6.5 
NFS1 1.5E+08 2.6E+07 1.0E+07 1.2E+07 4.2E+07 0.0E+00 5.6 0.9 ∞ 
TEX264 2.1E+08 0.0E+00 0.0E+00 0.0E+00 1.0E+08 0.0E+00 ∞ 0 ∞ 
a Protein hits observed in the kemptide K-CLASP study.  The peptide intensity observed for each sample 
(WT: N-biotin kemptide crosslinking, MT: N-biotin mutant kemptide crosslinking) for the three trials (T1: trial 
1, T2: trial 2, T3: trial 3) is shown. Fold change for each trial was calculated by dividing the peptide intensity 
observed in the N-biotin kemptide crosslinking reaction by the peptide intensity observed for the N-biotin 
mutant kemptide crosslinking reaction. Infinity (∞) signifies that no peptides were observed in N-biotin 
mutant kemptide sample, making a numeric ratio calculation impossible.  The three K-CLASP hit kinases 
are yellow colored.  
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Figure A.2.7: Gel images from two replicates of the Miz1 K-CLASP experiment. 
Crosslinking reactions were carried out with MEF lysate and N-biotin Miz1 peptide (Miz1 
WT) in the presence of ATP-ArN3 (lanes 2, 5, and 8). Control reactions were performed 
with TNF untreated lysate and N-biotin Miz1 peptide (lanes 1, 4, and 7) or with N-biotin 
mutant Miz1 peptide (Miz1 mt) in place of N-biotin Miz1 peptide (lanes 3, 6, and 9). After 
reaction, biotinylated proteins were enriched using streptavidin resin. The input before 
streptavidin enrichment (11% loaded per gel, lanes 1-3), flow through (8% loaded per gel, 
lanes 4-6), and the elution from each sample (33% loaded per gel, lanes 7-9) were 
separated by SDS-PAGE and then stained for total proteins using SYPRO® Ruby stain 
(top gel). The shown gels were used in LC-MS/MS analysis.  
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Table A.2.2: Full listing of the 340 Miz1 K-CLASP hitsa  
Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Kif1b 0.0E+00 6.0E+09 1.1E+07 2.4E+07 0.0E+00 ∞ 2.2 ∞ 
Rps19 0.0E+00 3.0E+07 0.0E+00 2.3E+09 0.0E+00 ∞ ∞ ∞ 
Rab11b 1.8E+08 5.3E+08 0.0E+00 1.5E+09 1.7E+08 2.9 ∞ 3.1 
Rpl36a 0.0E+00 8.5E+06 0.0E+00 1.3E+09 1.3E+06 ∞ ∞ 6.5 
Lamp1 1.5E+09 7.0E+09 0.0E+00 1.3E+09 3.3E+09 4.6 ∞ 2.1 
Txn 0.0E+00 8.0E+07 0.0E+00 8.5E+08 3.6E+06 ∞ ∞ 21.9 
H3f3a 0.0E+00 1.4E+07 0.0E+00 8.9E+08 0.0E+00 ∞ ∞ ∞ 
Cd63 0.0E+00 7.9E+08 5.3E+07 1.2E+08 7.9E+07 ∞ 2.4 10.0 
Sfn 1.9E+08 1.8E+09 0.0E+00 7.6E+08 4.4E+08 9.6 ∞ 4.2 
Rac1 0.0E+00 1.6E+08 0.0E+00 5.2E+08 1.6E+06 ∞ ∞ 104.0 
Gps1 0.0E+00 5.1E+08 1.3E+07 1.2E+08 9.1E+07 ∞ 9.0 5.5 
Hnrnpf 1.0E+08 3.5E+08 0.0E+00 5.1E+08 4.9E+07 3.5 ∞ 7.2 
Ubr4 1.8E+07 4.2E+08 0.0E+00 4.8E+08 8.0E+07 23.1 ∞ 5.3 
Tagln2 2.8E+06 2.2E+07 0.0E+00 4.8E+08 3.7E+06 7.6 ∞ 5.8 
Rela 0.0E+00 4.2E+08 0.0E+00 1.6E+07 4.4E+07 ∞ ∞ 9.5 
Mme 0.0E+00 1.5E+08 0.0E+00 2.1E+08 4.6E+06 ∞ ∞ 32.4 
Wdr1 0.0E+00 3.3E+08 0.0E+00 1.8E+07 6.5E+07 ∞ ∞ 5.1 
Mad2l1 1.5E+07 3.5E+07 0.0E+00 2.9E+08 0.0E+00 2.4 ∞ ∞ 
Aco2 0.0E+00 2.8E+08 7.7E+06 5.6E+07 2.4E+07 ∞ 7.2 11.9 
Tmem109 0.0E+00 5.0E+06 0.0E+00 2.7E+08 0.0E+00 ∞ ∞ ∞ 
Zbtb17 0.0E+00 2.5E+08 0.0E+00 1.7E+07 4.3E+07 ∞ ∞ 5.9 
Psma5 2.6E+08 5.4E+08 0.0E+00 2.6E+08 1.1E+08 2.1 ∞ 4.9 
Ywhag 2.3E+08 5.9E+08 0.0E+00 2.4E+08 1.2E+08 2.6 ∞ 5.0 
Rab8a 0.0E+00 9.5E+06 0.0E+00 2.3E+08 0.0E+00 ∞ ∞ ∞ 
Sgpl1 0.0E+00 2.4E+08 5.3E+07 2.1E+08 6.2E+07 ∞ 4.0 3.8 
Mrps34 6.1E+06 1.5E+07 0.0E+00 2.2E+08 6.5E+06 2.5 ∞ 2.4 
Tardbp 4.7E+06 6.8E+07 0.0E+00 2.2E+08 3.6E+07 14.5 ∞ 1.9 
Rab11fip1 2.7E+07 4.2E+08 0.0E+00 2.1E+08 0.0E+00 15.7 ∞ ∞ 
Hmmr 0.0E+00 1.8E+08 0.0E+00 2.9E+07 7.2E+06 ∞ ∞ 24.3 
Mrc2 0.0E+00 1.9E+08 0.0E+00 1.3E+07 6.7E+06 ∞ ∞ 28.2 
Sar1a 2.8E+07 1.2E+08 0.0E+00 2.0E+08 1.4E+07 4.4 ∞ 9.1 
Cnn2 0.0E+00 3.7E+06 0.0E+00 1.8E+08 0.0E+00 ∞ ∞ ∞ 
Dync1i2 0.0E+00 1.6E+08 0.0E+00 2.5E+07 8.9E+07 ∞ ∞ 1.8 
Rps21 0.0E+00 3.1E+06 0.0E+00 1.8E+08 0.0E+00 ∞ ∞ ∞ 
Mrps26 0.0E+00 5.0E+07 0.0E+00 1.3E+08 1.9E+07 ∞ ∞ 2.6 
Psma7 1.0E+08 2.5E+08 0.0E+00 1.7E+08 6.9E+06 2.5 ∞ 37.0 
Msh6 0.0E+00 1.4E+08 0.0E+00 3.0E+07 2.8E+07 ∞ ∞ 4.9 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Arhgef40 0.0E+00 1.6E+08 0.0E+00 7.6E+06 5.8E+06 ∞ ∞ 27.1 
Slk 0.0E+00 1.6E+08 1.6E+07 1.2E+08 5.5E+07 ∞ 7.4 2.9 
Uba6 0.0E+00 1.3E+08 0.0E+00 2.7E+07 4.8E+07 ∞ ∞ 2.8 
Slc25a3 5.6E+06 1.8E+07 0.0E+00 1.6E+08 0.0E+00 3.2 ∞ ∞ 
Smchd1 0.0E+00 1.3E+08 0.0E+00 2.9E+07 2.0E+07 ∞ ∞ 6.7 
Rab6a 2.0E+07 2.1E+08 0.0E+00 1.6E+08 1.2E+07 10.8 ∞ 17.7 
Pitrm1 0.0E+00 1.4E+08 0.0E+00 1.4E+07 4.3E+07 ∞ ∞ 3.3 
Stat3 0.0E+00 1.6E+08 6.1E+06 9.8E+07 2.9E+07 ∞ 16.0 5.4 
Pus1 0.0E+00 4.4E+07 0.0E+00 1.0E+08 1.9E+07 ∞ ∞ 2.3 
Pdlim5 0.0E+00 2.1E+07 0.0E+00 1.3E+08 0.0E+00 ∞ ∞ ∞ 
Fam83h 0.0E+00 9.7E+07 0.0E+00 4.2E+07 3.5E+07 ∞ ∞ 2.8 
Las1l 0.0E+00 1.1E+08 0.0E+00 2.3E+07 1.4E+07 ∞ ∞ 8.2 
Iars 4.7E+07 3.4E+08 0.0E+00 1.3E+08 8.4E+07 7.1 ∞ 4.0 
Mrpl18 0.0E+00 3.7E+06 0.0E+00 1.3E+08 0.0E+00 ∞ ∞ ∞ 
Ranbp3 0.0E+00 6.8E+07 0.0E+00 5.9E+07 9.2E+06 ∞ ∞ 7.4 
Timm13 0.0E+00 6.3E+07 0.0E+00 5.9E+07 1.5E+07 ∞ ∞ 4.3 
Nptn 0.0E+00 1.0E+08 0.0E+00 1.4E+07 2.9E+07 ∞ ∞ 3.6 
Bax 0.0E+00 6.7E+07 0.0E+00 5.1E+07 4.4E+07 ∞ ∞ 1.5 
Pcyox1l 0.0E+00 1.2E+08 3.3E+06 2.5E+07 3.5E+07 ∞ 7.5 3.3 
Pdcd10 6.1E+06 1.5E+08 0.0E+00 1.1E+08 2.3E+07 24.3 ∞ 6.4 
Hk2 0.0E+00 8.3E+07 0.0E+00 2.8E+07 1.6E+07 ∞ ∞ 5.1 
Dync1li1 4.4E+07 1.0E+08 0.0E+00 1.0E+08 7.8E+06 2.3 ∞ 13.0 
Mars 2.5E+07 2.1E+08 0.0E+00 1.0E+08 7.4E+07 8.2 ∞ 2.8 
Tspan3 0.0E+00 5.8E+07 0.0E+00 4.0E+07 4.7E+07 ∞ ∞ 1.2 
Dnm1l 2.2E+07 8.3E+07 0.0E+00 9.7E+07 3.0E+07 3.8 ∞ 2.7 
Impact 0.0E+00 9.7E+07 8.2E+06 2.2E+07 1.1E+07 ∞ 2.6 8.9 
UPF0568 4.6E+07 1.8E+08 0.0E+00 9.5E+07 1.5E+07 4.0 ∞ 12.4 
Atp1b1 0.0E+00 6.9E+07 0.0E+00 2.3E+07 3.7E+07 ∞ ∞ 1.9 
Cops7a 4.8E+07 1.7E+08 0.0E+00 9.2E+07 0.0E+00 3.7 ∞ ∞ 
Lrp1 6.7E+07 4.5E+08 0.0E+00 9.0E+07 6.6E+07 6.7 ∞ 6.8 
Acaa2 4.2E+06 2.2E+07 0.0E+00 8.8E+07 0.0E+00 5.2 ∞ ∞ 
Diaph1 2.0E+07 2.5E+08 0.0E+00 8.7E+07 4.3E+07 12.7 ∞ 6.0 
Adsl 1.7E+07 7.7E+07 0.0E+00 8.6E+07 6.7E+07 4.5 ∞ 1.1 
Atp6v1d 0.0E+00 9.9E+06 0.0E+00 7.1E+07 0.0E+00 ∞ ∞ ∞ 
Inf2 3.4E+07 2.2E+08 0.0E+00 7.9E+07 7.1E+07 6.4 ∞ 3.1 
Ly75 0.0E+00 2.9E+07 0.0E+00 4.9E+07 2.9E+06 ∞ ∞ 10.2 
Pcolce 0.0E+00 4.3E+07 0.0E+00 3.4E+07 6.1E+06 ∞ ∞ 7.1 
Gdi2 4.5E+06 1.7E+08 0.0E+00 7.4E+07 1.2E+08 38.5 ∞ 1.4 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Uggt1 2.3E+07 9.6E+07 0.0E+00 7.4E+07 3.2E+07 4.2 ∞ 3.1 
Ddx42 0.0E+00 7.4E+07 1.7E+07 3.7E+07 3.8E+07 ∞ 2.2 1.9 
Ctnna1 0.0E+00 3.2E+07 0.0E+00 4.1E+07 9.1E+06 ∞ ∞ 3.6 
Pcm1 0.0E+00 1.9E+07 0.0E+00 5.4E+07 0.0E+00 ∞ ∞ ∞ 
Psmb6 0.0E+00 2.6E+07 0.0E+00 4.7E+07 9.7E+06 ∞ ∞ 2.6 
Adam9 0.0E+00 5.0E+07 0.0E+00 2.3E+07 9.0E+06 ∞ ∞ 5.5 
Psma6 9.2E+07 3.6E+08 0.0E+00 7.3E+07 1.0E+07 3.9 ∞ 35.5 
Ahcy 3.5E+07 2.8E+08 0.0E+00 7.0E+07 2.0E+08 8.2 ∞ 1.4 
Xpo7 0.0E+00 3.7E+07 0.0E+00 2.9E+07 8.6E+06 ∞ ∞ 4.3 
Ykt6 0.0E+00 3.0E+07 0.0E+00 3.5E+07 1.7E+07 ∞ ∞ 1.8 
Pelp1 0.0E+00 3.6E+07 0.0E+00 2.7E+07 2.0E+06 ∞ ∞ 18.2 
Etfdh 0.0E+00 5.0E+07 0.0E+00 1.2E+07 6.8E+06 ∞ ∞ 7.3 
Stt3b 0.0E+00 1.3E+07 0.0E+00 4.9E+07 0.0E+00 ∞ ∞ ∞ 
Sf3b1 0.0E+00 4.5E+07 0.0E+00 1.6E+07 1.6E+06 ∞ ∞ 29.2 
Npepps 3.1E+06 2.4E+08 0.0E+00 6.0E+07 5.6E+07 78.6 ∞ 4.3 
Prdx6 1.2E+08 3.0E+08 0.0E+00 6.0E+07 1.4E+08 2.4 ∞ 2.1 
Farsb 0.0E+00 5.9E+07 4.5E+06 5.0E+07 1.8E+07 ∞ 11.2 3.3 
Tpp2 0.0E+00 5.0E+07 0.0E+00 8.1E+06 1.5E+07 ∞ ∞ 3.4 
Wdr6 0.0E+00 5.8E+07 1.5E+07 3.6E+07 1.8E+07 ∞ 2.4 3.2 
Trip13 0.0E+00 4.1E+07 0.0E+00 1.7E+07 1.9E+07 ∞ ∞ 2.2 
Hcfc1 0.0E+00 2.6E+07 0.0E+00 3.1E+07 2.3E+06 ∞ ∞ 11.6 
Ak3 0.0E+00 3.4E+07 0.0E+00 2.2E+07 8.5E+06 ∞ ∞ 4.0 
Sec22b 0.0E+00 9.9E+06 0.0E+00 4.6E+07 0.0E+00 ∞ ∞ ∞ 
Kif2a 0.0E+00 5.5E+07 1.0E+07 2.9E+07 2.6E+07 ∞ 2.8 2.1 
Gstp1 6.5E+07 3.2E+08 0.0E+00 5.5E+07 1.6E+07 4.9 ∞ 19.9 
Tmem33 0.0E+00 4.2E+06 0.0E+00 5.0E+07 0.0E+00 ∞ ∞ ∞ 
Pex5 0.0E+00 3.7E+07 0.0E+00 1.7E+07 0.0E+00 ∞ ∞ ∞ 
Sdf2 0.0E+00 2.4E+07 0.0E+00 3.0E+07 0.0E+00 ∞ ∞ ∞ 
Acsl4 1.1E+06 1.8E+08 0.0E+00 5.3E+07 3.3E+07 157.6 ∞ 5.4 
Wdr26 0.0E+00 4.8E+07 0.0E+00 4.7E+06 2.4E+07 ∞ ∞ 2.0 
Csrp2 0.0E+00 1.3E+06 0.0E+00 5.1E+07 0.0E+00 ∞ ∞ ∞ 
Basp1 0.0E+00 5.2E+07 1.2E+07 2.5E+07 1.8E+07 ∞ 2.2 2.9 
Rala 5.7E+07 1.6E+08 0.0E+00 5.2E+07 3.1E+07 2.7 ∞ 4.9 
Med1 0.0E+00 3.0E+07 0.0E+00 2.0E+07 0.0E+00 ∞ ∞ ∞ 
Nsf 3.6E+07 7.5E+07 0.0E+00 4.9E+07 4.7E+06 2.1 ∞ 15.9 
Phldb2 0.0E+00 6.2E+06 0.0E+00 4.2E+07 0.0E+00 ∞ ∞ ∞ 
Ddx6 0.0E+00 1.4E+07 0.0E+00 3.2E+07 6.7E+06 ∞ ∞ 2.0 
Plxnb2 3.5E+07 1.2E+08 0.0E+00 4.6E+07 2.3E+07 3.5 ∞ 5.4 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Esyt1 2.2E+06 7.6E+07 0.0E+00 4.4E+07 1.4E+07 35.4 ∞ 5.4 
Exoc4 6.6E+06 3.8E+07 0.0E+00 4.3E+07 3.9E+06 5.8 ∞ 9.6 
Usp10 4.4E+06 1.4E+07 0.0E+00 4.2E+07 0.0E+00 3.3 ∞ ∞ 
Golga3 1.1E+07 5.2E+07 0.0E+00 4.1E+07 3.4E+07 4.7 ∞ 1.5 
Sec23b 4.2E+06 8.4E+07 0.0E+00 4.1E+07 7.0E+07 19.8 ∞ 1.2 
Mgea5 0.0E+00 2.0E+07 0.0E+00 2.1E+07 8.3E+06 ∞ ∞ 2.4 
Setd3 0.0E+00 3.3E+07 0.0E+00 4.1E+06 9.3E+06 ∞ ∞ 3.6 
Tkt 2.5E+08 7.1E+08 0.0E+00 3.7E+07 1.0E+08 2.9 ∞ 6.8 
Eif2b5 0.0E+00 3.2E+07 0.0E+00 4.4E+06 3.3E+06 ∞ ∞ 9.6 
Aco1 0.0E+00 2.1E+07 0.0E+00 1.6E+07 7.7E+06 ∞ ∞ 2.7 
Atp6v1c1 0.0E+00 1.9E+07 0.0E+00 1.7E+07 0.0E+00 ∞ ∞ ∞ 
Nr2f2 0.0E+00 3.1E+07 0.0E+00 5.1E+06 0.0E+00 ∞ ∞ ∞ 
Idh3g 2.1E+07 2.1E+08 0.0E+00 3.4E+07 3.8E+07 9.7 ∞ 5.4 
Ddx17 0.0E+00 3.4E+07 2.5E+07 6.7E+07 3.2E+07 ∞ 2.7 1.1 
Ak2 6.4E+06 2.7E+07 0.0E+00 3.4E+07 1.9E+07 4.2 ∞ 1.5 
Gtpbp4 0.0E+00 3.3E+07 1.4E+07 5.5E+07 2.8E+07 ∞ 3.8 1.2 
Snx4 0.0E+00 3.2E+07 1.5E+07 7.9E+07 2.2E+07 ∞ 5.1 1.5 
Fam3c 4.3E+07 1.8E+08 0.0E+00 3.2E+07 2.9E+07 4.1 ∞ 6.1 
Mob1a 3.4E+07 7.6E+07 0.0E+00 3.2E+07 1.4E+07 2.2 ∞ 5.3 
Smarcd2 0.0E+00 2.1E+07 0.0E+00 1.0E+07 0.0E+00 ∞ ∞ ∞ 
Kif2c 8.8E+06 5.5E+07 0.0E+00 3.1E+07 1.0E+07 6.3 ∞ 5.5 
Phb 6.0E+07 2.3E+08 0.0E+00 3.1E+07 4.1E+07 3.9 ∞ 5.6 
Sugt1 2.5E+07 1.1E+08 0.0E+00 3.1E+07 3.4E+07 4.5 ∞ 3.4 
Eci1 0.0E+00 9.2E+06 0.0E+00 2.1E+07 0.0E+00 ∞ ∞ ∞ 
Plekhf1 0.0E+00 6.5E+06 0.0E+00 2.4E+07 4.4E+06 ∞ ∞ 1.5 
Chmp4b 0.0E+00 2.9E+07 2.1E+07 4.7E+08 9.8E+05 ∞ 22.2 29.7 
Nemf 0.0E+00 1.2E+07 0.0E+00 1.7E+07 1.1E+07 ∞ ∞ 1.1 
Ist1 3.0E+07 8.8E+07 0.0E+00 2.8E+07 6.8E+07 3.0 ∞ 1.3 
Hspg2 0.0E+00 2.4E+07 0.0E+00 1.7E+06 1.2E+07 ∞ ∞ 2.0 
Timm44 5.5E+07 2.8E+08 0.0E+00 2.5E+07 0.0E+00 5.1 ∞ ∞ 
Nubp2 5.3E+06 3.5E+07 0.0E+00 2.5E+07 0.0E+00 6.5 ∞ ∞ 
Atp6v1h 5.6E+06 2.2E+08 0.0E+00 2.4E+07 1.4E+07 40.0 ∞ 16.6 
Dis3 7.5E+06 6.1E+07 0.0E+00 2.4E+07 3.2E+07 8.1 ∞ 1.9 
Smc1a 1.6E+07 1.9E+08 0.0E+00 2.3E+07 1.3E+07 12.1 ∞ 15.4 
Dhrs1 3.1E+07 1.1E+08 0.0E+00 2.2E+07 1.9E+07 3.7 ∞ 6.2 
Vps16 0.0E+00 9.8E+06 0.0E+00 1.1E+07 0.0E+00 ∞ ∞ ∞ 
Ncstn 3.5E+06 1.5E+08 0.0E+00 2.0E+07 7.5E+07 43.0 ∞ 2.0 
Lrrc47 0.0E+00 1.2E+07 0.0E+00 7.8E+06 0.0E+00 ∞ ∞ ∞ 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Ppm1a 0.0E+00 1.9E+07 7.5E+06 2.4E+07 3.3E+06 ∞ 3.2 5.7 
Aaas 0.0E+00 1.9E+07 1.3E+07 5.0E+07 0.0E+00 ∞ 3.8 ∞ 
Ythdf2 2.9E+07 1.3E+08 0.0E+00 1.8E+07 5.0E+07 4.7 ∞ 2.7 
Cnot10 0.0E+00 1.4E+07 0.0E+00 1.9E+06 0.0E+00 ∞ ∞ ∞ 
Rps27 0.0E+00 1.6E+07 3.3E+07 4.5E+09 0.0E+00 ∞ 137.4 ∞ 
Qki 0.0E+00 1.5E+07 4.0E+06 2.3E+07 8.3E+06 ∞ 5.7 1.8 
Emc1 1.2E+07 9.9E+07 0.0E+00 1.5E+07 4.5E+06 8.2 ∞ 21.8 
Mia3 8.4E+06 3.4E+07 0.0E+00 1.4E+07 1.9E+07 4.0 ∞ 1.8 
Smad3 0.0E+00 1.4E+07 6.7E+06 2.5E+07 3.2E+06 ∞ 3.7 4.4 
Myo1c 5.9E+06 1.7E+08 0.0E+00 1.4E+07 0.0E+00 29.0 ∞ ∞ 
Agps 1.5E+07 5.8E+07 0.0E+00 1.3E+07 5.9E+06 4.0 ∞ 9.9 
Aldh16a1 8.4E+06 7.0E+07 0.0E+00 1.3E+07 1.7E+07 8.4 ∞ 4.2 
Tex10 0.0E+00 5.4E+06 0.0E+00 8.0E+06 4.6E+06 ∞ ∞ 1.2 
Fam98a 0.0E+00 1.3E+07 2.9E+07 6.3E+07 1.0E+07 ∞ 2.2 1.3 
Hdgfrp2 0.0E+00 1.9E+06 0.0E+00 9.9E+06 0.0E+00 ∞ ∞ ∞ 
Myl12b 0.0E+00 1.1E+07 1.1E+07 1.2E+09 0.0E+00 ∞ 112.6 ∞ 
S100a11 3.4E+06 2.5E+07 0.0E+00 1.1E+07 2.2E+07 7.3 ∞ 1.1 
Cnot1 3.4E+06 3.9E+07 0.0E+00 1.1E+07 0.0E+00 11.4 ∞ ∞ 
Psma4 6.9E+06 1.6E+08 0.0E+00 9.8E+06 5.1E+07 22.8 ∞ 3.1 
Anpep 0.0E+00 7.5E+06 0.0E+00 1.9E+06 0.0E+00 ∞ ∞ ∞ 
Ganab 1.9E+07 2.6E+08 0.0E+00 8.7E+06 7.6E+07 13.6 ∞ 3.5 
Snrnp200 1.1E+07 4.1E+07 0.0E+00 8.6E+06 5.7E+06 3.9 ∞ 7.2 
Cwc22 0.0E+00 5.8E+06 0.0E+00 2.1E+06 0.0E+00 ∞ ∞ ∞ 
Cyfip1 5.6E+05 5.8E+07 0.0E+00 7.7E+06 1.8E+07 102.7 ∞ 3.2 
Cs 1.2E+07 4.9E+07 0.0E+00 7.5E+06 4.7E+07 4.1 ∞ 1.0 
Nat10 1.4E+07 8.7E+07 0.0E+00 6.4E+06 4.2E+06 6.0 ∞ 20.8 
Eif3j1 0.0E+00 5.6E+06 2.2E+07 1.1E+08 0.0E+00 ∞ 5.1 ∞ 
Aebp1 0.0E+00 1.6E+06 0.0E+00 2.8E+06 0.0E+00 ∞ ∞ ∞ 
Rnf213 9.7E+06 7.9E+07 0.0E+00 3.5E+06 1.1E+07 8.2 ∞ 6.9 
Pes1 2.0E+06 2.2E+07 0.0E+00 3.5E+06 0.0E+00 10.8 ∞ ∞ 
Ipo11 5.2E+06 2.5E+07 0.0E+00 2.9E+06 4.4E+06 4.8 ∞ 5.7 
Impa1 2.3E+07 1.9E+08 0.0E+00 2.6E+06 6.2E+07 8.1 ∞ 3.0 
Eea1 1.8E+06 1.0E+07 0.0E+00 1.3E+06 1.1E+06 5.9 ∞ 9.7 
S100a6 7.3E+06 2.5E+08 1.3E+07 2.5E+09 2.2E+08 34.0 185.4 1.1 
Mvp 2.8E+06 4.3E+08 1.1E+07 4.1E+07 2.4E+07 155.0 3.9 17.7 
Hist1h2ah 5.1E+06 2.5E+07 1.5E+07 1.6E+09 1.7E+07 5.0 110.2 1.4 
Txlna 4.7E+06 4.0E+08 1.4E+08 5.4E+08 1.2E+08 84.5 3.8 3.4 
Edc4 3.6E+07 1.9E+08 6.5E+06 5.1E+08 5.9E+07 5.3 79.0 3.2 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Ube4b 7.7E+05 5.6E+07 6.2E+06 2.4E+07 7.2E+06 73.2 3.9 7.9 
Rpl11 8.0E+07 2.1E+08 9.2E+07 6.5E+09 1.2E+08 2.6 71.0 1.8 
Tfrc 5.4E+08 2.7E+09 2.1E+08 1.4E+10 6.6E+08 5.0 66.6 4.1 
Ppp2r2a 2.8E+06 1.5E+08 3.8E+07 1.3E+08 1.4E+08 54.3 3.4 1.1 
Hnrnpm 5.7E+07 2.4E+08 1.8E+07 7.8E+08 5.5E+07 4.2 42.9 4.3 
Fam129b 7.3E+06 3.1E+08 4.7E+07 1.6E+08 8.1E+07 42.8 3.4 3.8 
Nup155 1.3E+07 5.7E+08 2.1E+07 5.5E+07 1.6E+07 43.3 2.6 36.0 
Actn4 1.7E+07 5.0E+08 7.5E+06 1.2E+08 5.9E+07 29.0 16.3 8.4 
Lap3 1.1E+07 2.8E+08 4.8E+06 9.6E+07 3.5E+07 25.0 19.8 8.0 
Eif3f 4.3E+07 1.8E+09 3.7E+08 8.7E+08 6.6E+08 41.9 2.3 2.8 
Dctn1 5.9E+07 8.8E+08 8.2E+06 2.2E+08 3.1E+08 14.9 27.2 2.8 
Hnrnph1 1.2E+08 3.1E+08 4.1E+06 1.5E+08 1.5E+07 2.6 37.7 20.5 
Atp1a1 9.6E+06 2.7E+08 1.9E+07 1.9E+08 4.0E+07 28.3 10.1 6.7 
Spr 1.4E+08 3.6E+08 1.8E+07 6.4E+08 1.2E+07 2.5 35.3 29.3 
Tagln 7.2E+06 2.7E+07 8.0E+06 2.7E+08 0.0E+00 3.7 33.5 ∞ 
Kif5b 9.2E+07 8.3E+08 7.0E+06 1.9E+08 5.0E+08 9.0 27.7 1.7 
Dhx9 2.8E+06 8.3E+07 2.1E+07 1.3E+08 0.0E+00 29.5 6.2 ∞ 
Glg1 2.6E+07 7.8E+08 2.5E+07 1.4E+08 7.7E+07 30.1 5.5 10.1 
Rps25 7.9E+07 5.1E+08 2.8E+08 7.4E+09 4.5E+08 6.4 26.8 1.1 
Ikbkap 1.5E+07 3.2E+08 7.0E+06 7.2E+07 3.6E+07 21.6 10.2 8.9 
Hook3 1.8E+07 4.6E+08 7.0E+06 3.9E+07 1.4E+08 25.3 5.5 3.4 
Rpl27a 8.5E+07 2.1E+08 7.9E+07 2.0E+09 1.1E+08 2.4 25.8 1.9 
Ap3b1 3.2E+07 9.3E+07 3.8E+06 9.5E+07 1.9E+07 2.9 25.1 5.0 
Sf3b3 1.7E+08 4.8E+08 1.8E+07 4.2E+08 1.7E+08 2.9 23.5 2.8 
Smc3 3.0E+07 6.2E+07 2.5E+06 5.8E+07 1.5E+07 2.1 23.5 4.1 
Prpf8 1.4E+07 1.5E+08 1.3E+07 1.9E+08 7.5E+06 10.3 14.5 19.5 
Ncln 7.3E+06 1.6E+08 4.0E+07 8.3E+07 3.2E+07 22.3 2.1 5.1 
Pcbp1 4.9E+07 1.6E+08 7.2E+07 1.4E+09 7.7E+07 3.3 19.8 2.1 
Usp9x 1.9E+07 2.4E+08 6.0E+06 6.0E+07 4.5E+07 12.4 10.0 5.3 
Ipo7 3.3E+08 8.7E+08 1.6E+07 2.9E+08 1.3E+08 2.6 18.6 6.8 
Ctps1 9.5E+07 6.5E+08 3.1E+07 4.2E+08 1.5E+08 6.8 13.4 4.3 
Aacs 5.9E+07 6.2E+08 3.4E+07 3.2E+08 7.4E+07 10.5 9.5 8.3 
Prdx4 2.8E+08 7.6E+08 1.1E+08 1.9E+09 7.7E+07 2.7 17.2 9.9 
Ipo9 2.9E+07 2.5E+08 7.5E+06 7.5E+07 8.2E+06 8.6 10.0 30.5 
Cand1 1.0E+08 1.2E+09 9.8E+07 6.8E+08 1.4E+08 11.1 6.9 8.3 
Larp7 3.4E+06 3.2E+07 6.6E+06 5.5E+07 0.0E+00 9.4 8.2 ∞ 
Tgm2 2.4E+07 3.0E+08 3.4E+07 1.7E+08 2.7E+07 12.5 5.1 11.3 
Mrpl28 3.0E+06 4.0E+07 3.3E+07 1.3E+08 0.0E+00 13.2 3.8 ∞ 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Eef1b 5.5E+07 5.9E+08 3.1E+07 1.9E+08 2.7E+07 10.8 6.1 21.8 
Gclm 1.5E+07 6.9E+07 8.8E+06 1.1E+08 0.0E+00 4.5 12.4 ∞ 
Slc25a5 5.2E+08 1.2E+09 2.7E+07 3.9E+08 1.8E+08 2.3 14.5 6.7 
Tuba4a 2.8E+07 3.5E+08 6.3E+06 2.7E+07 8.3E+06 12.6 4.2 41.6 
Itgav 1.0E+08 6.8E+08 6.3E+06 6.6E+07 1.4E+08 6.5 10.3 4.9 
Vcl 1.6E+09 5.5E+09 1.1E+08 1.4E+09 2.6E+09 3.4 12.4 2.1 
Myh10 7.9E+08 1.7E+09 4.5E+07 6.0E+08 8.0E+08 2.1 13.3 2.1 
Wdr18 1.8E+07 8.6E+07 1.4E+07 1.4E+08 7.3E+07 4.8 10.5 1.2 
Lepre1 7.4E+07 4.7E+08 1.4E+07 1.2E+08 7.5E+07 6.3 8.7 6.2 
Acly 1.7E+08 2.1E+09 6.9E+08 1.5E+09 7.8E+08 12.8 2.2 2.8 
Dync1h1 1.4E+09 7.5E+09 2.0E+08 1.8E+09 2.1E+09 5.6 9.2 3.6 
Ap2m1 1.3E+08 7.7E+08 1.4E+07 1.2E+08 2.7E+08 6.2 8.6 2.9 
Copa 3.3E+08 1.3E+09 4.1E+07 4.4E+08 3.3E+08 3.9 10.7 4.0 
Itga3 1.7E+07 1.6E+08 2.6E+06 1.3E+07 1.4E+08 9.3 5.1 1.1 
Mta2 2.0E+07 1.9E+08 5.5E+07 2.5E+08 1.8E+08 9.4 4.6 1.1 
Mov10 1.0E+08 5.9E+08 1.6E+07 1.4E+08 1.1E+08 5.7 8.4 5.5 
Cul4b 2.8E+07 6.0E+07 8.1E+06 9.4E+07 1.7E+07 2.2 11.5 3.6 
Eif6 2.7E+08 6.8E+08 4.6E+07 5.1E+08 5.9E+07 2.6 11.1 11.6 
Pc 2.8E+07 2.3E+08 4.1E+07 2.0E+08 7.7E+07 8.4 5.0 3.0 
Ywhab 4.4E+08 1.1E+09 1.1E+08 1.1E+09 2.2E+08 2.4 10.8 4.9 
Ilk 5.0E+06 5.2E+07 1.1E+07 2.9E+07 9.5E+06 10.4 2.7 5.5 
Copg1 8.6E+07 8.1E+08 5.9E+07 2.0E+08 1.5E+08 9.5 3.5 5.4 
Nup93 4.8E+07 4.4E+08 4.3E+07 1.6E+08 5.3E+07 9.1 3.8 8.2 
Ruvbl2 3.5E+08 9.1E+08 1.2E+08 1.3E+09 2.0E+08 2.6 10.3 4.6 
Sucla2 3.9E+07 2.9E+08 1.7E+07 9.2E+07 1.3E+08 7.4 5.4 2.2 
Ddb1 5.0E+07 3.7E+08 1.9E+07 9.7E+07 1.1E+08 7.4 5.2 3.3 
Eftud2 1.1E+08 7.2E+08 3.1E+07 1.7E+08 1.2E+08 6.7 5.5 6.1 
Cad 5.9E+08 2.4E+09 1.1E+08 8.8E+08 7.0E+08 4.1 7.8 3.4 
Acaca 4.9E+07 4.1E+08 5.7E+07 1.9E+08 1.6E+08 8.3 3.4 2.5 
Mcm2 1.4E+08 1.3E+09 1.6E+08 3.2E+08 2.9E+08 9.2 2.1 4.5 
Hk1 7.3E+07 6.2E+08 1.1E+08 3.0E+08 2.7E+08 8.4 2.8 2.3 
Tln1 8.8E+08 3.1E+09 1.2E+08 9.0E+08 1.4E+09 3.5 7.6 2.3 
Dak 2.7E+07 6.2E+07 6.8E+06 5.8E+07 5.0E+06 2.3 8.6 12.4 
Upf1 1.7E+08 1.3E+09 1.6E+08 4.3E+08 3.5E+08 7.9 2.7 3.8 
Acat1 1.1E+07 4.3E+07 3.6E+07 2.4E+08 9.0E+06 4.1 6.5 4.8 
Ap2a2 5.0E+07 2.5E+08 2.7E+07 1.5E+08 5.5E+07 5.1 5.3 4.6 
Luc7l3 2.0E+07 5.6E+07 5.8E+06 4.4E+07 6.3E+06 2.8 7.5 8.8 
Mcm3 2.5E+08 2.0E+09 3.7E+08 9.0E+08 5.9E+08 7.9 2.4 3.4 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Pfkl 9.3E+07 4.7E+08 2.1E+07 1.1E+08 7.5E+07 5.1 5.1 6.3 
Atxn10 5.9E+07 3.6E+08 1.6E+08 6.5E+08 3.1E+08 6.1 4.1 1.2 
Fdps 1.8E+08 8.1E+08 1.9E+07 1.1E+08 3.0E+08 4.4 5.7 2.7 
Itgb1 5.4E+08 3.1E+09 1.4E+08 5.8E+08 1.5E+09 5.9 4.1 2.0 
Hm13 7.0E+07 2.1E+08 1.7E+07 1.2E+08 1.2E+07 3.1 6.9 18.2 
Ruvbl1 2.2E+08 1.7E+09 1.9E+08 4.5E+08 4.6E+08 7.5 2.3 3.7 
Nomo1 1.3E+08 5.0E+08 3.7E+07 2.2E+08 2.4E+08 4.0 5.8 2.1 
Ipo5 2.4E+08 1.0E+09 1.7E+08 8.7E+08 5.0E+08 4.3 5.2 2.0 
Atp2a2 1.1E+08 4.2E+08 3.1E+07 1.7E+08 7.7E+07 3.8 5.5 5.5 
Me2 4.5E+07 2.7E+08 1.3E+07 4.2E+07 8.4E+07 6.0 3.2 3.2 
Srpr 2.4E+07 1.3E+08 3.1E+07 1.2E+08 1.9E+07 5.2 3.9 6.9 
Fam49b 4.2E+07 1.6E+08 1.9E+07 1.0E+08 2.1E+07 3.7 5.5 7.3 
Hadha 1.9E+08 8.2E+08 9.2E+07 4.4E+08 2.4E+08 4.3 4.8 3.4 
Myh9 1.3E+10 2.9E+10 7.8E+08 5.3E+09 2.0E+10 2.1 6.8 1.4 
Ranbp1 3.1E+08 7.5E+08 8.3E+07 5.4E+08 2.9E+08 2.4 6.6 2.6 
Ap2b1 8.6E+07 4.5E+08 1.4E+08 5.1E+08 2.4E+08 5.3 3.6 1.9 
Oxct1 4.6E+07 2.3E+08 6.3E+06 2.5E+07 3.1E+07 5.0 3.9 7.6 
Eif3l 2.0E+08 1.3E+09 2.6E+08 6.4E+08 4.1E+08 6.5 2.4 3.2 
Ddx56 3.8E+06 2.2E+07 1.6E+07 5.3E+07 0.0E+00 5.6 3.3 ∞ 
Eif3c 2.3E+08 1.1E+09 1.6E+08 6.5E+08 2.9E+08 4.8 4.1 3.8 
Rad23b 4.4E+07 2.9E+08 1.2E+07 2.7E+07 2.7E+07 6.7 2.2 10.7 
Mrto4 6.6E+07 1.8E+08 3.5E+07 2.1E+08 6.0E+07 2.8 6.1 3.1 
Ddx21 1.1E+08 5.8E+08 1.0E+08 3.2E+08 1.8E+08 5.5 3.2 3.2 
Dnm2 1.1E+08 3.6E+08 9.8E+06 5.1E+07 5.5E+07 3.4 5.2 6.5 
Eif3e 3.0E+08 1.8E+09 4.6E+08 1.1E+09 6.6E+08 6.2 2.3 2.8 
Copb2 5.6E+08 2.9E+09 2.6E+08 8.4E+08 7.8E+08 5.1 3.2 3.7 
Lars 8.3E+07 4.5E+08 5.2E+07 1.5E+08 6.4E+07 5.4 2.9 7.0 
Xpo1 6.4E+07 2.8E+08 1.1E+07 4.1E+07 3.9E+07 4.4 3.8 7.2 
Uba1 6.1E+08 3.7E+09 6.5E+08 1.4E+09 6.9E+08 6.0 2.1 5.3 
Rad50 6.4E+07 3.3E+08 2.4E+07 7.0E+07 3.4E+07 5.1 2.9 9.6 
Flnb 2.5E+09 5.4E+09 1.9E+08 1.1E+09 1.9E+09 2.2 5.8 2.9 
Ywhaz 3.1E+09 6.5E+09 2.0E+08 1.2E+09 7.3E+08 2.1 5.9 8.9 
Myof 6.1E+08 2.0E+09 1.7E+08 7.6E+08 5.9E+08 3.3 4.6 3.4 
Rfc2 3.5E+07 1.8E+08 3.1E+07 8.6E+07 2.2E+07 5.1 2.8 8.4 
Epb41l2 4.1E+07 8.2E+07 1.2E+07 6.9E+07 2.0E+07 2.0 5.8 4.0 
Flna 1.8E+10 4.1E+10 1.7E+09 9.3E+09 1.3E+10 2.3 5.5 3.2 
Dnaja3 2.9E+07 1.4E+08 1.3E+07 4.0E+07 2.8E+07 4.8 3.0 5.0 
Snd1 4.9E+08 2.8E+09 3.7E+08 7.6E+08 8.5E+08 5.6 2.0 3.3 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Aars 8.5E+08 4.7E+09 1.6E+09 3.2E+09 1.1E+09 5.5 2.0 4.1 
Gls 1.7E+08 5.7E+08 1.0E+08 4.3E+08 6.1E+07 3.3 4.2 9.4 
Mthfd1l 2.5E+08 1.3E+09 1.3E+08 3.0E+08 4.8E+08 5.0 2.4 2.6 
Ywhaq 4.3E+08 9.3E+08 8.4E+07 4.3E+08 1.5E+08 2.2 5.1 6.4 
Naa15 4.1E+07 1.8E+08 4.7E+06 1.3E+07 0.0E+00 4.3 2.7 ∞ 
Smc4 3.2E+08 1.4E+09 2.2E+08 5.4E+08 3.7E+08 4.4 2.4 3.8 
Pgk1 4.4E+08 1.5E+09 5.3E+07 1.8E+08 7.6E+08 3.3 3.4 1.9 
Mdh2 4.3E+08 1.4E+09 4.7E+07 1.6E+08 3.8E+08 3.2 3.5 3.7 
Cltc 1.5E+09 4.4E+09 3.6E+08 1.3E+09 7.0E+08 2.9 3.7 6.3 
Aldh18a1 2.7E+08 8.4E+08 1.5E+08 5.4E+08 2.9E+08 3.1 3.5 2.9 
Hsd17b4 2.2E+08 4.6E+08 2.2E+08 9.6E+08 2.2E+08 2.1 4.5 2.1 
Mrpl37 1.2E+07 5.2E+07 5.9E+07 1.3E+08 3.3E+07 4.4 2.2 1.6 
Cops3 6.4E+07 2.4E+08 3.5E+07 9.5E+07 1.8E+08 3.7 2.7 1.3 
Atp5a1 5.4E+08 2.1E+09 2.3E+08 5.7E+08 1.9E+08 3.9 2.5 11.3 
Cct6a 4.8E+08 2.1E+09 1.1E+09 2.3E+09 1.3E+09 4.3 2.1 1.5 
Tubb5 6.5E+09 2.5E+10 4.5E+09 1.1E+10 4.1E+09 3.8 2.5 6.0 
Tuba1b 2.4E+10 1.0E+11 1.5E+10 3.1E+10 2.2E+10 4.2 2.1 4.7 
Dnajc7 1.9E+08 4.4E+08 2.9E+07 1.2E+08 1.7E+08 2.3 3.9 2.6 
Snx2 2.2E+07 7.4E+07 4.5E+07 1.3E+08 6.0E+06 3.3 2.9 12.4 
Hdlbp 2.8E+08 1.1E+09 3.1E+08 7.6E+08 2.5E+08 3.7 2.5 4.1 
Lamp2 6.2E+08 2.5E+09 2.2E+08 4.8E+08 1.6E+09 4.0 2.2 1.6 
Copb1 2.9E+08 1.0E+09 1.4E+08 3.6E+08 2.6E+08 3.5 2.6 4.0 
Lrpprc 1.7E+08 5.1E+08 1.2E+08 3.6E+08 1.1E+08 3.0 3.1 4.5 
Akr1b1 4.8E+08 1.1E+09 7.8E+07 2.8E+08 4.6E+08 2.4 3.6 2.5 
Tes 1.0E+08 2.3E+08 1.1E+07 3.9E+07 5.1E+07 2.2 3.7 4.6 
Cyp20a1 1.0E+07 2.8E+07 5.7E+06 1.7E+07 0.0E+00 2.7 3.0 ∞ 
Tubb4b 2.3E+10 5.3E+10 8.4E+09 2.7E+10 1.1E+10 2.3 3.1 4.8 
Paics 1.6E+08 5.0E+08 5.9E+07 1.4E+08 4.1E+08 3.1 2.3 1.2 
Ssr1 3.2E+08 1.1E+09 8.5E+07 1.7E+08 1.9E+08 3.4 2.0 5.8 
Eef1g 2.8E+09 6.6E+09 1.3E+09 3.7E+09 1.4E+09 2.3 2.9 4.9 
Ehd1 3.7E+08 9.8E+08 4.0E+08 1.0E+09 3.5E+08 2.7 2.6 2.8 
Nsun2 4.3E+08 1.1E+09 1.6E+08 4.2E+08 3.7E+08 2.5 2.6 3.0 
Mtap 1.2E+08 2.8E+08 2.0E+07 5.8E+07 2.3E+07 2.3 2.9 12.4 
Psmd14 2.3E+08 7.0E+08 1.6E+08 3.5E+08 1.3E+08 3.0 2.1 5.3 
Fkbp5 5.2E+07 1.2E+08 4.7E+07 1.0E+08 8.0E+07 2.3 2.1 1.5 
Anxa4 3.9E+08 8.1E+08 5.9E+07 1.4E+08 7.5E+07 2.0 2.4 10.7 
Cdk1 7.7E+08 1.5E+09 2.8E+08 6.1E+08 1.4E+08 2.0 2.2 10.9 
Pak2 8.9E+07 1.0E+08 3.6E+07 1.4E+08 2.5E+07 1.1 3.8 4.1 
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Gene 
names T1 MT T1 WT T2 MT T2 WT 
T1 No 
TNF 
T1 Fold 
change 
T2 Fold 
change 
Fold 
change 
with No 
TNF 
Pbk 2.4E+07 3.7E+07 3.4E+07 6.9E+07 1.1E+07 1.5 2.0 3.4 
a Protein hits observed in the Miz1 K-CLASP study.  The peptide intensity observed for each sample (WT: 
N-biotin Miz1 peptide crosslinking in TNF treated lysates, MT: N-biotin mutant Miz1 peptide crosslinking in 
TNF treated lysates, No TNF: N-biotin Miz1 peptide crosslinking in TNF untreated lysates) for the two trials 
(T1: trial 1, T2: trial 2) is shown. T1 and T2 fold changes were calculated by dividing the peptide intensity 
observed in the N-biotin Miz1 peptide crosslinking in TNF treated sample by the peptide intensity observed 
for the N-biotin mutant Miz1 peptide crosslinking in TNF treated sample. Fold change with no TNF was 
calculated by dividing the peptide intensity observed in the N-biotin Miz1 peptide crosslinking in TNF treated 
sample by the peptide intensity observed for the N-biotin Miz1 peptide crosslinking in TNF untreated 
sample. Infinity (∞) signifies that no peptides were observed in either the N-biotin mutant Miz1 peptide 
crosslinking sample or the N-biotin Miz1 peptide crosslinking in TNF untreated lysate sample. The K-CLASP 
hit kinases are yellow colored.  
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APPENDIX B – CHAPTER 3 SUPPORTING INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure B.1: Replicates of gel images (A-B) from K-BIPS with OA mediated phosphatase 
inactivation.  Biotinylation was carried out with ATP-biotin and HeLa lysates treated with 
OA. Biotinylated proteins were purified using streptavidin resin after reaction and fractions 
from purification (input before strepatavidn purification, flow through and elution) were 
separated by SDS-PAGE and visualized by SYPRO®Ruby stain. Control reaction was 
carried out with HeLa lysates not treated with OA. Trial A shown as Figure 3.5. 
(B) (A) 
 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 
OA 1uM - + - - + - - + - - + - - + - - + - 
OA 10nM - - + - - + - - + - - + - - + - - + 
 input flow through elution input flow through elution 
 
Sypro®
Ruby  
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Table B.1: Full listing of the 71 hits from K-BIPS with OA mediated phosphatase 
inactivationa  
G
e
n
e
 
n
a
m
e
s
 
T1-OA T1+OA T2-OA T2+OA 
T1 Fold 
change 
T2 Fold 
change 
SMC1A 2.2E+03 0.0E+00 5.3E+02 0.0E+00 ∞ ∞ 
STAR 1.1E+02 0.0E+00 2.0E+02 0.0E+00 ∞ ∞ 
C1QBP 2.5E+03 3.7E+02 6.7E+01 0.0E+00 6.8 ∞ 
EIF2S1 7.2E+02 2.1E+02 3.8E+02 0.0E+00 3.4 ∞ 
TRMT10C 2.2E+02 0.0E+00 3.2E+02 1.6E+02 ∞ 2.1 
EPB41 6.4E+02 3.5E+02 3.4E+02 0.0E+00 1.8 ∞ 
DDX60L 4.0E+03 0.0E+00 3.9E+02 2.3E+02 ∞ 1.7 
HSPD1 1.7E+03 1.1E+03 6.8E+01 0.0E+00 1.5 ∞ 
BBS1 3.8E+02 2.6E+02 2.0E+02 0.0E+00 1.5 ∞ 
DAP3 1.3E+04 1.6E+02 8.6E+02 2.4E+02 80.7 3.6 
MRPL44 1.2E+04 2.1E+02 4.5E+02 1.8E+02 58.3 2.5 
TUBA1B 5.7E+05 1.0E+04 3.8E+04 2.3E+04 57.4 1.6 
TUBB 8.3E+04 1.7E+03 6.6E+03 2.4E+03 48.2 2.7 
LRPPRC 1.6E+04 4.5E+02 4.2E+03 8.2E+02 35.9 5.1 
EIF3A 1.1E+04 3.6E+02 9.6E+02 4.2E+02 29.3 2.3 
NCL 2.9E+04 1.3E+03 2.9E+03 8.0E+02 22.6 3.6 
PHGDH 5.6E+04 3.5E+03 2.8E+04 2.9E+03 15.8 9.5 
GCN1L1 2.0E+04 1.0E+03 1.3E+03 8.6E+02 19.8 1.5 
HSP90AB1 1.7E+05 9.6E+03 2.0E+04 1.1E+04 17.7 1.8 
TUBA4A 1.2E+04 7.3E+02 9.3E+02 5.3E+02 16.3 1.8 
EIF4A3 1.7E+04 1.2E+03 1.1E+03 6.3E+02 14.4 1.7 
EZR 2.9E+03 2.1E+02 6.9E+02 3.9E+02 13.6 1.8 
DDX1 7.1E+03 5.4E+02 7.7E+02 3.8E+02 13.2 2.0 
HLA-B 1.1E+03 4.8E+02 2.3E+03 1.9E+02 2.4 12.2 
DHX9 1.5E+04 1.3E+03 1.0E+03 4.7E+02 11.8 2.1 
PCNA 2.6E+03 2.2E+02 3.7E+02 1.9E+02 11.9 1.9 
ZNF83 7.8E+03 6.8E+02 4.7E+02 2.7E+02 11.5 1.7 
KATNAL2 1.5E+04 1.4E+03 2.0E+03 1.2E+03 11.0 1.7 
ACADVL 3.0E+03 1.3E+03 2.8E+03 2.8E+02 2.3 10.0 
TOM1L2 5.8E+03 9.4E+02 7.2E+02 1.4E+02 6.1 5.1 
EXTL3 3.1E+03 4.1E+02 8.3E+02 3.0E+02 7.6 2.8 
HSP90B1 1.7E+03 2.8E+02 7.9E+02 2.0E+02 6.2 4.0 
VDAC2 2.9E+04 7.6E+03 5.8E+04 9.6E+03 3.8 6.0 
CANX 3.4E+04 7.3E+03 2.2E+04 5.1E+03 4.7 4.4 
VDAC1 5.3E+04 1.9E+04 1.3E+05 2.1E+04 2.8 6.0 
GTF2H4 1.3E+03 2.2E+02 2.5E+02 9.1E+01 5.8 2.7 
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G
e
n
e
 
n
a
m
e
s
 
T1-OA T1+OA T2-OA T2+OA 
T1 Fold 
change 
T2 Fold 
change 
KIAA1755 5.3E+02 1.5E+02 4.9E+02 1.0E+02 3.6 4.7 
MCM3 4.4E+04 7.6E+03 1.5E+04 5.8E+03 5.8 2.5 
SERPINB6 7.4E+04 1.7E+04 1.2E+04 3.6E+03 4.4 3.3 
RALGAPA1 1.8E+03 9.7E+02 3.4E+03 6.0E+02 1.9 5.6 
TNFRSF21 3.4E+03 1.5E+03 6.5E+03 1.3E+03 2.4 5.0 
HORMAD1 1.5E+03 9.2E+02 9.5E+02 1.7E+02 1.6 5.5 
KPNB1 3.7E+04 8.2E+03 1.8E+04 7.0E+03 4.5 2.6 
HADHA 1.8E+04 6.3E+03 1.4E+04 3.6E+03 2.8 3.9 
CAD 1.4E+03 6.1E+02 2.0E+03 4.8E+02 2.3 4.1 
C3orf17 1.1E+03 4.0E+02 8.4E+02 2.5E+02 2.9 3.4 
HADHB 5.0E+04 1.9E+04 1.3E+04 4.3E+03 2.7 3.1 
WDR87 1.2E+03 4.6E+02 1.1E+03 3.6E+02 2.7 3.1 
RNF207 4.9E+02 1.4E+02 3.4E+02 1.7E+02 3.5 2.0 
IMMT 7.0E+02 2.6E+02 1.0E+03 3.8E+02 2.7 2.7 
ARFGEF2 1.2E+03 3.4E+02 4.7E+02 3.1E+02 3.6 1.5 
SERPINB1 1.1E+05 3.2E+04 1.8E+04 1.1E+04 3.3 1.7 
OR5H2 2.2E+03 9.4E+02 8.6E+02 3.3E+02 2.4 2.6 
C2orf78 4.8E+02 2.8E+02 4.9E+02 1.5E+02 1.7 3.2 
RYR2 4.3E+03 1.4E+03 2.3E+03 1.3E+03 3.0 1.8 
RDH13 3.1E+03 9.9E+02 6.8E+02 4.4E+02 3.2 1.5 
RPL27 7.4E+03 2.6E+03 1.2E+03 7.4E+02 2.9 1.6 
BDP1 7.0E+02 4.7E+02 1.2E+03 3.9E+02 1.5 3.0 
LDHA 1.8E+04 9.3E+03 1.6E+04 6.4E+03 1.9 2.5 
APMAP 3.8E+03 2.5E+03 1.8E+03 6.5E+02 1.5 2.8 
EEF2 3.6E+04 1.3E+04 1.4E+04 8.7E+03 2.7 1.6 
MSN 3.4E+05 1.3E+05 2.4E+05 1.5E+05 2.6 1.5 
KIF20B 2.1E+03 1.4E+03 5.6E+02 2.4E+02 1.5 2.3 
TPP1 3.1E+03 1.7E+03 6.8E+02 3.4E+02 1.8 2.0 
PML 1.4E+02 7.0E+01 1.2E+02 7.5E+01 2.0 1.6 
CALR 7.1E+02 3.7E+02 6.1E+02 3.7E+02 1.9 1.7 
ZNF618 1.8E+03 1.2E+03 2.6E+03 1.3E+03 1.5 2.0 
PPIA 1.0E+03 6.5E+02 7.4E+02 4.3E+02 1.6 1.7 
PKM 4.5E+04 3.0E+04 3.7E+04 2.1E+04 1.5 1.7 
TCF20 2.0E+03 1.2E+03 2.2E+03 1.5E+03 1.6 1.5 
HSPA6 3.4E+04 2.2E+04 4.5E+03 2.9E+03 1.6 1.5 
 a Protein hits observed in the K-BIPS study with OA mediated phosphatase inactivation. The TMT reporter 
intensity observed for each sample (-OA: Without okadaic acid, +OA: With okadaic acid) for the two trials 
(T1: trial 1, T2: trial 2) is shown. Fold change for each trial was calculated by dividing the TMT reporter 
intensity observed in the okadaic acid untreated sample (phosphatase active) by the TMT reporter intensity 
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observed for the okadaic acid treated sample (phosphatase inactive). Infinity (∞) signifies that no TMT 
reporters were observed in the okadaic acid treated sample, making a numeric ratio calculation impossible.  
The known substrates of the inhibited phosphatases are green colored. The K-BIPS hits that are not 
previously known substrates, but known to interact with the inhibited phosphatases are blue colored.  
 
 
 
 
 
 
 
 
 1 2 3 
Tm - + + 
Gb - - + 
 
Figure B.2: Replicates of gel images from assessment of Gaddd34 expression. 
Gadd34 expression was probed with Western blot (Top gel) in untreated cells (Lane 
1), cells treated with only Tm (Lane 2) and cell treated with both Tm and Gb (Lane 3). 
The bottom Sypro-Ruby stained gel shows equal protein loading. The arrow points to 
the band corresponding Gadd34. A cropped image of Trial 1 is shown in Figure 
3.8.Trial 2 and 3 were performed by N.Chinthaka.  
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Figure B.3: Replicates of gel images (A-C) from biotinylation reactions using PP1-
Gadd34 inactivated lysates. Biotinylation was carried out with HeLa lysates treated with 
Tm and Gb. Biotinylated proteins were separated by SDS-PAGE and visualized by 
Streptavdin-Cy5 (top) and SYPRO® Ruby stain (bottom).  Control reactions were carried 
out with HeLa untreated with both Tm and Gb and lysates treated only with Tm. Trial A 
shown as Figure 3.9. 
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Figure B.4: Replicates of gel images from K-BIPS with PP1-Gadd34 phosphatase 
inactivation. Biotinylation was carried out with lysates treated with Tm and Gb and with 
lysates treated only with Tm. After reaction, biotin tagged proteins were purified by 
Streptavdin resin and separated on SDS-PAGE. The input before streptavidin purification, 
flow through and elution was also loaded on gel along with the eluted proteins. Then total 
proteins were visualized with Sypro®Ruby stain. The gels were used for LC-MS/MS 
analysis.  
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Table B.2: Full listing of the 130 hits from K-BIPS with PP1-Gadd34 phosphatase 
inactivationa  
Gene names T1- Gb T1 + Gb T2 -Gb T2 +Gb T1 ratio T2 ratio 
RPS12 5.5E+07 0.0E+00 6.5E+06 0.0E+00 ∞ ∞ 
FHOD1 5.5E+06 0.0E+00 1.7E+07 0.0E+00 ∞ ∞ 
ARF1 2.1E+07 0.0E+00 1.7E+06 0.0E+00 ∞ ∞ 
STK3 5.6E+06 0.0E+00 1.5E+07 0.0E+00 ∞ ∞ 
IST1 1.2E+07 0.0E+00 6.4E+06 0.0E+00 ∞ ∞ 
SNRPF 1.9E+06 0.0E+00 6.4E+06 0.0E+00 ∞ ∞ 
EIF4G3 4.7E+06 0.0E+00 2.5E+06 0.0E+00 ∞ ∞ 
SLC9A3R1 5.5E+07 1.7E+06 3.1E+06 0.0E+00 31.3 ∞ 
RELA 1.1E+08 5.7E+06 4.4E+06 0.0E+00 20.0 ∞ 
TIMM50 2.6E+07 1.8E+06 2.0E+07 0.0E+00 14.5 ∞ 
FAM120A 3.3E+07 2.3E+06 2.7E+07 0.0E+00 14.0 ∞ 
FDPS 4.8E+08 3.8E+07 2.3E+07 0.0E+00 12.8 ∞ 
PTMA 1.6E+07 1.7E+06 4.7E+06 0.0E+00 9.0 ∞ 
GPI 3.2E+07 3.9E+06 4.2E+06 0.0E+00 8.1 ∞ 
PRDX4 5.7E+07 1.0E+07 1.3E+07 0.0E+00 5.7 ∞ 
AIMP2 1.9E+07 0.0E+00 8.4E+07 1.5E+07 ∞ 5.6 
CTBP2 3.0E+07 6.2E+06 4.8E+06 0.0E+00 4.9 ∞ 
FMR1 1.7E+07 3.6E+06 6.9E+06 0.0E+00 4.7 ∞ 
TIAL1 1.9E+07 4.7E+06 1.0E+07 0.0E+00 4.1 ∞ 
HMGB1P1 1.4E+06 4.4E+05 4.6E+06 0.0E+00 3.1 ∞ 
MAPK1 2.0E+08 6.9E+07 1.1E+07 0.0E+00 2.9 ∞ 
ITPR1 6.2E+06 0.0E+00 3.9E+06 1.5E+06 ∞ 2.5 
PPP2R4 1.0E+08 0.0E+00 8.3E+06 3.3E+06 ∞ 2.5 
STARD7 1.7E+07 0.0E+00 7.4E+06 3.1E+06 ∞ 2.4 
VPS26B 1.1E+07 0.0E+00 1.2E+07 5.1E+06 ∞ 2.4 
CAPN2 1.6E+06 0.0E+00 2.6E+08 1.1E+08 ∞ 2.3 
VPS13A 3.5E+05 0.0E+00 9.9E+06 4.4E+06 ∞ 2.3 
SNX2 3.0E+07 0.0E+00 1.5E+07 6.5E+06 ∞ 2.2 
NARS 7.4E+05 0.0E+00 2.0E+07 9.2E+06 ∞ 2.2 
ERLIN1 8.3E+06 0.0E+00 6.2E+06 2.9E+06 ∞ 2.1 
CKAP4 2.4E+06 0.0E+00 9.2E+07 4.4E+07 ∞ 2.1 
PUF60 4.8E+07 0.0E+00 4.0E+07 2.0E+07 ∞ 2.0 
TNPO2 1.5E+07 0.0E+00 3.9E+06 2.0E+06 ∞ 2.0 
CAPRIN1 1.3E+08 0.0E+00 1.7E+08 8.7E+07 ∞ 2.0 
MYO18A 2.2E+06 1.1E+06 1.9E+07 0.0E+00 2.0 ∞ 
IGF2BP3 1.1E+07 5.7E+06 2.2E+06 0.0E+00 1.9 ∞ 
SYNCRIP 9.4E+06 0.0E+00 2.5E+08 1.4E+08 ∞ 1.8 
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Gene names T1- Gb T1 + Gb T2 -Gb T2 +Gb T1 ratio T2 ratio 
DAP3 7.2E+06 0.0E+00 1.0E+07 5.9E+06 ∞ 1.7 
PITPNA 5.5E+05 0.0E+00 2.0E+08 1.2E+08 ∞ 1.7 
DNAJB11 4.8E+07 0.0E+00 1.5E+07 8.9E+06 ∞ 1.7 
TIMM44 3.3E+07 1.9E+07 1.7E+06 0.0E+00 1.7 ∞ 
RRM2 7.3E+07 0.0E+00 1.1E+08 6.6E+07 ∞ 1.6 
ATP6V0D1 3.4E+07 0.0E+00 1.1E+08 7.0E+07 ∞ 1.5 
THUMPD1 1.3E+06 0.0E+00 4.6E+06 3.0E+06 ∞ 1.5 
CSNK2A3 1.5E+07 0.0E+00 1.3E+07 9.0E+06 ∞ 1.5 
RNF213 2.1E+05 0.0E+00 6.0E+07 4.3E+07 ∞ 1.4 
MRPS9 5.6E+08 0.0E+00 1.3E+07 9.5E+06 ∞ 1.4 
ANP32E 1.1E+07 0.0E+00 6.7E+07 4.9E+07 ∞ 1.4 
WDR5 5.9E+07 0.0E+00 2.2E+07 1.6E+07 ∞ 1.4 
PSMC3 7.8E+07 6.2E+07 1.3E+07 0.0E+00 1.3 ∞ 
KHDRBS1 5.4E+07 0.0E+00 3.5E+07 2.7E+07 ∞ 1.3 
SMG9 5.9E+06 0.0E+00 7.5E+06 5.8E+06 ∞ 1.3 
NUP37 5.8E+07 0.0E+00 2.7E+07 2.1E+07 ∞ 1.3 
COPS5 9.0E+07 0.0E+00 1.4E+08 1.1E+08 ∞ 1.3 
STRAP 5.7E+08 9.6E+06 1.9E+08 6.7E+07 59.1 2.8 
GOT2 3.0E+08 6.2E+06 1.4E+08 1.0E+08 48.4 1.4 
ARHGDIA 8.2E+07 2.3E+06 4.6E+06 3.6E+06 35.2 1.3 
GAPVD1 4.8E+07 1.4E+06 1.2E+07 9.0E+06 34.7 1.3 
EEF1D 1.4E+09 4.1E+07 6.3E+08 3.8E+08 33.9 1.7 
DYNC1LI2 2.6E+07 7.7E+05 1.4E+07 1.1E+07 34.1 1.3 
G3BP1 1.6E+08 6.3E+06 1.6E+08 1.1E+08 25.7 1.5 
ACOT7 9.0E+08 4.3E+07 4.9E+07 2.6E+07 20.8 1.9 
UBE2Z 5.0E+08 2.7E+07 1.6E+07 5.1E+06 18.4 3.0 
PARVA 1.5E+08 8.4E+06 2.6E+08 1.1E+08 17.4 2.3 
PSAT1 6.0E+08 3.5E+07 9.3E+07 5.9E+07 17.3 1.6 
RPL10A 6.9E+07 4.2E+06 1.5E+08 1.1E+08 16.5 1.5 
PPA1 3.7E+08 2.4E+07 6.6E+07 4.2E+07 15.2 1.6 
PDHB 2.4E+08 1.6E+07 6.7E+07 3.6E+07 14.7 1.8 
RBBP7 9.8E+07 8.7E+06 6.3E+07 2.6E+07 11.3 2.5 
FXR1 1.0E+07 1.1E+06 1.1E+07 4.3E+06 9.8 2.6 
ALDOC 4.7E+08 4.9E+07 2.3E+07 8.4E+06 9.4 2.7 
ST13 9.5E+07 1.1E+07 5.6E+07 1.8E+07 8.6 3.1 
NACA 3.2E+08 3.2E+07 1.0E+09 7.8E+08 10.1 1.3 
CAPG 5.4E+08 1.5E+08 4.8E+06 6.4E+05 3.7 7.5 
ACTR2 2.7E+08 2.9E+07 3.6E+07 2.4E+07 9.6 1.5 
PLXNB2 5.4E+07 5.6E+06 2.2E+07 1.8E+07 9.6 1.3 
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Gene names T1- Gb T1 + Gb T2 -Gb T2 +Gb T1 ratio T2 ratio 
NAP1L4 2.2E+07 3.1E+06 1.1E+07 2.8E+06 6.9 3.8 
PICALM 5.3E+08 1.4E+08 1.5E+07 2.2E+06 3.9 6.8 
TALDO1 5.3E+08 5.8E+07 1.8E+08 1.2E+08 9.2 1.5 
GNB2 8.4E+07 9.2E+06 1.5E+08 1.2E+08 9.1 1.3 
VPS26A 3.6E+08 4.1E+07 2.1E+08 1.3E+08 8.7 1.6 
SH3GL1 4.5E+07 5.5E+06 1.6E+07 8.6E+06 8.1 1.8 
ALDOA 5.5E+09 1.2E+09 1.9E+08 4.3E+07 4.5 4.5 
VIM 6.2E+08 8.9E+07 5.2E+09 2.6E+09 7.0 2.0 
SEH1L 5.9E+07 8.6E+06 1.9E+07 9.1E+06 6.8 2.1 
PTPN12 1.9E+07 2.8E+06 1.2E+07 5.7E+06 6.6 2.1 
TWF1 2.3E+08 3.2E+07 8.6E+07 6.5E+07 7.1 1.3 
NDRG1 8.6E+08 1.3E+08 5.4E+07 3.2E+07 6.6 1.7 
HNRNPAB 8.7E+06 1.3E+06 5.4E+07 4.1E+07 6.6 1.3 
EIF3M 7.6E+08 1.4E+08 2.0E+07 8.3E+06 5.4 2.5 
HSD17B4 6.4E+08 1.1E+08 1.4E+08 6.5E+07 5.6 2.1 
TUBA4A 1.4E+08 3.9E+07 2.0E+07 4.8E+06 3.6 4.1 
NDC1 5.4E+06 8.9E+05 4.5E+06 3.1E+06 6.1 1.5 
HM13 1.9E+07 3.3E+06 5.9E+06 3.9E+06 5.8 1.5 
PRKAR2A 5.1E+07 8.4E+06 3.4E+07 2.7E+07 6.0 1.3 
PSMD13 4.2E+08 9.1E+07 4.5E+06 1.7E+06 4.6 2.6 
RAN 1.2E+09 6.8E+08 3.7E+07 7.2E+06 1.8 5.1 
MAP2K3 7.4E+07 1.6E+07 3.8E+07 2.7E+07 4.7 1.4 
SEPHS1 6.5E+07 2.4E+07 1.4E+07 4.3E+06 2.7 3.3 
NAP1L1 1.6E+08 3.6E+07 1.7E+08 1.1E+08 4.6 1.5 
VAT1 8.5E+07 2.2E+07 2.0E+08 9.2E+07 3.8 2.2 
GALE 1.8E+08 4.1E+07 3.6E+07 2.4E+07 4.5 1.5 
CALU 2.2E+07 7.0E+06 3.9E+08 1.3E+08 3.1 2.9 
ANXA2 1.4E+10 3.0E+09 6.4E+09 5.0E+09 4.5 1.3 
RPL26L1 1.5E+07 3.8E+06 1.3E+07 8.0E+06 4.0 1.6 
SMARCC1 2.5E+07 1.3E+07 6.5E+06 2.0E+06 1.9 3.3 
ENO1 9.2E+08 3.0E+08 3.7E+08 1.7E+08 3.0 2.2 
GMPS 1.2E+08 3.2E+07 1.9E+08 1.2E+08 3.6 1.6 
DNAJA1 1.3E+08 3.7E+07 4.9E+07 2.8E+07 3.4 1.7 
SFN 1.3E+08 3.8E+07 1.4E+07 8.5E+06 3.5 1.6 
PSMC2 1.3E+08 5.9E+07 6.5E+07 2.3E+07 2.3 2.8 
EIF3G 5.6E+07 1.9E+07 5.8E+07 3.1E+07 3.0 1.8 
RPLP0 3.9E+09 1.1E+09 7.8E+09 5.7E+09 3.4 1.4 
PPP2R1B 1.7E+07 6.8E+06 6.5E+06 2.9E+06 2.5 2.2 
MDH1 2.1E+08 7.0E+07 3.7E+08 2.1E+08 3.0 1.7 
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Gene names T1- Gb T1 + Gb T2 -Gb T2 +Gb T1 ratio T2 ratio 
EIF2S1 1.2E+09 5.1E+08 5.4E+08 2.3E+08 2.4 2.3 
UBE3A 2.9E+06 8.7E+05 2.3E+07 1.7E+07 3.3 1.3 
UBQLN2 2.0E+06 1.6E+06 1.1E+07 3.3E+06 1.3 3.3 
BZW1 6.8E+07 2.0E+07 3.3E+07 2.6E+07 3.3 1.3 
SFPQ 6.0E+08 1.8E+08 4.0E+07 3.1E+07 3.3 1.3 
PRKAR1A 2.4E+07 7.4E+06 5.1E+07 3.9E+07 3.2 1.3 
PGAM1 6.0E+07 3.2E+07 8.9E+06 3.6E+06 1.9 2.5 
PDIA6 2.0E+08 1.1E+08 2.8E+08 1.1E+08 1.8 2.5 
SF3A1 2.3E+07 1.1E+07 2.2E+07 9.7E+06 2.1 2.2 
NUDC 2.7E+08 1.1E+08 2.5E+07 1.5E+07 2.5 1.7 
sept7 9.4E+05 4.4E+05 1.5E+08 7.2E+07 2.1 2.0 
LAP3 2.6E+07 1.1E+07 3.3E+07 1.9E+07 2.3 1.7 
CFL1 1.9E+08 9.7E+07 3.3E+07 1.6E+07 2.0 2.0 
SUCLG2 4.1E+06 2.0E+06 1.4E+07 7.3E+06 2.1 1.9 
FKBP10 2.7E+07 1.0E+07 3.2E+07 2.4E+07 2.6 1.3 
a Protein hits observed in the K-BIPS study with PP1-Gadd34 inactivation. The peptide intensity observed 
for each sample (-Gb: Without guanabenz, +Gb: With guanabenz) for the two trials (T1: trial 1, T2: trial 2) 
is shown. Fold change for each trial was calculated by dividing the peptide intensity observed in the 
guanabenz untreated sample (PP1-Gadd34 active) sample by the peptide intensity observed for the 
guanabenz treated sample (PP1-Gadd34 inactive). Infinity (∞) signifies that no peptides were observed in 
the guanabenz treated sample, making a numeric ratio calculation impossible.  EIF2S1, the known 
substrate of PP1-Gadd34 is green colored. 
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Figure B.5: Full gel images from streptavidin enrichment of COPS5 from biotinylated 
PP1-Gadd34 active and PP1-Gadd34 inactive lysates. Biotinylation was carried out with 
HeLa lysates treated with Tm and Gb or with lysates treated with only Tm. Biotinylated 
proteins were then enriched with streptavidin resin and the input, flow through, wash and 
elution were separated by SDS-PAGE and visualized with a COPS5 antibody. The arrow 
indicates the band corresponding to COPS5. Trial 2 is shown in Figure 3.11.  
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Figure B.6: Full gel images from streptavidin enrichment of WDR5 from biotinylated PP1-
Gadd34 active and PP1-Gadd34 inactive lysates. Biotinylation was carried out with HeLa 
lysates treated with Tm and Gb or with lysates treated with only Tm. Biotinylated proteins 
were then enriched with streptavidin resin and the input, flow through, wash and elution 
were separated by SDS-PAGE and visualized by a WDR5 specific antibody by Western 
blot. The arrow indicates the band corresponding to WDR5. Trial 3 is shown in Figure 
3.11.  
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Figure B.7: Full gel images from streptavidin enrichment of CAPRIN1 from biotinylated 
PP1-Gadd34 active and PP1-Gadd34 inactive lysates. Biotinylation was carried out with 
HeLa lysates treated with Tm and Gb or with lysates treated with only Tm. Biotinylated 
proteins were then enriched with streptavidin resin and the input, flow through, wash and 
elution were separated by SDS-PAGE and visualized by a CAPRIN1 specific antibody by 
Western blot. The arrow indicates the band corresponding to CAPRIN1. Trial 1 shown in 
Figure 3.11. Trial 2 was performed by N.Chinthaka.  
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Figure B.8: Full gel images from streptavidin enrichment of G3BP1 from biotinylated 
PP1-Gadd34 active and PP1-Gadd34 inactive lysates. Biotinylation was carried out with 
HeLa lysates treated with Tm and Gb or with lysates treated with only Tm. Biotinylated 
proteins were then enriched with streptavidin resin and the input, flow through, wash and 
elution were separated by SDS-PAGE and visualized by a G3BP1 specific antibody by 
Western blot. The arrow indicates the band corresponding to G3BP1.Trial 1 shown in 
Figure 3.11.Trial 2 and 3 were carried out by N.Chinthaka.    
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Figure B.9: Assessment of MYPT1 knockdown in L6 myoblasts treated with and without 
doxycycline. L6 myoblast lysates were separated on SDS-PAGE. Total proteins were 
visualized with Sypro®Ruby stain and MYPT1 was probed with an anti-MYPT1 antibody. 
Arrow points to MYPT1. Trial 1 is shown in Figure 3.12. 
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Figure B.10: Replicates of gel images from K-BIPS with PP1-MYPT1 phosphatase 
inactivation. Biotinylation was carried out with L6 lysates treated with doxycycline (Dox) 
and without Dox. Biotin tagged proteins were purified by streptavidin and separted on 
SDS-PAGE. The input before streptavidin resin, flow through, and the last wash were 
also separated on SDS-PAGE. Total proteins were then visualized by Sypro®Ruby stain. 
All three gels were used in LC-MS/MS analysis.  
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Table B.3: The 14 K-BIPS hits enriched in all three trials from the study with PP1-
MYPT1 phosphatase inactivationa 
Gene 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox 
t-test 
T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Average 
Ratio 
Copg2 
2.3E
+08 
7.2E
+07 
2.3E
+08 
1.7E
+08 
0.0E
+00 
1.6E
+08 0.01 1.3 ∞ 1.4 ∞ 
Cnp 
2.7E
+08 
2.1E
+08 
3.9E
+08 
9.9E
+07 
0.0E
+00 
2.2E
+08 0.01 2.7 ∞ 1.8 ∞ 
Akt1 
2.7E
+07 
3.1E
+07 
6.2E
+07 
0.0E
+00 
0.0E
+00 
4.3E
+07 0.02 ∞ ∞ 1.4 ∞ 
Nptn 
1.7E
+08 
1.6E
+08 
2.2E
+08 
2.2E
+07 
1.2E
+07 
1.4E
+08 0.04 7.4 12.9 1.5 7.3 
Aldh9a1 
1.2E
+09 
3.0E
+08 
2.0E
+08 
1.0E
+09 
1.7E
+08 
2.2E
+07 0.01 1.2 1.8 9.1 4.0 
Actr2 
3.2E
+09 
5.2E
+08 
1.0E
+09 
2.5E
+09 
7.3E
+07 
5.8E
+08 0.03 1.3 7.2 1.8 3.4 
Cops4 
2.2E
+09 
2.4E
+08 
3.2E
+08 
2.0E
+09 
4.3E
+07 
1.6E
+08 0.00 1.1 5.5 2.0 2.9 
Pdia3 
3.0E
+10 
7.0E
+09 
1.1E
+10 
2.0E
+10 
2.0E
+09 
4.2E
+09 0.03 1.5 3.5 2.6 2.5 
Fxr1 
1.2E
+09 
5.0E
+08 
7.2E
+08 
9.1E
+08 
1.6E
+08 
2.6E
+08 0.01 1.4 3.2 2.7 2.4 
Fkbp9 
3.6E
+08 
3.0E
+08 
4.6E
+08 
1.7E
+08 
1.0E
+08 
3.3E
+08 0.02 2.1 3.1 1.4 2.2 
anxa1 
4.0E
+10 
2.7E
+09 
4.9E
+09 
3.8E
+10 
1.0E
+09 
1.9E
+09 0.03 1.1 2.7 2.6 2.1 
Glud1 
4.1E
+09 
6.2E
+08 
1.1E
+09 
3.4E
+09 
2.4E
+08 
5.1E
+08 0.03 1.2 2.6 2.2 2.0 
Bre 
2.3E
+08 
2.2E
+07 
1.2E
+08 
2.0E
+08 
6.8E
+06 
8.3E
+07 0.04 1.1 3.2 1.4 1.9 
Pdia6 
1.3E
+10 
2.3E
+09 
3.9E
+09 
1.1E
+10 
1.1E
+09 
2.4E
+09 0.01 1.1 2.1 1.6 1.6 
a Protein hits observed in all three trials in the K-BIPS study with PP1-MYPT1 inactivation. The peptide 
intensity observed for each sample (-Dox: Without doxycycline, +Dox: With doxycycline) for the three trials 
(T1: trial 1, T2: trial 2, T3: trial 3) is shown. Fold change for each trial was calculated by dividing the peptide 
intensity observed in the doxycycline untreated sample (PP1-MYPT1 active) sample by the peptide intensity 
observed for the doxycycline treated sample (PP1-MYPT1 inactive). Infinity (∞) signifies that no peptides 
were observed in the doxycyline treated sample, making a numeric ratio calculation impossible. 
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Table B.4: The 161 K-BIPS hits enriched in at least two trials from the study with PP1-
MYPT1 phosphatase inactivationa 
Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
SHTN1 
2.2E+0
8 
6.2E+0
7 
4.0E+0
7 
0.0E+0
0 
2.3E+0
7 
0.0E+0
0 ∞ 2.7 ∞ 
Rnpep  
1.8E+0
9 
2.2E+0
7 
8.6E+0
7 
1.2E+0
9 
0.0E+0
0 
0.0E+0
0 1.5 ∞ ∞ 
Mllt4  
8.1E+0
6 
3.7E+0
7 
5.5E+0
7 
0.0E+0
0 
0.0E+0
0 
5.7E+0
7 ∞ ∞ 1.0 
Mogs  
5.4E+0
8 
0.0E+0
0 
4.6E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ 0.0 ∞ 
Plcg1  
2.5E+0
8 
1.8E+0
7 
1.8E+0
7 
2.9E+0
8 
0.0E+0
0 
0.0E+0
0 0.9 ∞ ∞ 
Fcgrt  
7.9E+0
6 
8.0E+0
7 
1.7E+0
7 
0.0E+0
0 
0.0E+0
0 
1.0E+0
8 ∞ ∞ 0.2 
Fh  
5.8E+0
9 
5.8E+0
7 
1.4E+0
8 
4.1E+0
9 
0.0E+0
0 
0.0E+0
0 1.4 ∞ ∞ 
Gsk3a  
1.6E+0
8 
1.6E+0
8 
4.9E+0
7 
1.4E+0
8 
0.0E+0
0 
0.0E+0
0 1.2 ∞ ∞ 
Mif  
4.4E+0
8 
2.4E+0
8 
6.4E+0
7 
0.0E+0
0 
0.0E+0
0 
1.4E+0
8 ∞ ∞ 0.5 
Rab8b  
1.2E+0
7 
4.2E+0
7 
1.6E+0
7 
0.0E+0
0 
0.0E+0
0 
1.6E+0
7 ∞ ∞ 1.0 
Grpel1  
7.0E+0
7 
9.7E+0
6 
6.0E+0
6 
0.0E+0
0 
0.0E+0
0 
6.7E+0
7 ∞ ∞ 0.1 
Adprh  
1.2E+0
8 
1.7E+0
5 
2.1E+0
7 
0.0E+0
0 
0.0E+0
0 
7.5E+0
7 ∞ ∞ 0.3 
Atg5  
7.1E+0
7 
1.5E+0
7 
2.4E+0
7 
7.0E+0
7 
0.0E+0
0 
0.0E+0
0 1.0 ∞ ∞ 
Ssu72  
0.0E+0
0 
3.4E+0
7 
1.9E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 0.0 ∞ ∞ 
Exosc9  
1.1E+0
8 
2.1E+0
7 
6.0E+0
6 
2.1E+0
8 
0.0E+0
0 
0.0E+0
0 0.5 ∞ ∞ 
Med4  
2.2E+0
6 
1.7E+0
7 
2.5E+0
7 
0.0E+0
0 
0.0E+0
0 
4.7E+0
7 ∞ ∞ 0.5 
Nucb1  
7.4E+0
8 
5.8E+0
6 
2.9E+0
7 
7.2E+0
8 
0.0E+0
0 
0.0E+0
0 1.0 ∞ ∞ 
Ndufs2  
3.6E+0
8 
7.2E+0
6 
4.8E+0
7 
3.3E+0
8 
0.0E+0
0 
0.0E+0
0 1.1 ∞ ∞ 
Pex14  
0.0E+0
0 
2.0E+0
7 
7.6E+0
7 
1.4E+0
7 
0.0E+0
0 
0.0E+0
0 0.0 ∞ ∞ 
Emc10  
2.7E+0
7 
3.1E+0
7 
3.2E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ ∞ ∞ 
Snx17  
0.0E+0
0 
4.8E+0
7 
7.7E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 0.0 ∞ ∞ 
Pdcd10  
3.4E+0
7 
0.0E+0
0 
1.4E+0
8 
0.0E+0
0 
1.6E+0
8 
0.0E+0
0 ∞ 0.0 ∞ 
Entpd5  
5.4E+0
6 
6.3E+0
7 
2.2E+0
8 
0.0E+0
0 
0.0E+0
0 
2.0E+0
8 ∞ ∞ 1.1 
Fam3c  
6.2E+0
7 
0.0E+0
0 
5.2E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ 0.0 ∞ 
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Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Akr7a2  
5.8E+0
8 
1.7E+0
8 
2.2E+0
7 
3.0E+0
8 
0.0E+0
0 
0.0E+0
0 1.9 ∞ ∞ 
Xab2  
1.1E+0
8 
9.1E+0
5 
8.5E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ ∞ ∞ 
Gde1  
6.6E+0
6 
0.0E+0
0 
1.8E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ 0.0 ∞ 
Haus1  
3.6E+0
7 
0.0E+0
0 
1.8E+0
7 
0.0E+0
0 
0.0E+0
0 
0.0E+0
0 ∞ 0.0 ∞ 
Ola1  
2.2E+0
9 
1.9E+0
7 
7.5E+0
7 
3.0E+0
9 
0.0E+0
0 
1.1E+0
7 0.7 ∞ 6.9 
Tmem214  
5.3E+0
7 
0.0E+0
0 
1.1E+0
8 
0.0E+0
0 
0.0E+0
0 
2.5E+0
7 ∞ 0.0 4.5 
Emc2  
2.3E+0
7 
2.7E+0
8 
9.4E+0
8 
8.7E+0
6 
2.3E+0
8 
3.3E+0
8 2.6 1.1 2.9 
Ostc  
0.0E+0
0 
1.1E+0
8 
1.8E+0
8 
0.0E+0
0 
2.0E+0
7 
8.0E+0
7 0.0 5.2 2.3 
Otub1  
1.4E+0
8 
1.7E+0
8 
3.5E+0
8 
2.1E+0
7 
2.0E+0
7 
6.1E+0
7 6.4 8.5 5.8 
Aasdhppt  
0.0E+0
0 
1.1E+0
7 
2.5E+0
7 
0.0E+0
0 
0.0E+0
0 
6.4E+0
6 0.0 ∞ 3.8 
Acad11  
0.0E+0
0 
2.7E+0
8 
2.5E+0
8 
0.0E+0
0 
7.4E+0
6 
8.6E+0
6 0.0 36.7 29.1 
Cul3  
6.1E+0
8 
0.0E+0
0 
1.6E+0
7 
2.3E+0
8 
0.0E+0
0 
0.0E+0
0 2.7 0.0 ∞ 
Nek7  
2.8E+0
5 
3.0E+0
8 
7.0E+0
8 
0.0E+0
0 
5.2E+0
7 
3.6E+0
8 ∞ 5.7 1.9 
Macf1  
5.8E+0
8 
2.3E+0
8 
4.1E+0
8 
1.2E+0
8 
1.0E+0
8 
4.5E+0
8 4.9 2.2 0.9 
Ppm1g  
1.0E+0
8 
4.2E+0
7 
7.8E+0
7 
2.6E+0
8 
1.9E+0
7 
1.2E+0
7 0.4 2.2 6.6 
Trip12  
2.9E+0
7 
0.0E+0
0 
4.2E+0
7 
5.0E+0
6 
0.0E+0
0 
0.0E+0
0 5.8 0.0 ∞ 
Prkci  
0.0E+0
0 
7.1E+0
6 
3.4E+0
7 
0.0E+0
0 
0.0E+0
0 
2.7E+0
6 0.0 ∞ 12.5 
Bin1  
0.0E+0
0 
1.0E+0
8 
2.0E+0
7 
0.0E+0
0 
4.8E+0
7 
4.7E+0
6 0.0 2.1 4.2 
Ptk2  
4.5E+0
7 
3.0E+0
7 
5.4E+0
7 
5.5E+0
7 
0.0E+0
0 
1.3E+0
7 0.8 ∞ 4.1 
Atic  
3.3E+0
9 
4.5E+0
8 
3.5E+0
8 
4.7E+0
9 
2.6E+0
7 
8.1E+0
7 0.7 17.1 4.4 
Kif3c  
3.8E+0
8 
3.0E+0
7 
1.2E+0
8 
0.0E+0
0 
3.7E+0
7 
5.9E+0
7 ∞ 0.8 2.1 
Kif1b  
2.8E+0
7 
0.0E+0
0 
7.1E+0
7 
5.2E+0
6 
0.0E+0
0 
2.9E+0
7 5.4 0.0 2.5 
Got2  
1.8E+1
0 
3.1E+0
9 
9.9E+0
9 
1.1E+1
0 
1.3E+0
9 
2.9E+0
9 1.5 2.3 3.4 
Ldha  
4.3E+0
9 
1.8E+0
9 
3.3E+0
9 
7.9E+0
8 
8.8E+0
8 
2.4E+0
9 5.4 2.0 1.4 
Cat  
2.8E+0
9 
1.2E+0
8 
1.9E+0
8 
2.0E+0
9 
0.0E+0
0 
4.5E+0
7 1.4 ∞ 4.2 
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Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Gstp1  
1.1E+0
7 
3.0E+0
8 
3.5E+0
8 
0.0E+0
0 
1.1E+0
8 
3.5E+0
8 ∞ 2.6 1.0 
Scd2  
0.0E+0
0 
2.3E+0
7 
1.9E+0
8 
0.0E+0
0 
0.0E+0
0 
3.2E+0
7 0.0 ∞ 5.9 
Acox1  
4.1E+0
8 
2.1E+0
7 
3.5E+0
7 
1.9E+0
8 
6.8E+0
6 
2.2E+0
7 2.1 3.2 1.6 
App  
1.2E+0
8 
9.6E+0
6 
0.0E+0
0 
4.0E+0
7 
0.0E+0
0 
4.4E+0
7 2.9 ∞ 0.0 
Ppia  
0.0E+0
0 
1.0E+0
8 
7.6E+0
8 
0.0E+0
0 
3.5E+0
7 
2.7E+0
8 0.0 2.9 2.8 
Aldh3a1  
3.8E+0
8 
3.2E+0
9 
6.3E+0
9 
2.2E+0
7 
1.1E+0
9 
1.6E+0
9 17.8 2.8 3.9 
Apeh  
9.7E+0
8 
0.0E+0
0 
3.3E+0
6 
2.3E+0
8 
0.0E+0
0 
0.0E+0
0 4.2 0.0 ∞ 
Spn  
0.0E+0
0 
8.6E+0
7 
1.6E+0
8 
0.0E+0
0 
0.0E+0
0 
4.4E+0
7 0.0 ∞ 3.6 
Pgk1  
8.7E+1
0 
1.2E+0
8 
1.0E+0
9 
8.0E+1
0 
5.5E+0
6 
3.3E+0
8 1.1 21.6 3.0 
Acly  
9.2E+0
9 
7.1E+0
8 
4.0E+0
9 
6.1E+0
9 
1.6E+0
8 
1.8E+0
9 1.5 4.4 2.2 
Nup62  
9.5E+0
8 
1.4E+0
7 
8.2E+0
7 
3.7E+0
8 
0.0E+0
0 
7.0E+0
7 2.6 ∞ 1.2 
Mat2a  
6.4E+0
9 
2.8E+0
8 
5.4E+0
8 
6.5E+0
9 
0.0E+0
0 
5.5E+0
7 1.0 ∞ 9.7 
Itga1  
1.1E+0
8 
7.3E+0
6 
0.0E+0
0 
2.6E+0
7 
0.0E+0
0 
0.0E+0
0 4.2 ∞ 0.0 
Cpt2  
2.4E+0
8 
4.8E+0
7 
5.7E+0
7 
1.2E+0
8 
2.2E+0
7 
4.4E+0
7 2.1 2.1 1.3 
Ptpn1  
2.4E+0
8 
1.3E+0
8 
2.2E+0
7 
7.3E+0
7 
7.7E+0
7 
0.0E+0
0 3.3 1.6 ∞ 
Xdh  
1.5E+0
6 
4.5E+0
7 
2.9E+0
8 
0.0E+0
0 
4.7E+0
7 
5.6E+0
7 ∞ 1.0 5.2 
Rpn2  
2.9E+0
8 
1.7E+0
9 
3.4E+0
9 
8.6E+0
7 
4.1E+0
8 
1.9E+0
9 3.4 4.2 1.8 
Hibadh  
4.2E+0
8 
0.0E+0
0 
8.1E+0
7 
2.0E+0
7 
0.0E+0
0 
0.0E+0
0 21.1 0.0 ∞ 
Rnh1  
2.4E+0
8 
3.0E+0
8 
2.5E+0
8 
3.9E+0
7 
5.3E+0
7 
2.3E+0
8 6.2 5.6 1.1 
Serpinb2  
5.2E+0
6 
3.2E+0
8 
5.1E+0
8 
0.0E+0
0 
1.3E+0
8 
6.1E+0
8 ∞ 2.4 0.8 
Lta4h  
3.2E+0
9 
3.3E+0
8 
1.4E+0
9 
4.1E+0
9 
4.3E+0
7 
7.3E+0
7 0.8 7.6 18.9 
Ezr  
7.9E+0
9 
9.5E+0
7 
6.7E+0
7 
3.9E+0
9 
1.3E+0
7 
1.6E+0
8 2.0 7.0 0.4 
Uqcrc2  
8.8E+0
6 
3.9E+0
8 
8.2E+0
8 
7.7E+0
7 
1.2E+0
8 
2.3E+0
8 0.1 3.2 3.5 
Gpc1  
9.7E+0
7 
1.9E+0
8 
4.3E+0
8 
2.3E+0
7 
2.6E+0
7 
5.8E+0
8 4.3 7.2 0.8 
Ywhab  
2.6E+0
7 
3.3E+0
9 
2.5E+0
9 
4.7E+0
6 
1.4E+0
9 
1.5E+0
9 5.5 2.3 1.7 
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Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Ldlr  
4.1E+0
7 
1.0E+0
8 
2.5E+0
8 
8.6E+0
5 
2.5E+0
7 
2.3E+0
8 47.7 4.1 1.1 
Ak1  
0.0E+0
0 
2.9E+0
7 
4.5E+0
7 
0.0E+0
0 
0.0E+0
0 
2.0E+0
7 0.0 ∞ 2.2 
Ldhb  
1.5E+1
0 
8.9E+0
6 
0.0E+0
0 
1.6E+0
9 
0.0E+0
0 
0.0E+0
0 9.6 ∞ 0.0 
Pfkm  
1.7E+0
9 
1.1E+0
8 
6.9E+0
8 
7.9E+0
8 
2.1E+0
7 
8.6E+0
8 2.2 5.3 0.8 
St13  
2.6E+0
9 
2.4E+0
8 
9.9E+0
7 
1.3E+0
9 
1.1E+0
7 
2.1E+0
8 2.1 22.3 0.5 
Rab4b  
0.0E+0
0 
1.5E+0
8 
2.6E+0
7 
0.0E+0
0 
3.9E+0
7 
0.0E+0
0 0.0 3.9 ∞ 
Lum  
1.2E+0
9 
5.4E+0
8 
6.0E+0
8 
3.5E+0
7 
2.5E+0
8 
4.2E+0
7 33.9 2.2 14.1 
Ap1b1  
5.2E+0
8 
2.8E+0
7 
4.1E+0
8 
4.8E+0
8 
1.1E+0
7 
1.4E+0
8 1.1 2.5 3.0 
Nckap1  
4.9E+0
8 
4.7E+0
7 
4.1E+0
8 
2.1E+0
8 
1.3E+0
7 
2.5E+0
8 2.3 3.7 1.6 
Casp3  
2.0E+0
7 
7.1E+0
7 
8.7E+0
7 
0.0E+0
0 
1.5E+0
6 
8.1E+0
7 ∞ 46.1 1.1 
Actb  
1.1E+0
9 
1.1E+0
9 
1.6E+0
9 
4.1E+0
7 
3.3E+0
8 
1.7E+0
9 26.3 3.4 0.9 
Chp1  
0.0E+0
0 
9.6E+0
7 
9.1E+0
7 
0.0E+0
0 
4.0E+0
7 
1.5E+0
7 0.0 2.4 6.0 
Rhoa  
2.2E+0
7 
1.8E+0
9 
4.9E+0
8 
0.0E+0
0 
3.6E+0
8 
1.2E+0
9 ∞ 5.1 0.4 
Pafah1b1  
2.7E+0
9 
9.3E+0
7 
1.4E+0
8 
1.5E+0
9 
0.0E+0
0 
3.4E+0
7 1.8 ∞ 4.1 
Eif4e  
2.8E+0
7 
8.4E+0
6 
1.8E+0
8 
0.0E+0
0 
1.5E+0
7 
7.2E+0
6 ∞ 0.6 25.4 
Eif2b3  
1.3E+0
8 
3.4E+0
7 
5.9E+0
7 
2.4E+0
7 
0.0E+0
0 
6.6E+0
7 5.5 ∞ 0.9 
Nagk  
1.9E+0
8 
0.0E+0
0 
2.1E+0
7 
1.5E+0
7 
0.0E+0
0 
0.0E+0
0 12.9 0.0 ∞ 
Stim1  
3.0E+0
7 
0.0E+0
0 
2.6E+0
6 
1.3E+0
7 
0.0E+0
0 
0.0E+0
0 2.3 0.0 ∞ 
Arpc2  
1.5E+0
7 
1.0E+0
8 
5.1E+0
8 
7.3E+0
6 
1.1E+0
7 
4.5E+0
8 2.1 9.3 1.1 
Pgls  
1.6E+0
8 
3.9E+0
8 
4.3E+0
8 
1.8E+0
8 
1.1E+0
8 
7.5E+0
7 0.9 3.6 5.8 
Slc25a11  
5.7E+0
7 
0.0E+0
0 
3.2E+0
8 
0.0E+0
0 
0.0E+0
0 
9.0E+0
7 ∞ 0.0 3.5 
Aldh6a1  
4.5E+0
7 
2.4E+0
8 
1.6E+0
8 
0.0E+0
0 
1.0E+0
8 
1.0E+0
8 ∞ 2.3 1.6 
Rabggtb  
4.0E+0
8 
0.0E+0
0 
5.5E+0
7 
6.6E+0
7 
0.0E+0
0 
0.0E+0
0 6.1 0.0 ∞ 
Tomm34  
0.0E+0
0 
1.6E+0
7 
5.8E+0
7 
8.0E+0
7 
0.0E+0
0 
7.4E+0
6 0.0 ∞ 7.8 
Aldh16a1  
2.0E+0
8 
5.6E+0
8 
1.9E+0
9 
9.8E+0
6 
2.7E+0
8 
6.4E+0
8 20.3 2.1 3.0 
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Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Dnajc10  
2.0E+0
8 
3.4E+0
8 
1.4E+0
9 
1.9E+0
7 
1.0E+0
7 
1.5E+0
9 10.7 34.1 0.9 
Wdr18  
0.0E+0
0 
3.0E+0
7 
1.4E+0
8 
4.1E+0
6 
0.0E+0
0 
1.6E+0
7 0.0 ∞ 8.4 
C1galt1c1  
1.6E+0
7 
0.0E+0
0 
6.7E+0
7 
0.0E+0
0 
0.0E+0
0 
2.1E+0
7 ∞ 0.0 3.2 
Gmps  
4.1E+0
9 
6.4E+0
7 
1.0E+0
8 
4.3E+0
9 
2.4E+0
7 
2.1E+0
7 0.9 2.7 4.8 
Golim4  
1.6E+0
7 
5.8E+0
8 
1.3E+0
9 
0.0E+0
0 
2.3E+0
8 
8.3E+0
8 ∞ 2.5 1.5 
Slc30a7  
5.6E+0
7 
1.1E+0
8 
2.7E+0
7 
3.8E+0
8 
4.1E+0
7 
0.0E+0
0 0.1 2.5 ∞ 
Ufm1  
0.0E+0
0 
8.8E+0
7 
1.8E+0
7 
0.0E+0
0 
2.3E+0
7 
0.0E+0
0 0.0 3.8 ∞ 
Mlec  
0.0E+0
0 
3.1E+0
8 
9.4E+0
8 
0.0E+0
0 
1.2E+0
8 
4.6E+0
8 0.0 2.6 2.1 
Aip  
5.3E+0
8 
8.4E+0
7 
1.0E+0
8 
1.3E+0
8 
7.3E+0
7 
2.0E+0
7 4.0 1.1 5.0 
Tmed9  
5.4E+0
5 
1.6E+0
9 
1.2E+0
9 
0.0E+0
0 
6.9E+0
8 
1.4E+0
9  2.3 0.8 
Spc25  
6.6E+0
5 
2.8E+0
7 
8.9E+0
8 
5.2E+0
7 
0.0E+0
0 
3.3E+0
8 0.0 ∞ 2.7 
Herc4  
2.7E+0
8 
2.5E+0
7 
4.7E+0
7 
7.7E+0
7 
0.0E+0
0 
5.3E+0
7 3.5 ∞ 0.9 
Uxs1  
0.0E+0
0 
4.1E+0
7 
7.7E+0
7 
0.0E+0
0 
1.1E+0
7 
3.2E+0
6 0.0 3.6 23.9 
Ctps2  
1.4E+0
9 
0.0E+0
0 
1.2E+0
6 
6.1E+0
8 
0.0E+0
0 
0.0E+0
0 2.3 0.0 ∞ 
Emc3  
5.9E+0
7 
1.0E+0
8 
3.4E+0
8 
0.0E+0
0 
3.6E+0
7 
5.4E+0
6 ∞ 2.8 63.6 
Ccdc47  
1.7E+0
8 
3.4E+0
7 
6.4E+0
8 
1.7E+0
8 
1.6E+0
7 
2.2E+0
8 1.0 2.1 3.0 
Tars  
1.9E+1
0 
3.5E+0
7 
1.0E+0
8 
1.4E+1
0 
1.4E+0
7 
3.9E+0
7 1.3 2.5 2.7 
Abhd6  
1.4E+0
7 
1.6E+0
8 
1.5E+0
8 
0.0E+0
0 
9.8E+0
6 
1.5E+0
8 ∞ 16.3 1.0 
Eci2  
0.0E+0
0 
1.9E+0
8 
2.3E+0
8 
0.0E+0
0 
7.7E+0
7 
1.0E+0
8 0.0 2.5 2.2 
Tmx2  
0.0E+0
0 
2.8E+0
7 
2.4E+0
8 
4.1E+0
6 
8.9E+0
6 
5.9E+0
7 0.0 3.1 4.0 
Pelo  
2.5E+0
8 
1.5E+0
8 
4.5E+0
8 
1.1E+0
8 
3.9E+0
7 
1.2E+0
8 2.3 3.9 3.9 
Ubr5  
2.1E+0
7 
3.8E+0
6 
0.0E+0
0 
9.9E+0
6 
0.0E+0
0 
0.0E+0
0 2.1 ∞ 0.0 
Rcn2  
5.6E+0
7 
7.2E+0
7 
4.3E+0
7 
2.0E+0
7 
3.2E+0
7 
1.4E+0
8 2.8 2.3 0.3 
Kif2c  
3.4E+0
7 
0.0E+0
0 
1.6E+0
8 
0.0E+0
0 
4.5E+0
7 
4.5E+0
7 ∞ 0.0 3.5 
Dpysl3  
4.4E+0
8 
1.9E+0
8 
4.2E+0
8 
3.8E+0
8 
4.7E+0
7 
8.8E+0
7 1.2 4.0 4.7 
167 
 
 
 
Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Eif2ak2  
0.0E+0
0 
4.2E+0
7 
8.1E+0
7 
0.0E+0
0 
0.0E+0
0 
1.6E+0
7 0.0 ∞ 5.1 
Tpm3  
1.0E+0
7 
1.1E+0
9 
9.4E+0
8 
0.0E+0
0 
3.7E+0
8 
9.8E+0
8 ∞ 3.0 1.0 
Gbp2  
1.1E+0
8 
1.2E+0
8 
7.0E+0
7 
6.0E+0
7 
2.5E+0
7 
2.9E+0
7 1.9 4.7 2.4 
Aldh7a1  
3.0E+0
9 
5.8E+0
8 
1.6E+0
8 
3.5E+0
9 
2.8E+0
7 
2.7E+0
7 0.9 20.4 6.0 
Leprel4  
2.0E+0
7 
2.6E+0
8 
5.1E+0
8 
3.8E+0
6 
1.1E+0
8 
4.4E+0
8 5.3 2.4 1.2 
Hsph1  
5.5E+0
9 
8.9E+0
8 
1.2E+0
9 
3.3E+0
9 
2.6E+0
8 
5.2E+0
8 1.7 3.4 2.3 
Gsn  
0.0E+0
0 
2.7E+0
7 
2.3E+0
8 
1.1E+0
7 
1.1E+0
7 
9.1E+0
7 0.0 2.4 2.5 
Lap3  
8.5E+0
8 
2.2E+0
9 
3.0E+0
9 
3.5E+0
8 
7.5E+0
8 
1.8E+0
9 2.4 2.9 1.7 
Cops3  
2.0E+0
9 
1.9E+0
8 
1.0E+0
8 
1.9E+0
9 
6.0E+0
7 
4.8E+0
7 1.0 3.3 2.1 
Nup35  
0.0E+0
0 
3.2E+0
7 
1.2E+0
7 
0.0E+0
0 
7.7E+0
6 
0.0E+0
0 0.0 4.2 ∞ 
Pycr2  
3.2E+0
8 
2.5E+0
8 
5.8E+0
8 
2.0E+0
7 
8.3E+0
7 
1.0E+0
9 16.0 3.0 0.6 
Hgh1  
7.5E+0
6 
1.7E+0
8 
6.0E+0
8 
1.2E+0
8 
7.7E+0
6 
1.3E+0
8 0.1 22.6 4.5 
Capg  
9.7E+0
8 
4.0E+0
8 
6.4E+0
8 
1.0E+0
9 
8.9E+0
7 
2.7E+0
8 0.9 4.5 2.3 
Tsg101  
4.4E+0
8 
3.0E+0
7 
3.9E+0
7 
1.9E+0
8 
3.7E+0
6 
5.3E+0
6 2.3 8.3 7.4 
Cops8  
0.0E+0
0 
1.8E+0
8 
1.7E+0
7 
0.0E+0
0 
9.8E+0
6 
3.5E+0
6 0.0 17.9 4.7 
Gpi  
1.1E+0
9 
3.9E+0
6 
3.6E+0
7 
1.1E+0
9 
0.0E+0
0 
1.2E+0
7 1.1 ∞ 3.1 
Sars  
9.4E+0
8 
4.1E+0
6 
1.8E+0
6 
4.5E+0
8 
0.0E+0
0 
2.4E+0
7 2.1 ∞ 0.1 
Asah1  
2.8E+0
7 
1.3E+0
8 
4.2E+0
8 
0.0E+0
0 
2.4E+0
7 
4.3E+0
8 ∞ 5.4 1.0 
Pds5b  
8.8E+0
6 
0.0E+0
0 
1.3E+0
7 
1.0E+0
6 
0.0E+0
0 
0.0E+0
0 8.8 0.0 ∞ 
Rbbp7  
1.3E+1
0 
6.2E+0
8 
1.4E+0
9 
8.9E+0
9 
2.4E+0
8 
7.2E+0
8 1.4 2.6 2.0 
Apob  
3.3E+0
7 
1.7E+0
8 
1.8E+0
8 
0.0E+0
0 
4.1E+0
7 
1.6E+0
8 ∞ 4.2 1.1 
Ehd3  
5.0E+0
8 
3.9E+0
8 
5.0E+0
8 
1.2E+0
8 
8.0E+0
7 
7.0E+0
8 4.1 4.9 0.7 
Ppp4r1  
2.2E+0
8 
7.5E+0
7 
5.0E+0
7 
7.4E+0
7 
1.8E+0
7 
2.9E+0
7 2.9 4.1 1.7 
Khdrbs1  
5.0E+0
8 
3.5E+0
7 
9.4E+0
7 
4.2E+0
8 
1.4E+0
7 
2.5E+0
7 1.2 2.6 3.8 
Pi4k2a  
5.6E+0
8 
0.0E+0
0 
3.0E+0
8 
1.4E+0
8 
0.0E+0
0 
1.4E+0
6 4.0 0.0 215.0 
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Gene 
Name 
T1 
-Dox 
T2 
-Dox 
T3 
-Dox 
T1 
+Dox 
T2 
+Dox 
T3 
+Dox T1 
Ratio  
T2 
Ratio 
T3 
Ratio 
Arpc1a  
1.4E+0
7 
0.0E+0
0 
6.8E+0
7 
0.0E+0
0 
0.0E+0
0 
2.6E+0
7 ∞ 0.0 2.6 
Arl6ip5  
1.2E+0
8 
9.9E+0
7 
1.4E+0
8 
2.6E+0
7 
6.5E+0
7 
5.1E+0
7 4.6 1.5 2.8 
Wnk1  
5.4E+0
7 
3.6E+0
7 
0.0E+0
0 
0.0E+0
0 
1.3E+0
7 
0.0E+0
0 ∞ 2.7 0.0 
Cul5  
2.0E+0
8 
3.1E+0
7 
2.5E+0
7 
6.8E+0
7 
1.5E+0
7 
1.3E+0
8 3.0 2.1 0.2 
Ccs  
0.0E+0
0 
3.7E+0
7 
6.8E+0
7 
0.0E+0
0 
0.0E+0
0 
2.7E+0
7 0.0 ∞ 2.5 
Prpf19  
3.8E+0
9 
3.4E+0
8 
2.3E+0
8 
1.7E+0
9 
1.1E+0
8 
3.3E+0
8 2.3 3.0 0.7 
Htra1  
7.9E+0
6 
1.8E+0
8 
5.4E+0
8 
9.0E+0
5 
7.6E+0
7 
4.6E+0
8 8.8 2.4 1.2 
Lepre1  
4.0E+0
8 
1.3E+0
9 
1.6E+0
9 
1.0E+0
8 
3.7E+0
8 
4.8E+0
8 3.8 3.5 3.3 
Clic4  
7.1E+0
6 
8.3E+0
8 
3.6E+0
9 
3.3E+0
6 
2.1E+0
8 
1.6E+0
9 2.2 3.9 2.3 
Actn1  
8.2E+0
9 
2.3E+0
6 
5.2E+0
8 
7.7E+0
9 
0.0E+0
0 
1.1E+0
8 1.1 ∞ 4.8 
Nap1l1  
7.4E+0
9 
3.4E+0
8 
1.0E+0
9 
2.8E+0
9 
5.0E+0
7 
7.3E+0
8 2.6 6.8 1.4 
aProtein hits enriched in at least two replicates ( at least 2 fold enrichment in at least two replicates) in the 
K-BIPS study with PP1-MYPT1 phosphatase inactivation.  The peptide intensity observed for each sample 
(-Dox: Without doxycycline, +Dox: With doxycycline) for the three trials (T1: trial 1, T2: trial 2, T3: trial 3) is 
shown. Fold change for each trial was calculated by dividing the peptide intensity observed in the 
doxycycline untreated sample (PP1-MYPT1 active) sample by the peptide intensity observed for the 
doxycycline treated sample (PP1-MYPT1 inactive). Infinity (∞) signifies that no peptides were observed in 
the doxycyline treated sample, making a numeric ratio calculation impossible. 
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ABSTRACT 
 
DEVELOPMENT OF TOOLS FOR PHOSPHOSITE-SPECIFIC KINASE 
IDENTIFICATION AND DISCOVERY OF PHOSPHATASE SUBSTRATES 
by 
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                                                   May 2017 
Advisor: Dr. Mary Kay Pflum 
Major: Chemistry (Biochemistry) 
Degree: Doctor of Philosophy 
Phosphorylation is a ubiquitous post translational modification implicated in many 
diseases, such as cancer. The phosphorylation status of cellular proteins is regulated by 
the activity of kinases and phosphatases. The biological significance of many 
phosphorylation events remain unknown because the methods to determine which kinase 
or phosphatase is responsible for phosphorylation are limited. Previously, we established 
kinase-catalyzed labeling where kinases accept γ-modified ATP analogs, such as ATP-
arylazide and ATP-biotin, to label phosphoproteins. To study substrates of kinases and 
phosphatases, here we developed two new methods using kinase-catalyzed labeling. As 
one application, we developed K-CLASP (Kinase-catalyzed CrossLinking And 
Streptavdin Purification) to identify the in-cellulo kinase of a phosphorylated site on a 
protein. In this case, we used ATP-arylazide to mediate crosslinking between a biotin 
tagged peptide carrying a phosphosite of interest and the respective kinase. Using Protein 
kinase A (PKA) and its known peptide substrate kemptide, we demonstrated that K-
CLASP is capable of identifying PKA as the kinase responsible for kemptide 
phosphorylation in cell lysates. Then we used K-CLASP to identify the kinases that 
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phosphorylate S178 of the Miz1 protein in a collaboration project. For phosphatase 
substrate identification, we developed K-BIPS (Kinase-catalyzed Biotinylation to Identify 
Phosphatase Substrates). In prior work, we observed that labeling of phosphoproteins by 
ATP-biotin is reduced when phosphatases are inactive. The phosphatase dependency of 
biotinylation is due to the presence of already existing phosphorylation, which prevents 
ATP-biotin labeling. Therefore, in K-BIPS, ATP-biotin labeling is carried out after the 
inactivation of a particular phosphatase. The loss in biotinylation can then be analyzed to 
reveal substrates. To establish K-BIPS as a viable method, we carried out ATP-biotin 
labeling in lysates treated with the general phosphatase inhibitor okadaic acid. Many 
known phosphatase substrates were observed validating our method. Then as further 
applications, we used K-BIPS to explore substrates of PP1-Gadd34 and PP1-MYPT1 
phosphatase complexes. The results demonstrate that K-BIS-Phos is a feasible method 
for phosphatase substrate identification. In summary, we have developed two chemical 
tools based on kinase-catalyzed labeling that will enhance our understanding of 
phosphorylation events mediated by kinases and phosphatases.   
 
 
 
 
 
 
 
 
 
 
201 
 
 
 
AUTOBIOGRAPHICAL STATEMENT 
PAVITHRA DEDIGAMA ARACHCHIGE 
Education 
 Wayne State University, Detroit, MI (August, 2011-Present) 
Ph.D. Department of Chemistry, Major in Biochemistry. GPA: 3.94. Advisor: Mary Kay Pflum. 
Dissertation: Development of tools for phosphosite-specific kinase identification and discovery of 
phosphatase substrates.  
 University of Colombo, Sri Lanka (August, 2006-August, 2010) 
Bachelor of Science (B.Sc). Major in Biochemistry and Molecular Biology. GPA: 3.5, First Class 
Honors. Dissertation: : “Real Time PCR based High Resolution Melting Analysis to detect JAK2 
mutation” 
Publications 
 Dedigama-Arachchige, P. M.; Chinthaka, N.;  Pflum, M. K., K-BIPS, A method for 
phosphatase substrate identification. Manuscript in preparation.  
 Dedigama-Arachchige, P. M.; Zhang, X.; Yi, Z.; Pflum, M. K., Identification of PP1-MYPT1 
substrates in L6 myoblasts. Manuscript in preparation.  
 Garre, S.; Faner, T.; Dedigama-Arachchige, P. M.; Pflum, M. K., “Kinase-catalyzed 
Crosslinking and Immunoprecipitation (K-CLIP) is a Kinase-substrate Identification Tool: 
Application to p53” Manuscript in preparation. 
 Dedigama-Arachchige, P. M.; Pflum, M. K., K-CLASP: A tool to identify phosphosite specific 
kinases and interacting proteins. ACS Chem Biol, 2016, In press 
 Anthony, T. M.; Dedigama-Arachchige, P. M.; Embogama, D. M.; Faner, T. R.; Fouda, A. E.; 
Pflum, M.K. ATP analogs in protein kinase research. Kinomics: Approaches and Applications, 
Martic, S.; Kraatz, H. B., Eds. VCH-Wiley: 2014 (All authors contributed equally to this work) 
Presentations  
 Dedigama-Arachchige, P.M & Pflum, M.K. Exploiting kinase-catalyzed labeling to unravel the 
cellular phosphorylation network. Gordon Research Conference – Bioorganic Chemistry, 
Andover, NH. June 2016  
 Dedigama-Arachchige, P.M & Pflum, M.K. Exploiting kinase-catalyzed labeling to unravel the 
cellular phosphorylation network. 47th Central Regional Meeting (CERM) –American 
Chemical Society. Covington, KY. May 2016 
 Dedigama-Arachchige, P.M & Pflum, M.K. Exploiting kinase cosubstrate promiscuity to 
identify phosphatase substrates. 7th Annual Midwest Graduate Research Symposium, 
University of Toledo. April 2016 
 
